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Abstract 
For neurodegenerative diseases, interventions during the early stages of the disease, before 
significant neurodegeneration has occurred, are associated with an increased probability of 
slowing or halting the disease process. In order to intervene early, it is essential that an 
accurate diagnosis is obtained and that disease progression can be monitored. This is 
particularly relevant for Parkinson’s disease (PD; International Classification of Diseases 
version 10) because significant neurodegeneration has already occurred by the time the 
clinical motor symptoms are present. Therefore, the development of translatable, high-
throughput biomarkers for large scale population screening is a crucial area of research. Of 
promise are the emerging “omics” technologies, which enable the detection of preclinical 
biomolecule fluctuations associated with the development of different diseases.  
One such field is glycomics which is the study of the set of sugar structures, hereon in known 
as glycans, in a given protein, cell or tissue. Notably, the functional diversity of proteins is 
increased by several magnitudes with the addition of glycans, a process known as 
glycosylation. The glycosylation of certain proteins, including immunoglobulin G (IgG), has 
been found to remain fairly stable over short periods of time, with modifications thought to 
result from changes in the cellular environment or disease presence. Indeed, IgG has the ability 
to exert both anti-inflammatory and pro-inflammatory effects throughout the body and these 
properties are controlled by the N-glycosylation of the fragment crystallisable (Fc) portion.  
To our knowledge, this was the first time that the potential of using IgG glycomic biomarkers 
to identify people with PD, as well as identify people with PD who are at risk of cognitive 
decline, was investigated. It was demonstrated that the peripheral IgG glycome in the PD cases 
was indicative of an increased capacity to biologically age. While advancing age has previously 
been associated with modifications to the glycosylation of IgG, making them more pro-
inflammatory, advancing age was only associated with significant increases in modifications to 
the peripheral IgG glycome that infer more pro-inflammatory IgG in the PD cases but not the 
controls. In PD, the severity of the underlying pathology increases as the individual ages and, 
therefore, is a confounder of the effect of advancing age on pro-inflammation. Consequently, 
the peripheral IgG in people with PD have a propensity to become more pro-inflammatory at a 
faster rate as they age, and this may be linked to the severity of pathology during the course of 
the disease. PD has a heterogeneous presentation of clinical symptoms, and many factors 
contribute to the development of the disease. While this is true, it was demonstrated that the 
peripheral IgG glycome does not have utility in identifying risk of cognitive decline, which 
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would result from progression of PD pathology in the central nervous system (CNS). These 
results are indicative of the peripheral IgG interacting with PD pathology in the enteric nervous 
system (ENS) as well as when it propagates from the ENS to the CNS along the vagal nerve. 
Inflammation may facilitate the neuron-to-neuron propagation of PD inclusions along this 
pathway and thus be a contributor to PD development during the prodromal phase. Hence, 
the peripheral IgG glycome may be useful as a novel biomarker of PD presence in the 
prodromal phase of the disease. 
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1.0   Introduction 
For neurodegenerative diseases, interventions during the early stages of the disease, before 
significant neurodegeneration has occurred, are associated with an increased probability of 
slowing or halting the disease process. In order to intervene early, it is essential that an 
accurate diagnosis is obtained and that disease progression can be monitored. This is 
particularly relevant for Parkinson’s disease (PD; International Classification of Diseases 
version 10 code G20) because significant neurodegeneration has already occurred by the time 
the clinical motor symptoms are present. Therefore, the development of translatable, high-
throughput biomarkers for large scale population screening is a crucial area of research. A 
biomarker is defined as "a characteristic that is objectively measured and evaluated as an 
indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention” (Atkinson et al., 2001). Of promise are the emerging “omics” 
technologies which enable the detection of preclinical biomolecule fluctuations associated 
with the development of different diseases, and include such research fields as genomics, 
proteomics, metabolomics and glycomics.  
Glycomics is the study of the set of sugar structures, hereafter referred to as glycans, in a given 
protein, cell or tissue. Notably, there are over 82,000 proteins in the Protein Data Bank (RCSB 
Protein Data Bank, 2013) and the functional diversity of proteins are increased by several 
magnitudes with post-translational modifications, including the addition of glycans (Lu et al., 
2011). These modifications are part of the biosynthesis of many proteins (Varki et al., 2009), 
and are not template driven (Lu et al., 2011; Varki et al., 2009). Of the many types of post-
translational modifications, glycosylation is amongst the most common and complex (Khoury 
et al., 2011; Lu et al., 2011; Saldova et al., 2012; Tharmalingam et al., 2013), and is the process 
of attaching a glycan to a protein or lipid to form a glycoprotein or glycolipid, respectively 
(Varki et al., 2009). Glycans are more information-dense than other macromolecules (DeMarco 
& Woods, 2008; Nelson et al., 2008). Moreover, multiple glycan structures can attach to a 
protein at a given time (Lu et al., 2011), and the number of ways a glycan can be modified 
makes them highly diverse (Varki et al., 2009).  
The glycosylation of certain proteins, including immunoglobulin G (IgG), has been found to 
remain fairly stable over short periods of time, such as a year (Horvat et al., 2011; Knezevic et 
al., 2009; Lu et al., 2011), with modifications thought to result from changes in the cellular 
environment or disease presence (Knezevic et al., 2009; Lauc & Zoldo, 2010; Lu et al., 2011; 
Pucic et al., 2010; Zhang et al., 2012). The purpose of this thesis was to analyse the peripheral 
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IgG glycome and determine its utility in identifying people with PD, through a case-control 
epidemiological approach, as well as identifying risk of cognitive impairment. However, to fully 
realise the potential of peripheral IgG N-glycans as a biomarker, a sound understanding of PD 
development, presentation and progression is necessary. 
 
 1.1   Parkinson’s Disease (PD) 
PD is a complex chronic disease that is degenerative in nature, incurable and associated, 
although not caused by, advancing age. It is the second most common neurodegenerative 
disease in Australia, exceeded only by Alzheimer’s disease, with an estimated 1 in every 350 
individuals in the general population living with PD (Deloitte Access Economics, 2011). In 2011, 
the total cost of PD to Australia was $775.4 million which mainly reflects individually incurred 
costs over the course of the disease; the cost per person with PD approximately $12,000 per 
year and a median of 12.2 years lived post-diagnosis (Deloitte Access Economics, 2011).  
James Parkinson first recorded PD in his 1817 publication “An Essay on the Shaking Palsy” and 
described Shaking Palsy (Paralysis Agitans) as: 
Involuntary tremulous motion, with lessened muscular power, in parts not in action 
and even when supported; with a propensity to bend the trunk forward, and to pass 
from a walking to a running pace: the senses and intellects being uninjured. 
(Parkinson, 1817, p. 1)  
PD is still characterised by the classical motor symptoms of resting tremor, rigidity, 
bradykinesia, postural instability, and impaired coordination. However, unlike James 
Parkinson’s 1817 description of PD, it is now recognised that non-motor symptoms also play a 
vital role in the consequences of the disease. These include psychoses, autonomic failure, 
digestive dysfunction, sleep abnormalities, fatigue, apathy, non-smoking related cancers, 
cognitive impairment and dementia (Russell et al., 2014). In particular, enteric nervous system 
(ENS) and olfactory dysfunction precede the clinical presentation of PD by years in many cases 
(Derkinderen et al., 2011; Kuo et al., 2010; Lebouvier et al., 2010), and cognitive impairment 
develops in about 80% of PD cases during the course of the disease (Aarsland et al., 2003; Hely 
et al., 2008).  
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PD can be inherited or idiopathic. Although more than 85% of PD cases are of idiopathic origins 
(Lesage & Brice, 2009; Meissner et al., 2011), having a sibling with PD infers a risk of 
developing the disease that is two to seven times greater than in the general population 
(Marder et al., 2003; Sveinbjörnsdóttir et al., 2000). Moreover, PD has 18 known gene loci 
associated with an increased risk of the disorder (Thenganatt & Jankovic, 2014). While risk 
does not necessarily equate to PD development, people who have genetic mutations 
associated with increased risk are thought to be more vulnerable to environmental insults 
(Meissner et al., 2011). PD is therefore a model disorder for studying how genes and the 
environment can interact and negatively impact an individual. While a gene-environment 
interaction is hypothesised, it is still unknown what causes idiopathic PD. Indeed, determining 
the mechanisms by which pathogenesis is initiated is a requisite to identifying valid biological 
markers of PD.  
Like most chronic diseases, there is a prodromal phase whereby individuals with PD pathology 
have no or mild clinical symptoms that are not currently characterised as being associated with 
PD (Braak et al., 2003; Del Tredici & Braak, 2012). It is during this phase that the key PD-
associated inclusions, alpha-synuclein immunoreactive Lewy bodies and Lewy neurites, begin 
developing in vulnerable nervous tissues. These become more severe and progress to other 
vulnerable projection neurons, particularly dopaminergic neurons (Del Tredici & Braak, 2012). 
An individual will be diagnosed as having clinical PD when a suboptimal pathological level is 
breached (Wang et al., 2014). Braak and colleagues (2003) have demonstrated this to be the 
point where a substantial amount of dopaminergic neurons within the substantia nigra (SN) 
pars compacta have been lost to apoptosis, with surviving dopaminergic neurons containing 
the aforementioned alpha-synuclein immunoreactive inclusions. Progression of pathology 
continues through the basal forebrain and mesocortex to the neocortical regions of the brain 
with concomitant cognitive decline (Braak et al., 2003).  
Given the extensive neurodegeneration present at the time of diagnosis, the translation of 
neuroprotective and disease-modifying interventions often fails (Meissner et al., 2011). Much 
research in the realm of chronic disorders, including PD, is now focused on defining clinically 
translatable biomarkers that can be used to identify individuals within the suboptimal, 
prodromal phase of a disease.  
1.1.1   Prodromal Phase 
While familial forms of PD have been identified, there is little agreement on the cause of 
idiopathic PD. Two pathways to degeneration of the SN, however, are hypothesised; 
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anterograde degeneration from the olfactory bulb towards the temporal lobe, and retrograde 
degeneration originating in the ENS and travelling via the afferent parasympathetic vagal nerve 
fibres to the dorsal motor nucleus of the vagus (Hawkes et al., 2007). Importantly, these are 
the only nervous tissues in the body that are exposed to environmental substances and as 
such, are vulnerable to insult.  
Olfactory dysfunction is one of the most common observations in people with PD. Notably 
many individuals have the perception that their sense of smell is lost many years, sometimes 
decades, before they are diagnosed with PD (Derkinderen et al., 2011). Post mortem PD 
studies have solidified these claims by identifying alpha-synuclein immunoreactive inclusions 
in the olfactory bulb that advance to other olfactory structures (Braak et al., 2003). A 
prerequisite of the involvement of olfactory dysfunction in the progression of PD pathology to 
non-olfactory cortical regions is subcortical involvement from Lewy aggregates that have 
progressed from the lower medulla oblongata to the basal forebrain (Braak et al., 2003). 
However, the appearance of these inclusions appears to be subsequent to the development of 
Lewy pathology in the periphery. 
Other symptoms known to develop preclinical to or early in PD include dysphagia, nausea, 
gastroparesis, reduced bowel movement frequency and dyschesia (Derkinderen et al., 2011; 
Kuo et al., 2010; Lebouvier et al., 2010), all of which are involved in the ENS. Notably, ENS 
dysfunction occurs in newly diagnosed people with PD, therefore it is unlikely to be caused by 
medications (Kuo et al., 2010). In rodent models, it has been reported to occur prior to 
dysfunction in the autonomic innervation of the heart or olfaction, and prior to pathological 
changes in the medulla oblongata (Kuo et al., 2010). The ENS, the gastrointestinal tracts own 
intrinsic nervous system, is comprised of an extensive integrative network of neurons 
organised into two plexuses; the myenteric plexus and the submucosal plexus (Cersosimo & 
Benarroch, 2008; Furness, 2012). Intestinal motility and secretion are controlled by the ENS 
through local enteric reflexes and reflexes that pass through sympathetic ganglions, largely 
independent of extrinsic innervation by the central nervous system (CNS) (Cersosimo & 
Benarroch, 2008; Furness, 2012). There are, however, multiple reflexes that pass through the 
CNS and return to the gastrointestinal tract (Cersosimo & Benarroch, 2008; Furness, 2012). 
Dopaminergic neurons are present as a small population of the intrinsic innervation of both 
plexuses of the ENS, and changes in dopaminergic function are associated with marked 
changes to colonic motility (Cersosimo & Benarroch, 2008; Derkinderen et al., 2011; Kuo et al., 
2010). Braak and colleagues (2006) demonstrated the presence of alpha-synuclein 
immunoreactive Lewy neurites in the axons of the submucosal and myenteric plexus neurons 
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during the very early stages of idiopathic PD. Moreover, Kuo and colleagues (2010) found ENS 
dysfunction in mice to be directly linked to mutant alpha-synuclein expression and aggregation 
rather than abnormal CNS innervation of the gut, suggesting that ENS dysfunction is the result 
of an intrinsic rather than an extrinsic defect. Indeed, it is evident that the primary pathological 
features of PD occur in both the CNS and the ENS, and the damage to the ENS most likely 
precedes damage in the CNS, however the initiator of the neurodegenerative process is still 
unknown.   
One school of thought is that genetically vulnerable people are being exposed to an 
environmental toxin or pathogens that then damage vulnerable nervous tissues, i.e. the 
olfactory bulb and the ENS, initiating the neurodegenerative process (Jang et al., 2009; Pan-
Montojo et al., 2010; Taylor et al., 2013). Animal models of PD support the notion of an 
interplay between genetic mutations and the environment (Jang et al., 2009; Taylor et al., 
2013). Indeed, environmental toxins including pesticides such as rotenone and paraquat are 
commonly used to induce PD-like progression of pathology in rodent models.  
Rotenone is an organic pesticide that directly inhibits mitochondrial complex I in mice, 
disrupting the electron transport chain and inducing the loss of SN dopaminergic neurons 
(Tanner et al., 2011). This is significant as mitochondrial dysfunction is implicated in the 
pathogenesis of PD. Systemic administration of rotenone fails to induce the pathological 
features of PD (Pan-Montojo et al., 2010); however, intragastric administration has been used 
with promising results. Ingested rotenone mimics the characteristic staging pattern of PD 
pathology found in humans, with changes progressing from the ENS to the CNS (Pan-Montojo 
et al., 2010; Tanner et al., 2011). Pan-Montojo and colleagues (2010) found intracellular 
accumulation of alpha-synuclein within the neurons of the ENS, dorsal motor nucleus of the 
vagus, intermediolateral nucleus in the spinal cord and the SN following chronic intragastric 
exposure to rotenone.  
Paraquat is another environmental toxin and commonly used herbicide which is utilised to 
influence PD-like progression of pathology in animal models. It has been reported that PD is 
2.5 times more likely to develop in people who have ever been exposed to rotenone when 
compared to paraquat (Tanner et al., 2011). Nevertheless, paraquat produces cellular changes 
associated with PD, including increased production of free radicals leading to oxidative stress, 
selective SN injury and aggregation of misfolded insoluble alpha-synuclein (Henchcliffe & Beal, 
2008; Tanner et al., 2011). Moreover, paraquat exposure causes an earlier age of clinical PD 
onset in rodent models when compared to mitochondrial complex I inhibitors, such as 
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rotenone. This is important as oxidative stress is a presumed pathophysiological characteristic 
of familial PD (Tanner et al., 2011). Unfortunately paraquat is still one of the most widely used 
pesticides worldwide, therefore making it a potential public health concern (Tanner et al., 
2011). 
Although the degenerative pathway may begin in both the olfactory bulb and the ENS, it 
appears that it is the Lewy inclusions originating in the ENS that propagate along the afferent 
parasympathetic vagal nerve to the dorsal motor nucleus of the vagus that precedes the 
neurodegeneration of the SN pars compacta (Braak, de Vos, et al., 2006; Braak et al., 2003). 
Indeed, deposition of Lewy pathology in surviving projection neurons extending from the 
dorsal motor nucleus of the vagus, through to the medulla oblongata and eventually to the SN, 
may be a direct route of neuronal insult (Braak et al., 2003). While more work remains to be 
done in characterising the prodromal phase, understanding the underlying mechanisms of this 
phase will be critical for the development of sensitive and valid biomarkers of PD. 
 
1.1.2   Clinical Phase 
1.1.2.1   Motor Characteristics 
The United Kingdom Brain Bank Criteria (UKBBC) are used worldwide for clinically diagnosing 
PD (Hughes et al., 1992). The criteria rely upon a patient having at least bradykinesia, plus one 
of the other motor symptoms of PD (e.g. resting tremor, rigidity, postural instability), as well as 
the absence of a number of exclusion criteria. PD is highly heterogeneous, which may 
complicate clinical diagnosis. As such, research regarding the clinical heterogeneity of PD has 
used large data sets with a focus on clustering clinical features rather than utilising individual 
case reports. Jankovic and colleagues (1990) released one of the earliest classifications of PD 
subtypes using the United PD Rating Scale (UPDRS) subscales II and III. They successfully 
subtyped PD into two clinical groups, tremor dominant and non-tremor dominant or postural 
instability and gait dysfunction (PIGD) subtypes, with an ‘indeterminate’ subtype of those that 
cannot be classified into either group. Subsequently, an additional two PD subtypes were 
proposed based on the age of diagnosis and progression rate of the disease; young-onset PD 
and rapid disease progression PD (Lewis et al., 2005; Selikhova et al., 2009; Thenganatt & 
Jankovic, 2014). Interestingly, people with rapid disease progression PD tend to have a worse 
prognosis than young-onset PD; a slower progressing syndrome that is most often tremor 
dominant and less likely to lead to cognitive decline.  
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In 2008, the Movement Disorder Society (MDS) released an updated version of the UPDRS, 
namely the MDS-sponsored UPDRS revision (MDS-UPDRS; Goetz et al., 2008). The objective 
was to make the MDS-UPDRS more comprehensive with several new items added to assess the 
non-motor aspects of PD, and place a greater emphasis on distinguishing between milder 
symptoms (Goetz et al., 2008). The MDS-UPDRS is the current gold standard for determining 
the clinical subtype of a person with PD using the equations described by Stebbins et al. 
(2013). These equations are summarised in the Methods (see Section 2.3.3.1).  
Delineating the natural history of a PD subtype is of interest as patients respond differently to 
certain medications depending on their motor and cognitive symptoms (Eggers et al., 2011; 
Eggers et al., 2012), and these differences may also be detected as different levels of certain 
biomarkers. Studies utilising iodine 123–radiolabeled 2β-carbomethoxy-3β-(4-iodophenyl)-N-
(3-fluoropropyl) nortropane with single-photon emission computed tomography ([123I]FP-CIT-
SPECT) have demonstrated its usefulness for imaging the extent and pattern of dopamine 
transporter loss in the striatum between tremor dominant and non-tremor dominant PD 
subtypes (Eggers et al., 2011; Eggers et al., 2012). Indeed, not only do PD patients with a 
tremor dominant subtype show a distinct loss of dopamine uptake in the caudate nucleus and 
the lateral putamen, but their non-tremor dominant counterparts demonstrate a distinct loss 
in dopaminergic projections to the dorsal putamen (Eggers et al., 2011; Eggers et al., 2012). 
Furthermore, compared to tremor dominant PD the progression of dopaminergic loss in 
people with a non-tremor dominant subtype is more severe in the bilateral putamen and this 
progression correlates with a worsening of phenotype (Eggers et al., 2011; Eggers et al., 2012). 
Therefore, these subtypes have different aetiopathological pathways of PD development and 
progression.  
Pathologically, alpha-synuclein immunoreactive Lewy bodies and Lewy neurites from the 
medulla oblongata have increased by this stage in severity and propagated to other vulnerable 
long and slender projection neurons, particularly dopaminergic neurons in the SN (Braak et al., 
2003; Del Tredici & Braak, 2012). The aggregation of alpha-synuclein disrupts the intracellular 
activity of these dopaminergic neurons, eventually causing them to degenerate and release 
neuromelanin into the surrounding tissue (Collins et al., 2012; Perry et al., 2010). The SN 
dopaminergic neurons are involved in the extrapyramidal system that controls muscle tone, 
balance, subconscious regulation of movement, and reflex activity. Hence, the degeneration of 
such neurons leads to the presentation of the classical motor symptoms that define PD.  
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1.1.2.2   Cognitive Impairment and Dementia Development 
The occurrence of dementia is increasingly being recognised as a complication of PD (Litvan et 
al., 2012; Marras et al., 2013; Svenningsson et al., 2012), particularly in the later stages of the 
disease. It is associated with faster disease progression and an increased mortality rate 
compared to healthy-aged controls, people with PD or people with Alzheimer’s disease (de Lau 
et al., 2005; Dewey & Saz, 2001; Emre et al., 2007; Irwin et al., 2012; Reid et al., 1996). The 
prevalence of dementia in PD ranges from 19.7 to 35.3% (Aarsland et al., 2003; Baldivia et al., 
2011; de Lau et al., 2005; Hobson & Meara, 2004; Hoegh et al., 2013; Levy et al., 2002; Rana et 
al., 2012; Riedel et al., 2008); however, 78.2 to 83% of people with PD will develop dementia 
during the course of the disease (Aarsland et al., 2003; Hely et al., 2008). People with PD have 
a 2.6 to 5.9-fold increased risk of developing dementia (Aarsland et al., 2003; de Lau et al., 
2005; Hobson & Meara, 2004; Williams-Gray et al., 2013) and a 1.29 to 1.83-fold increased risk 
of mortality compared to the general population (de Lau et al., 2005; Hughes et al., 2004; 
Williams-Gray et al., 2013). Furthermore, people with PD dementia have a 1.9 to 2.5-fold 
increased risk of mortality compared to the general population (Hely et al., 2008; Hughes et al., 
2004), higher than that of PD alone. 
The subsequent development of dementia in many cases is associated with the clinical motor 
subtype in PD. Alves and colleagues (2006) found that the development of dementia almost 
exclusively occurred in those with a PIGD subtype. Importantly, the transition from a tremor 
dominant to a PIGD, non-tremor dominant clinical subtype was unidirectional, irreversible and 
predicted subsequent dementia (Alves et al., 2006). Non-dopaminergic deficits are thought to 
cause PIGD in PD because people with this motor subtype respond poorly to dopaminergic 
therapy (Muller et al., 2013). An increase in neocortical amyloid-beta plaques, pathology 
normally associated with Alzheimer’s disease, is presumed to be the mechanism of cognitive 
dysfunction in people with a PIGD subtype (Muller et al., 2013; Sellal, 2006). Furthermore, 
elderly people with PIGD unrelated to PD show an increased incidence of cognitive impairment 
(Yarnall et al., 2013). Alves and colleagues (2006), at the four year follow-up of their 
population-based PD cohort, reported that 42 of 128 patients (32.8%) had developed 
dementia and 41 of these (97.6%) had the PIGD-dominant PD subtype. At eight years, 48 out of 
84 patients (57%) had developed dementia, all of whom had the PIGD-dominant PD subtype 
(Alves et al., 2006). Consequently, determining the clinical subtype of a patient with PD is 
important for prognosis of the disorder, and may be predictive of the development of 
cognitive impairment and dementia.  
9 
 
The presence of mild cognitive impairment (MCI) is often detected at diagnosis and may be a 
possible indication of the future development of dementia (Leroi et al., 2012; Litvan et al., 
2012; Svenningsson et al., 2012). A recent multicentre analysis (n=1346; Aarsland et al., 2010) 
found that MCI was prevalent in 25.8% of people with newly diagnosed PD, non-amnestic MCI 
the most common at baseline, a finding corroborated by other studies (Litvan et al., 2012; Nie 
et al., 2012; Reid et al., 1996). Importantly, non-amnestic dementia development is most likely 
caused by the progression of PD pathology whereas amnestic dementia is most likely caused 
by Alzheimer’s disease-type pathology (Reid et al., 1996). Cognitive dysfunction, therefore, is 
not exclusively a complication of the later stages of PD as MCI can begin to have an impact on 
quality of life much sooner than anticipated. Furthermore, impairment of semantic fluency, 
categorical memory, during the clinical phase of PD is a predictor of cognitive impairment (Hu 
et al., 2014; Pereira et al., 2014; Williams-Gray et al., 2009). Categorical memory deficits are 
linked to temporal lobe dysfunction, which may be caused by differential progression of PD 
(Ibarretxe-Bilbao et al., 2011). The animal naming task is one tool used to assess semantic 
fluency in PD, with a low score indicating impairment and risk of cognitive impairment 
(summarised in the Methods, Section 2.3.3.2).   
Pathologically, the development of PD dementia is associated with the propagation of alpha-
synuclein immunoreactive Lewy inclusions from the mesocortex to the neocortex, particularly 
the premotor areas, primary motor field, and sensory association areas (Braak et al., 2003). 
Upon macroscopic inspection, the SN pars compacta has lost its black colour by this point due 
to extensive degeneration of dopaminergic neurons and the release of neuromelanin into the 
surrounding extracellular tissue during the process (Braak et al., 2003). There is also a 
reduction in the number of neurons containing Lewy pathology due to the extensive neuronal 
loss (Braak et al., 2003). Knowledge of the differential development of idiopathic PD will 
expand understanding of why the disease is so heterogeneous and why dementia develops in 
most but not all people with PD, as well as allow for the development of biomarkers that can 
diagnose and monitor the progression of the disease. The development of valid biomarkers 
will be a product of deciphering the interaction of genetic and environmental factors, and how 
an individual is predisposed to the development of PD. 1.2   Inflammation in PD 
A degree of inflammation is associated with PD, both in the CNS and in the periphery. 
Inflammation, caused by mitochondrial dysfunction and oxidative stress, is associated with the 
propagation of alpha-synuclein pathology. This multistep process begins with the misfolding of 
endogenous alpha-synuclein protein that subsequently aggregates into higher order oligomers 
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and disrupts normal cellular function (Angot et al., 2012). Both in vitro and in vivo studies 
support neuron-to-neuron transmission of alpha-synuclein oligomers through healthy cells 
endocytosing previously exocytosed protein aggregates of affected cells (Desplats et al., 2009; 
Lee, 2013; Olanow & Brundin, 2013; Volpicelli-Daley et al., 2011). Further evidence for this 
propagation is provided by post-mortem studies of PD patients who had striatal human foetal 
cell transplants 11 to 16 years prior to death (Kordower et al., 2008; Li et al., 2008; Li et al., 
2010). Li and colleagues (2010) reported that 2 to 5% of 12 to 16 year old grafted 
dopaminergic neurons contained alpha-synuclein immunoreactive Lewy bodies. Undoubtedly, 
Lewy pathology is evident in the host striatum surrounding transplanted human foetal cells 
(Kordower et al., 2008; Li et al., 2008; Li et al., 2010) and thus further supports the hypothesis 
that PD pathology propagates from neuron-to-neuron. Interestingly, it has been demonstrated 
that a higher degree of microglial activation, and hence increased neuroinflammation, occurs 
in these grafts compared with host striatum or SN (Hirsch & Hunot, 2009; Kordower et al., 
2008).  
 
1.2.1   Neuroinflammation 
Neuroinflammation is a key contributor to the neurodegenerative processes in PD and 
Alzheimer’s disease, as well as multiple sclerosis (Gyoneva et al., 2014). In PD, 
neuroinflammation may facilitate the neuron-to-neuron spread of Lewy inclusions (Tomé et 
al., 2013). Factors influencing the development of inflammation include alpha-synuclein 
protein aggregation, mitochondrial dysfunction and increased levels of oxidative species 
(Hirsch & Hunot, 2009; Kordower et al., 2008; Taylor et al., 2013). In the CNS, these cause the 
activation of resident microglia and astrocytes, increased levels of inflammatory mediators 
such as cytokines and chemokines, and an infiltration of CD4+ and CD8+ T-cell lymphocytes 
into nervous tissue in an attempt to resolve the conspirator of the inflammation (Collins et al., 
2012; Hirsch & Hunot, 2009; Perry et al., 2010). The normal function of these glial cells, 
especially the microglia, is to maintain an inflammatory homeostasis within the CNS (Gyoneva 
et al., 2014). However, persistent inflammatory stimuli can lead to the overproduction of pro-
inflammatory factors potentiating neuronal damage through the generation of reactive oxygen 
species, particularly superoxide and hydrogen peroxide (Keane et al., 2011; Taylor et al., 2013). 
Mitochondrial dysfunction and oxidative stress exist in unison, further promoting the 
detriment of the other. In brief, mitochondrial outer membrane permeabilisation occurs in 
response to intracellular stress eventually leading to over generation of reactive oxygen 
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species and the release of cytochrome c, and other apoptotic-initiating proteins normally 
contained within the mitochondria, into the cytoplasm which then form a multiprotein 
complex that triggers the caspase-9 to caspase-3 proteolytic cascade (Galluzzi et al., 2011). 
Furthermore, dopamine metabolises into hydrogen peroxide and decreased activity of 
mitochondrial complex I sub units overwhelms cells with superoxide (Hauser & Hastings, 
2013), thus increasing the likelihood of accumulation of reactive oxygen species and 
intracellular stress within dopaminergic neurons. Indeed, decreased activity of the 
mitochondrial complex I sub units is observed in the SN and frontal cortex of people with PD 
(Hauser & Hastings, 2013; Henchcliffe & Beal, 2008). Therefore, dopaminergic neurons, as well 
as other long and slender projections neurons (Del Tredici & Braak, 2012), are particularly 
vulnerable to oxidative damage and apoptosis. 
Oxidative stress is a cytotoxic condition that occurs when there is an overproduction or 
accumulation of reactive oxygen species within the cell thereby causing reduced electron 
transfer rates through mitochondrial complex I subunits (Hauser & Hastings, 2013; Henchcliffe 
& Beal, 2008; Taylor et al., 2013). Oxidative damage to endogenous alpha-synuclein within 
dopaminergic neurons can result in protein aggregation, an effect that might partially explain 
the cellular toxicity of the protein (Henchcliffe & Beal, 2008). Moreover, intracellular 
accumulation of alpha-synuclein protein promotes oxidative damage as well as encouraging 
the mitochondria to release cytochrome c into the cytoplasm (Henchcliffe & Beal, 2008).  
Endogenous alpha-synuclein is thought to function as a chaperone molecule in neurons with 
the primary role of maintaining the proteins that constitute soluble N-ethylmaleimide-
sensitive factor attachment protein receptor (SNARE)-complexes (Volpicelli-Daley et al., 2011). 
SNARE complexes are involved in the exocytosis of neurotransmitters at the presynaptic 
terminal, and repeated release of neurotransmitters requires cycles of SNARE-complex 
assembly and disassembly (Burré et al., 2010). However, mice that overexpress alpha-
synuclein have swollen and morphologically abnormal mitochondria, whereas knockout mice 
models demonstrate increased resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP), a neurotoxin with similar mode of action as rotenone, through modulation of 
mitochondrial complex I activity (Henchcliffe & Beal, 2008). Therefore, alpha-synuclein may 
somehow be involved in chaperoning these environmental toxins to the mitochondria or other 
parts of the cell that then promote intracellular stress.  
When stressed dopaminergic neurons release neuromelanin into the surrounding tissue, it 
disrupts homeostasis and causes the activation of microglia (Collins et al., 2012; Perry et al., 
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2010) and other inflammatory mechanisms. Once activated, the microglia retract their 
processes that normally penetrate the surrounding three-dimensional space in a ‘resting’ 
state, and move in an amoeboid-like fashion to areas of insult, with persistent 
neuroinflammation causing the microglia to become phagocytic (Gyoneva et al., 2014; 
Kettenmann et al., 2011; Tansey & Goldberg, 2010). Interestingly, activated microglial cells are 
one of the biggest producers of reactive oxygen species in the CNS and thus promote further 
oxidative stress and neuronal damage when chronic stimuli are present (Kettenmann et al., 
2011; Taylor et al., 2013). Furthermore, microglia are rarely replaced, have a long lifespan, and 
as such, are involved in many age-related neurodegenerative diseases (Gyoneva et al., 2014; 
Tansey & Goldberg, 2010). The release of neuromelanin also stimulates the pro-inflammatory 
cytokines, such as tumour-necrosis-factor alpha (TNF-α) and interleukin 6 (IL-6), that 
perpetuate chronic neuroinflammation. 
 
1.2.2   Systemic Inflammation 
Although neuroinflammation was originally thought to be isolated from the periphery, it is 
now known that a bi-directional interaction occurs between the CNS and peripheral immune 
systems. Microglia are suggested to engage peripheral immune cells to act on the brain 
resulting in an interplay between their phenotypes (Sanchez-Guajardo et al., 2013). Takeda 
and colleagues (2014) summarised these interaction pathways as the vagal nerve (the route 
that alpha-synuclein propagates from the ENS to the CNS), the circumventricular organs which 
lack a proper blood-brain-barrier (BBB), such as the neurohypophysis and pineal gland, and 
direct infiltration of monocytes and inflammatory lipid mediators, such as prostaglandins, 
through the BBB. Mice models of neuroinflammation demonstrate these interactions by 
exhibiting activated microglia that respond more slowly to tissue damage compared with 
healthy mice following systemically administered lipopolysaccharide (Gyoneva et al., 2014). 
Importantly, the BBB in Alzheimer’s disease brains is increasingly permeable to peripheral 
immune cells due to protein aggregation within the CNS (Takeda et al., 2014). Therefore the 
study of systemic inflammation in Alzheimer’s disease and PD may provide important 
information about the neurodegenerative process. 
Systemic inflammation is evident due to increased levels of pro-inflammatory cytokines, 
particularly IL-6 and TNF-α, and may contribute to the progression of PD (Collins et al., 2012; 
Perry et al., 2010; Reale et al., 2009; Sanchez-Guajardo et al., 2013). However, these profile 
alterations appear to be associated with the non-motor symptoms of PD and other diseases 
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with neuroinflammatory processes. Increased TNF-α is associated with cognitive decline in PD 
and Alzheimer’s disease (Holmes et al., 2009; Menza et al., 2010; Reale et al., 2009). 
Additionally, plasma levels of both soluble TNF-α receptors (sTNFR1 and sTNFR2) are increased 
in PD patients (Rocha et al., 2014), and certain single nucleotide polymorphisms (SNPs) in the 
TNF promoter are associated with PD (Sanchez-Guajardo et al., 2013). Increased levels of IL-6 
are also associated with poorer performance in cognitive tasks in multiple sclerosis patients 
(Patanella et al., 2010) and an increased risk of all-cause dementia (Koyama et al., 2012). 
Increased levels of interferon gamma (INF-γ) (Reale et al., 2009) and C-reactive protein (CRP) 
(Koyama et al., 2012) are implicated in PD and all-cause dementia, respectively. Indeed, 
increased levels of systemic pro-inflammatory cytokines are correlated with chronic 
neurodegeneration. Thus, it is reasonable to consider that profiling of blood plasma cytokines 
and other inflammatory markers could provide a valid and non-invasive means of assessing 
neuroinflammation in relation to PD. 
Cytokines are communicative biomolecules that influence other inflammatory mediators and 
immunoglobulin-producing B-cell lymphocytes in the body. The immunoglobulins are a group 
of glycoproteins involved in adaptive immunity that account for approximately 20% of all 
plasma proteins, among which IgG is the most abundant. Lewy bodies and about a third of 
dopaminergic neurons within the SN show strong immunolabelling for IgG (Sanchez-Guajardo 
et al., 2013). In fact the proportion of immunolabelled neurons within PD patient’s brains has 
been demonstrated to be positively associated with the number of activated microglia and 
negatively associated with the number of dopaminergic neurons in the SN (Sanchez-Guajardo 
et al., 2013). Thus, surface coating of IgG may be indicative of degradation early in the disease 
process (Sanchez-Guajardo et al., 2013). Additionally, immunoglobulins against alpha-synuclein 
are not only found in the cerebral spinal fluid (CSF) of familial PD patients, but also in their 
blood plasma (Sanchez-Guajardo et al., 2013), supporting the hypothesis of a bi-directional 
interaction between the CNS and the periphery. 
IgG is involved in the innate and adaptive immune systems, has the ability to exert both anti- 
and pro-inflammatory responses throughout the body, and to infiltrate the CNS. IgG consist of 
two light and two heavy polypeptide chains which are joined by covalent bonds to form a “Y” 
shaped structure (see Fig. 1). There are four classes of IgG within humans and each differs in 
their heavy chains, and therefore the fragment crystallising (Fc) portion (Anthony et al., 2012). 
The N-glycans of the Fc portion control the inflammatory properties of IgG.  The attached N-
glycans are structurally important; IgG lacking Fc N-glycans have a closed conformation which 
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may hinder Fcγ-receptor (Fcγ-R) binding (Krapp et al., 2003). The monosaccharides that form 
the attached N-glycans alter IgG effector function by changing the conformation of the Fc 
fragment and the affinity for a number of receptors, such as the affinity of IgG-Fc for Fcγ-RIIIa 
and the classical complement component C1q (Krapp et al., 2003; Nimmerjahn et al., 2007; 
Shade & Anthony, 2013). Although originally thought of as being a result of enzymatic 
competition due to studies in vitro, the biosynthesis of the attached N-glycans is a predesigned 
outcome fitted to the needs of the producing B-cell lymphocyte (Pucic et al., 2011) under the 
influence of its cellular environment, including numerous cytokines and other modulating 
factors (Wang et al., 2011). This makes the study of these glycan moieties biologically 
important in terms of the contribution of IgG to inflammation in the pathogenesis of PD. 
 
 
 
Figure 1: Structure of the IgG glycoprotein. The purple domains represent the heavy chains (‘H’) and the orange 
domains represent the light chains (‘L’). Further, the IgG glycoprotein has two portions that infer different 
properties; the fragment antigen-binding (Fab) and fragment crystallising (Fc) portions. The Fab and Fc portions are 
connected by a hinge region containing disulphide bonds. The Fab portion contains the antigen binding cleft and 
with its variable regions (VL and VH) is responsible for recognising and attaching to specific antigens. The Fc portion 
contains the glycans within the CH2 domains of both heavy chains, and is responsible for effector functions by 
binding to Fc receptors (FcR’s) on natural killer and other inflammatory cells. Changes to the attached glycan 
moieties can significantly alter effector function of the IgG glycoprotein.   
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1.2.3   N-glycans of IgG 
Of the many types of post-translational modification, N-glycosylation is the most abundant 
(Horvat et al., 2011; Lu et al., 2011; Robinson et al., 2012; Zhang et al., 2012). Many plasma 
proteins are modified by covalently-bound glycans that are biologically important for normal 
physiological processes, including; the folding (Robinson et al., 2012) and function of proteins 
(Yamaguchi et al., 2012; Zhang et al., 2012), cell-to-cell adhesion and communication (Horvat 
et al., 2011; Lauc & Zoldo, 2010; Lu et al., 2011; Nelson et al., 2008), self-recognition in 
immune response (DeMarco & Woods, 2008; Lauc & Zoldo, 2010; Nelson et al., 2008), lectin 
binding (Blow, 2009; Lauc & Zoldo, 2010; Nelson et al., 2008), and resistance to proteolysis 
(Yamaguchi et al., 2012; Zhang et al., 2012). Moreover, N-glycans are essential for life as life 
cannot sustain past the embryonic stage if absent, and congenital disorders of glycosylation 
exist (Knezevic et al., 2009; Pucic et al., 2010). An altered glycan can change the structure and 
function of the whole glycoprotein, and it is believed that this may account for much of the 
phenotypic variation in humans (Horvat et al., 2011; Knezevic et al., 2009). There are three 
major structural types of N-glycans; high mannose, complex, and hybrid  
(Fig. 2). Although all types can occur, the vast majority of IgG-Fc N-glycans are of the complex 
type (Krištić et al., 2014; Pucic et al., 2011). 
 
 
 
Figure 2: Three major structural types of N-glycans.  
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N-glycans are biosynthesised sequentially (see Fig. 3) on dolichol pyrophosphate donor 
molecules using a combination of hundreds of genes that code for glycosyltransferases, 
glycosidases and sugar nucleotides (Horvat et al., 2011; Knezevic et al., 2009). They then 
covalently bind to the nitrogen of asparagine (Asn) residues on the terminus of the 
polypeptide at the recognition sequence Asn-X-Ser/Thr, whereby X is any amino acid except 
proline and ends with serine (Ser) or threonine (Thr) (Horvat et al., 2011; Knezevic et al., 2009; 
Robinson et al., 2012; Zhang et al., 2012). N-glycan biosynthesis occurs in a step-wise fashion, 
commencing on the membrane of the endoplasmic reticulum (see Fig. 3, step 1). Here, two N-
acetylglucosamine (GlcNAc) and five mannose sugar nucleotides are assembled onto the 
dolichol pyrophosphate donor molecule on the cytoplasmic side of the endoplasmic reticulum 
membrane, and subsequently the whole structure flips so that it is on the luminal side of the 
membrane (see Fig. 3, step 2; Taylor & Drickamer, 2011). A further four mannose and three 
glucose (Glc) sugar nucleotides are added before the dolichol-bound precursor glycan is 
transferred to an Asn recognition sequence by oligosaccharyltransferase (see Fig. 3, step 5; 
Taylor & Drickamer, 2011). The polypeptide is then folded into its respective protein and, 
following removal of the three Glc via two trimming steps, the glycoprotein is transferred to 
the cis portion of the Golgi apparatus for further processing (see Fig. 3, step 6-7; Nelson et al., 
2008; Taylor & Drickamer, 2011; Varki et al., 2009). Different glycosidases and 
glycotransferases remove and add, respectively, different sugar nucleotides throughout the 
processing steps in the Golgi apparatus, from the cis Golgi to the trans Golgi (see Fig. 3, step 
8). Subsequently, the final IgG is secreted or delivered to the plasma membrane of the B-cell 
lymphocyte (see Fig. 3, step 9).  
IgG, transferrin and fibrinogen are the most prevalent glycoproteins in the plasma proteome. 
IgG has been studied extensively as its glycan moieties are known to have a downstream 
influence on effector functions; that is, whether it is anti-inflammatory or pro-inflammatory. 
Effector function of an IgG is controlled by the attachment of an N-glycan to the Fc portion at 
Asn-297 on both heavy chains in the CH2 domain (see Fig. 1). The majority of these N-glycans 
are complex biantennary structures (see Fig. 2), however a high degree of heterogeneity exists 
due to the presence or absence of sugar nucleotides (Pucic et al., 2010; Zhang et al., 2012). In 
total, over 30 IgG glycoforms have been identified (Arnold et al., 2007; Shade & Anthony, 
2013) and the two glycan moieties that attach to a single IgG in the Fc portion may vary 
leading to greater variability in effector function (Nimmerjahn et al., 2007). The most prevalent 
IgG glycoforms are pictured in Appendix 1. As previously mentioned, the biosynthesis of the 
attached N-glycans is a predesigned outcome fitted to the needs of the producing B-cell 
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lymphocyte. Indeed, even alterations to the IgG-Fc N-glycan moieties that appear structurally 
minute can significantly change the affinity of IgG to different receptors (see Fig. 4). 
Changes in IgG glycosylation are associated with a number of chronic diseases, including: 
rheumatoid arthritis (Gindzienska-Sieskiewicz et al., 2007; Malhotra et al., 1995; Troelsen et 
al., 2012), metabolic syndrome (Lauc et al., 2013; Lu et al., 2011), inflammatory bowel disease 
(Lauc et al., 2013; Nakajima et al., 2011), systemic lupus erythematosus (Lauc et al., 2013), 
haematological cancers (Lauc et al., 2013), thyroid cancer (Chen et al., 2012), gastric cancer 
(Kodar et al., 2012), lung cancer (Chen et al., 2013), ovarian cancer (Saldova et al., 2007), 
multiple sclerosis (Lauc et al., 2013), and more recently Alzheimer’s disease and progressive 
MCI (Lundström et al., 2014). The most studied glycosylation trait in IgG is the lack of terminal 
galactose and sialic acid residues; i.e. agalactosylated IgG-Fc glycoforms. Agalactosylated IgG 
has been linked to an array of chronic diseases, such as rheumatoid arthritis and systemic 
lupus erythematosus. In fact, a marked increase in agalactosylated IgG in rheumatoid arthritis 
patients was one of the first glycan biomarker discoveries (Arnold et al., 2007). Following this 
discovery, Malhotra et al. (1995) demonstrated that amassed agalactosylated IgG had a high 
affinity to the lectin mannose-binding protein (MBL). An increase in agalactosylated IgG is also 
associated with advancing age (Pucic et al., 2011; Ruhaak et al., 2010).  
The addition of N-acetylneuraminic acid, hereafter referred to as sialic acid, to the terminating 
end of the IgG-Fc N-glycan has a similar anti-inflammatory effect to the addition of core fucose 
(Scallon et al., 2007). Sialylated IgG-Fc N-glycans have a lower affinity for Fcγ-RIIIa on natural 
killer cells leading to an anti-inflammatory effect (Böhm et al., 2012; Scallon et al., 2007). 
Anthony (2011) postulated that the mechanism by which sialylated, particularly α2-6 
sialylated, IgG-Fc glycans can have an anti-inflammatory effect is by binding dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), a C-type lectin 
which is present on dendritic cells, to the protein portion of the IgG-Fc which causes the 
production of more FcγRIIb receptors on natural killer cells. FcγRIIb are inhibitory receptors 
that act to reduce inflammation by preventing the activation of FcγRIIIa and other excitatory 
receptors (Anthony, 2011). However, it has not been reported whether its absence leads to 
such a high increase in antibody-dependent cell cytotoxicity (ADCC) as seen with the lack of 
core fucose.  
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Figure 3: A summary of the biosynthesis of IgG glycoprotein. ① N-glycan biosynthesis begins on the endoplasmic 
reticulum membrane where two N-acetylglucosamines (UDP-GlcNAc) and five mannose (GDP-Man) sugar 
nucleotides are attached to a dolichol-phosphate (Dolichol-P) donor molecule on the cytoplasmic side. ② The 
whole Dolichol-P attached N-glycan is flipped so it is on the luminal side of the endoplasmic reticulum. ③ Dolichol-
P flips individual sugar nucleotides from the cytoplasm to the lumen. ④ In tandem, the ribosomes biosynthesise 
the polypeptide structure of the IgG. ⑤ Oligosaccharyltransferase transfers N-glycan moiety from Dolichol-P to 
Asparagine (Asn) 297 on the growing polypeptide. ⑥ Following the correct folding of the IgG heavy chain, three N-
acetylglucosamines sugarnucelotides are removed and this signals the transfer of the IgG heavy chain from the 
endoplasmic reticulum to the Golgi apparatus. ⑦-⑧ The IgG components move through the Golgi apparatus 
where different glycosyltransferases and glycosidases add and remove (respectively) different sugar nucleotides to 
the glycan moiety. ⑨ All four components of the IgG, two heavy chains (purple) and two light chains (orange), are 
assembled following excretion from the trans Golgi, with the final IgG glycoprotein been secreted from the B-cell 
lymphocyte or attaching to the plasma membrane of the B-cell.  
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Figure 4: Effector functions caused by modifications to IgG glycosylation. 
 
 
A lack of core fucose leads to a 100-fold increase in ADCC making these IgG more pro-
inflammatory (Shields et al., 2002). Conversely, the addition of fucose to the asparagine-
attached core N-acetylglucosamine (GlcNAc) of the IgG-Fc N-glycan has an anti-inflammatory 
effect by inhibiting Fcγ-RIIIa receptor binding (Shields et al., 2002). Fcγ-RIIIa are expressed on 
the surface of natural killer cells (Pucic et al., 2011) and have a role in initiating ADCC (Shields 
et al., 2002). Previous studies (Lauc et al., 2013; Pucic et al., 2011) have shown that the vast 
majority of IgG N-glycans are core fucosylated, hence they are designed to inhibit ADCC 
activation subsequent to many IgG binding to an antigen (via the antigen-binding cleft;  
see Fig. 1). However, structural analysis of the IgG-Fc/FcγRIIIa complex has demonstrated that 
specific glycans on FcγRIIIa are also essential for the effect of core fucose (Ferrara et al., 2011). 
The presence of a bisecting GlcNAc has also been associated with enhanced ADCC activation 
via Fcγ-RIIIa binding (Zou et al., 2011) but to a lesser degree than the absence of core fucose 
(Shields et al., 2002). 
Mannose-rich glycans have an increased affinity for MBL which initiates the lectin complement 
cascade via opsonisation of IgG and the cells to which they are bound (Fujita, 2002; Malhotra 
et al., 1995). Both mannose and GlcNAc (GlcNAc to a lesser degree than mannose) are 
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prominent ligands for MBL and are usually found on the surface of pathogens, such as bacteria 
and viruses (Fujita, 2002; Maupin et al., 2012). Other monosaccharides, such as sialic acid and 
galactose, normally decorate mammalian glycoproteins and have undetectable affinity for MBL 
(Fujita, 2002; Maupin et al., 2012). This enables the specific recognition of glycans on pathogen 
cell surfaces. However, this innate immunity system can malfunction and has been implicated 
in many disease processes due to an increase in agalactosylated and mannose-rich N-glycans. 
In rheumatoid arthritis, MBL recognises clusters of agalactosylated IgG within the synovial 
joints and activates the lectin complement cascade which contributes to inflammation by 
damaging the surrounding tissue (Arnold et al., 2007). Additionally, an increase in 
agalactosylated N-glycans is correlated with an increase in disease severity in rheumatoid 
arthritis patients (Malhotra et al., 1995). Therefore, both IgG with high-mannose glycans and 
agalactosylated glycans could cause an increased activation of complement-caused 
inflammation. 
Glycan biomarkers used for Alzheimer’s disease have already been researched, with some 
examples of success (Angata et al., 2012; Chen et al., 2010; Lundström et al., 2014; Rensburg 
et al., 2004). In the case of PD and PD dementia, both age and disease related glycan 
biomarkers would be useful. One of the main risk factors for PD and PD dementia is age, 
suggesting that evidence of early ageing in the glycome may be connected to PD presence. 
Also, motor impairments are thought to be apparent at stage three to four of the Braak staging 
hypothesis (Braak, Bohl, et al., 2006; Braak et al., 2003), and mild cognitive symptoms are 
frequently present at the time of diagnosis, thus increasing the risk of progression to dementia 
(Shi et al., 2010). The variability seen in the glycome could provide novel glycan biomarkers for 
PD, not just detecting disease presence but also differentiating between subtypes and 
predicting progression to cognitive impairment. 
 
 
 1.3   Overview, Specific Aims and Hypotheses 
Studies on genetically complex diseases, such as idiopathic PD, have led to discoveries of gene 
mutations that increase the risk of disease development. However, the contribution of these 
risk gene mutations to disease development in certain people but not others is less known. It is 
evident that an interaction between the genome and the environment exists. Glycomics is 
emerging as a prominent field of science in the quest for biomarker discovery, and 
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modifications to the glycosylation of many proteins, including IgG, are proposed to contribute 
to the holistic picture of a disease phenotype. Solely, these modifications will provide an 
interphenotype of disease: a link between the genome, the environment and the disease 
phenotype.  
 
Study 1 – IgG N-glycans as a Novel Biomarker of Disease Presence 
Aim: To identify changes in the peripheral IgG glycome in a PD patient cohort compared with 
an age- and gender-matched control cohort representative of a ‘normally’ aged population 
that represent an interphenotype of the disease.  
Therefore, the hypotheses are: 
• The peripheral IgG glycome profile will be different in people with PD compared with a 
control population. 
• Modifications to the peripheral IgG glycome in people with PD will be pro-
inflammation in nature.   
 
Study 2 – Utility of IgG N-glycans in Identifying Risk of Cognitive Decline 
Aim: To determine whether the peripheral IgG glycome has utility in identifying risk of 
cognitive decline in people with PD. 
Therefore, the hypotheses are: 
• Modifications to the peripheral IgG glycome profile will reflect different clinical motor 
subtypes of PD, specifically the PIGD motor subtype which infers a high risk of 
cognitive impairment. 
• Modifications to the peripheral IgG glycome profile will be different in people with PD 
who have semantic fluency impairment, and hence are at a high risk of developing 
cognitive impairment.  
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2.0   Methods 2.1   Study Samples 
2.1.1   Ethics Approval 
Before participating in the larger cohort studies, all individuals gave informed consent. This 
including consenting to their de-identified data and blood samples being used in related 
studies. The longitudinal ParkC study was approved by the Edith Cowan University Human 
Research Ethics Committee [Project 2736], and the larger study of the control group was 
approved by the appropriate Ethics Board of the University of Zagreb Medical School, Croatia. 
This thesis conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was 
approved by the Edith Cowan University Human Research Ethics Committee [Project 9927]. 
 
2.1.2   Participants 
In total, the plasma samples of 196 participants were utilised in this study; 94 PD cases and 
102 individuals as a matched control group.  
The PD cases are a subgroup of the Parkinson’s Centre (ParkC) ongoing community-based 
longitudinal study (n=243) investigating the “cognitive and motor heterogeneity in idiopathic 
Parkinson’s disease” (Bucks et al., 2011; Cruise et al., 2011). As part of the study participants 
are asked to complete a demographic questionnaire as well as numerous validated 
questionnaires assessing mood, sleep, quality of life, cognitive assessments and a motor 
assessment.  Participants are given the option to provide a sample of their blood for genetic 
and related analyses, and hence there was no control on the final number of PD cases 
obtained. 
The control participants were age- and gender-matched to the PD cases and are a part of a 
larger longitudinal study (n=969), described elsewhere (Knezevic et al., 2009). The controls 
represent a ‘normally-aged’ comparative Caucasian population in this study, with some 
individuals who have mild to chronic diseases other than dementia included among the 
healthy. This information was considered in the interpretation of the results. 
 
2.1.3   Acquired Data 
De-identified data from both cohorts was provided for this study including: age, gender, height 
and weight, and comorbidities. Specific comorbidities acquired from each cohort were slightly 
24 
 
different and as such were not comparable. Hence, they are not reported here. However, the 
fact that comorbidities existed within each cohort is worth mentioning.  
Further information provided on the subset of ParkC participants included: age at clinical PD 
diagnosis, animal naming task score, and raw MDS-UPDRS data. This information was utilised 
in Study 2.  
 
2.1.4   Collection of Blood Samples 
Blood samples were collected, processed and stored in the freezer at -80°C until analysis. 
Plasma (50 µL) was used for glycan analysis by ultra performance liquid chromatography 
(UPLC).  
 2.2   Glycan Analysis 
2.2.1   Site of Analysis 
The analysis of the plasma IgG glycans was outsourced to Genos, Ltd; a research-intensive 
small to medium enterprise based in Zagreb, Croatia. Genos Ltd has expertise in molecular 
genetics and glycomics. They perform contract research, analysis and service for universities, 
hospitals and private individuals within Europe and overseas. The following are the procedures 
(entire section 2.2 Glycan Analysis) used for the analyses in the study, which have been used 
previously by Genos Ltd (Knezevic et al., 2009; Lauc et al., 2013; Pucic et al., 2011). 
 
2.2.2   IgG Isolation 
Plasma samples (50 μL) were diluted 10 × with binding buffer and applied to the 96-well 
Protein G monolithic plate (BIA Separations, Ajdovščina, Slovenia; Pucic et al., 2011). The plate 
was then washed five times with 5 column volumes of binding buffer (1X PBS, pH 7.4) to 
remove unbound proteins. IgG was released from the protein G monoliths using 5 column 
volumes of elution solvent (0.1 M formic acid, pH 2.5). Eluates were collected in a 96-deep-
well plate and immediately neutralised to pH 7.0 with neutralisation buffer (1 M ammonium 
bicarbonate) to maintain the IgG stability.  
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2.2.3   N-glycans Release and Labelling 
Isolated IgG samples were dried in a vacuum centrifuge. After drying, proteins were denatured 
with the addition of 30 μL 1.33% sodium dodecyl sulfate (w/v) (Invitrogen, Carlsbad, CA, USA) 
and incubated at 60 °C for 10 min. Subsequently, 10 μL 4% Igepal-CA630 (Sigma-Aldrich, St. 
Louis, MO, USA) and 0.5 mU of PNGase F (ProZyme, Hayward, CA) in 10 μL 5× PBS were added 
to the samples. The samples were incubated overnight at 37 °C for N-glycan release. 
The released N-glycans were subsequently labelled with 2-aminobenzamide (2-AB). The 
labelling mixture was freshly prepared by dissolving 2-AB (Sigma-Aldrich, St. Louis, MO, USA) in 
dimethyl sulphoxide (DMSO; Sigma-Aldrich, St. Louis, MO, USA) and glacial acetic acid (Merck, 
Darmstadt, Germany) mixture (17:3 (v/v)) to a final concentration of 48 mg/mL. A volume of 
25 μL of labelling mixture was added to each N-glycan release sample in the 96-well plate. 
Also, 25 μL of freshly prepared reducing agent solution (2-picoline borane (Sigma-Aldrich, St. 
Louis, MO, USA) in DMSO – concentration of 106.96 mg/ml) was added and the plate was 
sealed using adhesive tape. Mixing was achieved by shaking for 10 min, followed by incubation 
at 65 °C for 2 hr. Samples were brought to 80% acetonitrile (ACN) (v/v) by adding 400 μL of 
ACN (J.T. Baker, Phillipsburg, NJ). 
 
2.2.4   Cleaning and Elution of Labelled Glycans using Hydrophilic Interaction 
Chromatography - Solid Phase Extraction (HILIC-SPE) 
Free label and reducing agent were removed from the samples using HILIC-SPE. An amount of 
200 μL of a 0.1 g/mL suspension of microcrystalline cellulose (Merck, Darmstadt, Germany) in 
water was applied to each well of a 0.45 μm GHP filter plate (Pall Corporation, Ann Arbor, MI, 
USA). Solvent was removed by application of vacuum using a vacuum manifold (Millipore 
Corporation, Billerica, MA, USA). All wells were prewashed using 5 × 200 μL water, followed by 
equilibration using 3 × 200 μL acetonitrile/water (80:20, v/v). The samples were loaded in to 
the wells and subsequently washed 7 × using 200 μL of acetonitrile/water (80:20, v/v). 
Glycans were eluted 2 × with 100 μL of water and combined eluates were stored at –20 °C until 
analysis. 
 
2.2.5   Ultra-Performance Liquid Chromatography (UPLC) 
Fluorescently labelled N-glycans were separated by UPLC on a Waters Acquity UPLC 
instrument (Waters, Milford, MA) consisting of a quaternary solvent manager, sample 
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manager and a FLR fluorescence detector set with excitation and emission wavelengths of 330 
nm and 420 nm, respectively. The UPLC instrument utilised Empower 2 software (Waters, 
Milford, MA). Labelled N-glycans were separated on a Waters BEH Glycan chromatography 
column, 100 × 2.1 mm i.d., 1.7 μm BEH particles, with 100 mM ammonium formate, pH 4.4, as 
solvent A and acetonitrile as solvent B. The UPLC separation method used a linear gradient of 
75–62% acetonitrile at a flow rate of 0.4 ml/min in a 25 min analytical run. Samples were 
maintained at 5 °C before injection, and the separation temperature was 60 °C.  
The system was calibrated using an external standard of hydrolyzed and 2-AB labelled glucose 
oligomers from which the retention times for the individual glycans were converted to glucose 
units. Data processing was performed using an automatic processing method with a traditional 
integration algorithm after which each chromatogram was manually corrected to maintain the 
same intervals of integration for all the samples.  
The chromatograms obtained were all separated in the same manner into 24 glycan peaks for 
the total glycome and 15 peaks in the neutral glycome. The neutral glycome is the sum of all 
the neutral glycans in the total glycome, i.e. GPn total = Σ GP1:15 raw values. The relative 
abundances of glycan peak (GP) were normalised to the total integrated area, e.g. GP1 = GP1 
raw value / GP total * 100.  
 
2.2.6   Derived Traits 
Derived traits were approximated from the ratios of glycan peaks, as previously described 
(Pucic et al., 2011). The minor glycan peak GP3 was excluded from all the calculations because 
in some samples it co-eluted with a contaminant that significantly affected its value.  
Derived traits were defined as: the percentage of sialylation of fucosylated galactosylated 
structures without bisecting GlcNAc in total IgG glycans, FGS/(FG + FGS) = SUM(GP16 + GP18 + 
GP23)/SUM(GP16 + GP18 + GP23 + GP8 + GP9 + GP14)* 100; the percentage of sialylation of 
fucosylated galactosylated structures with bisecting GlcNAc in total IgG glycans, FBGS/(FBG + 
FBGS) = SUM(GP19 + GP24)/SUM(GP19 + GP24 + GP10 + GP11 + GP15)* 100; the percentage 
of sialylation of all fucosylated structures without bisecting GlcNAc in total IgG glycans, FGS/(F 
+ FG + FGS) = SUM(GP16 + GP18 + GP23)/SUM(GP16 + GP18 + GP23 + GP4 + GP8 + GP9 + 
GP14)* 100; the percentage of sialylation of all fucosylated structures with bisecting GlcNAc in 
total IgG glycans, FBGS/(FB + FBG + FBGS) = SUM(GP19 + GP24)/SUM(GP19 + GP24 + GP6 + 
GP10 + GP11 + GP15)* 100; the percentage of monosialylation of fucosylated 
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monogalactosylated structures in total IgG glycans, FG1S1/(FG1 + FG1S1) = GP16/SUM(GP16 + 
GP8 + GP9)* 100; the percentage of monosialylation of fucosylated digalactosylated structures 
in total IgG glycans, FG2S1/(FG2+FG2S1+FG2S2) = GP18/SUM(GP18 + GP14 + GP23)* 100; the 
percentage of disialylation of fucosylated digalactosylated structures in total IgG glycans, 
FG2S2/(FG2 + FG2S1 + FG2S2) = GP23/SUM(GP23 + GP14 + GP18)* 100; the percentage of 
monosialylation of fucosylated digalactosylated structures with bisecting GlcNAc in total IgG 
glycans, FBG2S1/(FBG2 + FBG2S1 + FBG2S2) = GP19/SUM(GP19 + GP15 + GP24)* 100; the 
percentage of disialylation of fucosylated digalactosylated structures with bisecting GlcNAc in 
total IgG glycans, FBG2S2/(FBG2 + FBG2S1 + FBG2S2) = GP24/SUM(GP24 + GP15 + GP19)* 100; 
ratio of all fucosylated (± bisecting GlcNAc) monosialylated and disialylated structures in total 
IgG glycans, FtotalS1/FtotalS2 = SUM(GP16 + GP18 + GP19)/SUM(GP23 + GP24); ratio of 
fucosylated (without bisecting GlcNAc) monosialylated and disialylated structures in total IgG 
glycans, FS1/FS2 = SUM(GP16 + GP18)/GP23; ratio of fucosylated (with bisecting GlcNAc) 
monosialylated and disialylated structures in total IgG glycans, FBS1/FBS2 = GP19/GP24; ratio 
of all fucosylated sialylated structures with and without bisecting GlcNAc, FBStotal/FStotal = 
SUM(GP19 + GP24)/SUM(GP16 + GP18 + GP23); ratio of fucosylated monosialylated structures 
with and without bisecting GlcNAc, FBS1/FS1 = GP19/SUM(GP16 + GP18); the incidence of 
bisecting GlcNAc in all fucosylated monosialylated structures in total IgG glycans, FBS1/(FS1 + 
FBS1) = GP19/SUM(GP16 + GP18 + GP19); ratio of fucosylated disialylated structures with and 
without bisecting GlcNAc, FBS2/FS2 = GP24/GP23; the incidence of bisecting GlcNAc in all 
fucosylated disialylated structures in total IgG glycans, FBS2/(FS2 + FBS2) = GP24/SUM(GP23 + 
GP24).  
The following derived traits were approximated only from the ratios of glycan peaks containing 
neutral glycan as a major structure. First, the relative abundance of each neutral glycan peak 
(GP1n - GP15n) was calculated from the total neutral glycan fraction (SUM(GP1:GP15)) and then 
traits were defined as: the percentage of agalactosylated structures in total neutral glycan 
fraction, G0n = SUM(GP1n + GP2n + GP4n + GP6n); the percentage of monogalactosylated 
structures in total neutral glycan fraction, G1n = SUM(GP7n + GP8n + GP9n + GP10n + GP11n); the 
percentage of digalactosylated structures in total neutral glycan fraction, G2n = SUM(GP12n + 
GP13n + GP14n + GP15n); the percentage of all fucosylated (±bisecting GlcNAc) structures in 
total neutral glycan fraction, Fn total = SUM(GP1n + GP4n + GP6n + GP8n + GP9n + GP10n + GP11n + 
GP14n + GP15n); the percentage of fucosylation of agalactosylated structures, FG0n total/G0n = 
SUM(GP1n + GP4n + GP6n)/G0n * 100; the percentage of fucosylation of monogalactosylated 
structures, FG1n total/G1n = SUM(GP8n + GP9n + GP10n + GP11n)/G1n * 100; the percentage of 
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fucosylation of digalactosylated structures, FG2n total/G2n = SUM(GP14n + GP15n)/G2n * 100; the 
percentage of fucosylated (without bisecting GlcNAc) structures in total neutral glycan 
fraction, Fn = SUM(GP1n + GP4n + GP8n + GP9n + GP14n); the percentage of fucosylation 
(without bisecting GlcNAc) of agalactosylated structures, FG0n/G0n = SUM(GP1n + GP4n)/G0n * 
100; the percentage of fucosylation (without bisecting GlcNAc) of monogalactosylated 
structures, FG1n/G1n = SUM(GP8n + GP9n)/G1n * 100; the percentage of fucosylation (without 
bisecting GlcNAc) of digalactosylated structures, FG2n/G2n = GP14n/G2n * 100; the percentage 
of fucosylated (with bisecting GlcNAc) structures in total neutral glycan fraction, FBn = 
SUM(GP6n + GP10n + GP11n + GP15n); the percentage of fucosylation (with bisecting GlcNAc) of 
agalactosylated structures, FBG0n/G0n = GP6n/G0n * 100; the percentage of fucosylation (with 
bisecting GlcNAc) of monogalactosylated structures, FBG1n/G1n = SUM(GP10n + GP11n)/G1n * 
100; the percentage of fucosylation (with bisecting GlcNAc) of digalactosylated structures, 
FBG2n/GP2n = GP15n/G2n * 100; ratio of fucosylated structures with and without bisecting 
GlcNAc, FBn/Fn = FBn/Fn; the incidence of bisecting GlcNAc in all fucosylated structures in total 
neutral glycan fraction, FBn/Fn total = FBn/Fn total * 100; ratio of fucosylated non-bisecting GlcNAc 
structures and all structures with bisecting GlcNAc, Fn/(Bn + FBn) = Fn/(GP13n + FBn); ratio of 
structures with bisecting GlcNAc and all fucosylated structures (± bisecting GlcNAc), Bn/(Fn + 
FBn) (‰) = GP13n/(Fn+ % FBn) * 1000; ratio of fucosylated digalactosylated structures with and 
without bisecting GlcNAc, FBG2n/FG2n = GP15n/GP14n; the incidence of bisecting GlcNAc in all 
fucosylated digalactosylated structures in total neutral glycan fraction, FBG2n/(FG2n + FBG2n) = 
GP15n/(GP14n + GP15n) × 100; ratio of fucosylated digalactosylated nonbisecting GlcNAc 
structures and all digalactosylated structures with bisecting GlcNAc, FG2n/(BG2n + FBG2n) = 
GP14n/(GP13n + GP15n); ratio of digalactosylated structures with bisecting GlcNAc and all 
fucosylated digalactosylated structures (±bisecting GlcNAc), BG2n/(FG2n + FBG2n) (‰) = 
GP13n/(GP14n + GP15n) * 1000. 
 
 2.3   Statistical Analysis 
All analyses were performed using R statistical programming language (R Core Team, 2014) 
through the R studio console (RStudio, 2014). Package details can be found next to each 
mentioned statistical method.  
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2.3.1   Batch Effects 
One often overlooked aspect of high-throughput data analysis is batch effects, defined as 
“…sub-groups of measurements that have qualitatively different behaviour across conditions 
and are unrelated to the biological or scientific variables in the study” (Leek et al., 2010). It 
exists because laboratory conditions, reagents and technicians vary between different batches, 
and can compound the biological effects within the data (Leek et al., 2010).  Blocking, 
organising samples for analysis so there is the same distribution of case/controls, gender or 
age on plates (i.e. plates are comparable), was used to control batch effects within the study 
(for blocking data, see Appendix 3).  
To explore batch effects, data tables were created for each plate that compared case status, 
age and gender. Boxplots were then created for visual inspection of batch effects (see 
Appendix 4) with case status faceted to see whether any common patterns of change existed 
for each individual GP. Principal component analysis (PCA; ‘stats’ package) was performed to 
check for clustering of plate samples. If batch effects existed, the principal components would 
predict groupings that would be according to plates rather than case status.  
 
2.3.2   Study 1: IgG N-Glycans as a Novel Biomarker of PD 
Q-Q plots, created using the ‘qqnorm’ function of the stats package (R Core Team, 2014), were 
employed to test the normality of each variable (participant characteristics, GPs and derived 
traits). Q-Q plots of untransformed variables are in Appendix 5. 
The vast majority of the glycan variables were non-normally distributed. Therefore, log-
transformations were applied to each of the non-normal glycan variables so that parametric 
tests could be utilised (Appendix 6). All variables, with the exception of three, were log-
normal. To qualify for a Students t-test (‘t.test’ function of the stats package with ‘var.equal’ 
argument equal to ‘TRUE’; R Core Team, 2014), the variables must fulfil the assumptions of 
independence, normality and homogeneity of variances. Both groups were independent of 
each other. Therefore, all variables that were normally (or log-normally) distributed were 
subjected to Levene’s test for homogeneity of variances, using ‘leveneTest’ function in the car 
package (Fox & Weisberg, 2011). Results of Levene’s test are in Appendix 7. Student’s t-tests 
could be performed on each GP and derived trait that met these assumption criteria. For 
glycan variables that met assumptions for independence and normality but not 
homoscedasticity, Welch’s t-test (‘t.test’ function of the stats package with ‘var.equal’ 
argument equal to ‘FALSE’; R Core Team, 2014) could be utilised which adjusts the degrees of 
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freedom (df) according to the unequal variances between the independent groups. The non-
parametric equivalent, Mann-Whitney U test (‘wilcox.test’ function in the stats package; R 
Core Team, 2014) was used for comparisons of means of the non-normal glycan variables; 
GP1, GP1n and GP22. The Chi-squared test (‘chisq.test’ function in the stats package; R Core 
Team, 2014) was used for comparing gender frequency in each group.  
Correlation matrices were calculated for both groups independently using the ‘rcorr’ function 
in the Hmisc package (Harrell, 2014). Spearman’s correlation coefficient (rs) was the method 
used as not all variables could be successfully transformed (‘type’ argument of the ‘rcorr’ 
function equal to ‘spearman’). rs is also more robust to strong outliers than the parametric 
equivalent, Pearson’s product-moment correlation coefficient (Niven & Deutsch, 2012). These 
coefficients will provide the effect size of an association.  
To test for statistically significant differences in effect sizes between the independent groups, 
Fisher’s r-to-z transformation was performed for each bivariate correlation, using the 
‘cocor.indep.groups’ function in the cocor package (Diedenhofen, 2013), where there was at 
least a moderate correlation (rs > |0.5|, P < 0.05) in one of the groups. A strong correlation 
was considered to be an rs > |0.7| (P < 0.05).  
Statistical significance was set at P < 8.06 x10-4 for Student’s and Welch’s t-test, Mann-Whitney 
U tests and Spearman’s correlation coefficient for each of the GPs and derived traits. This 
reflects the probability of committing a type I error controlling for multiple testing, i.e. a 𝑃-
value with Bonferroni correction. There were 62 tests of means performed in this study, 
therefore 𝑃 ≤ 0.05
62
≈ 0.000806 (i.e. P < 8.06 x10-4). For Fisher’s r-to-z, P was colour coded for 
values less than 0.05, 0.01 and 0.001 (red, yellow and green, respectively) in the correlation 
matrices (see Appendix 8).  
All graphical representations of the statistics were performed using the ‘ggplot’ function of the 
ggplot2 package in R (Wickham, 2009). 
 
2.3.3   Study 2: Utility of IgG N-Glycans in Identifying Risk of Cognitive Decline 
Non-parametric testing was used to analyse the different GPs and derived traits within the PD 
cases for the evaluated motor subtypes and risk of cognitive decline (animal naming task). 
Kruskal-Wallis one-way analysis of variance (‘kruskal.test’ function of the stats package; R Core 
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Team, 2014) was used to evaluate the variables with two or more groups. Statistical 
significance was set as above at P < 8.06 x10-4 to control for multiple tests of means. 
 
2.3.3.1   Motor Subtype Evaluation  
The MDS-UPDRS parts II and III were used to calculate a clinical motor subtype of PD for the 
purpose of this study, as previously described (Stebbins et al., 2013). Based on the score on 
particular items (0 for normal to 4 for severe), the PD cases were grouped into one of three 
clinical motor subtypes; tremor dominant (TD), postural instability and gait dysfunction (PIGD) 
dominant, or an indeterminate (ID) subtype for those that fell into neither of the TD or PIGD 
motor subtypes.  
Total tremor score was defined as the mean MDS-UPDRS tremor score at the items listed in 
Table 1. Likewise, total PIGD score was defined as the MDS-UPDRS PIGD score at the items 
listed in Table 1.  Motor subtype was classified as PIGD when the ratio total tremor score/total 
PIGD score was equal to or less than 1.0, whereas those with a ratio of 1.5 or more were 
defined as TD. When tremor/PIGD was more than 1.0 and less than 1.5, they were classified as 
an ID. Moreover, participants with a positive mean tremor score in the numerator but a zero 
mean PIGD score in the denominator were classified as TD; participants with a zero mean 
tremor score in the numerator and a positive mean PIGD score in the denominator were 
classified as PIGD; and participants with zeros in both the numerator and denominator were 
classified as ID. 
 
2.3.3.2   Risk of Cognitive Decline  
Semantic fluency dysfunction is associated with a higher risk of cognitive impairment and 
dementia development (Hu et al., 2014; Pereira et al., 2014; Williams-Gray et al., 2009). 
Therefore, the risk of cognitive decline was determined using the animal naming task. Briefly, 
ParkC participants are instructed to name as many types of animals as they can in 60 seconds. 
A single score is given for each correct type of animal. Repetitions or age variants of animals 
(cow, then calf) are two examples of responses that would not receive a score. Full conditions 
and scoring are included as Appendix 2. For this study and similar to a previous study 
(Williams-Gray et al., 2009), impaired semantic fluency was defined as a score less than 20. 
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Hence, a factor was created for statistical analyses whereby those who scored less than 20 had 
a level of ‘0’ and those who scored 20 or more had a level of ‘1’.  
 
 
Table 1: MDS-UPDRS items used to evaluate motor subtype. Mean tremor score is calculated by summing the 
given score at each of the listed tremor items and dividing by 11. Likewise, mean PIGD score is calculated by 
summing the given score at each of the listed PIGD items and dividing by 5. 
Tremor Score Items PIGD Score Items 
MDS-UPDRS Part II 
2.10  Tremor 2.12  Walking and balance 
 2.13  Freezing 
MDS-UPDRS Part III 
3.15  Postural tremor right UE 3.10  Gait 
3.15  Postural tremor left UE 3.11  Freezing of gait 
3.16  Kinetic tremor right UE 3.12  Postural stability 
3.16  Kinetic tremor left UE  
3.17  Rest tremor right UE  
3.17  Rest tremor left UE  
3.17  Rest tremor right LE  
3.17  Rest tremor left LE  
3.17  Rest tremor lip/jaw  
3.18  Rest constancy  
LE: Lower Extremity; PIGD: postural instability and gait disturbance dominant; UE: Upper Extremity. 
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3.0   Results 3.1   Study 1: IgG N-Glycans as a Novel Biomarker of PD 
3.1.1   Participants 
Summary statistics for the participants in this study are shown in Table 2. Controls were 
matched for age and gender; therefore, there was not a statistically significant difference  
(P < 8.06 x10-4) in age (t [194] = 0.4683, P = 0.640) or gender (χ2 [1, n=196] = 0.0048, P = 0.945) 
between the two independent groups (Fig. 5a). However, there was a statistically significant 
difference in BMI (t [194] = 3.7622, P = 0.0002) (Fig. 5b).  
 
 
Figure 5: Stacked bar graphs for summary statistics between groups, a) age and b) BMI. Age is in years. Normal, 
BMI 18 to 25; Overweight, BMI 25 to 30; Obese, BMI above 30. 
 
 
Inspecting the PD cases, there was not a statistically significant difference between the gender 
(χ2 [1, n=337] = 0.002, P = 0.9679) or age at entry to the study (t [1, 335] = 1.0424, P = 0.298) 
between the subgroup and the whole cohort of ParkC participants. Unfortunately height and 
weight data was not available for the entire ParkC cohort. As such, it was not possible to test 
differences in BMI between the subgroup and the whole ParkC cohort.  
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                Table 2: Summary statistics for the participants in the Study 1. 
  PD Cases Controls Between Group Differences 
    t-statistic P-value 
Participants n  94 102    
Age   x� (S) 66.65 (8.99) 67.26 (9.22) 0.4683 0.640 
Gender   n male (%) 65 (69.1%) 71 (69.6%) 0.0048 0.945 
BMI   x� (S) 26.40 (4.76) 28.61 (3.40) 3.7622 0.0002 
*χ2 statistic 
BMI, body mass index; x�, sample mean; S, sample standard deviation 
 
 
3.1.2   Batch Effects 
Summary statistics for each of the plates used for UPLC analysis are shown in Table 3. Blocking 
was performed to randomly place matched-samples on the same plate, i.e. those with the 
same gender and similar age, along with blanks (for blocking data, see Appendix 3). Samples 
were unevenly distributed between the plates; considerably fewer samples were on plate 3 
due to one plate being filled before the next. Boxplots were created for each of the GPs and 
are included as Appendix 4. However, overall there were only mild batch effects and these did 
not appear to translate through the study. 
 
 
                         Table 3: Summary statistics for the distribution of Study 1 samples on plates for UPLC analysis. 
  
Age M  Age  M  x� (S) n (%) x� (S) n (%) 
Plate 1 
PD Case  (n=42) Control  (n=45) 
64.12 (10.82) 26 (61.9%) 65.04 (11.49) 28 (62.2%) 
Plate 2 
PD Case  (n=42) Control  (n=44) 
68.98 (5.89) 30 (71.4%) 69.30 (5.99) 31 (70.5%) 
Plate 3 
PD Case  (n=10) Control  (n=13) 
67.50 (9.35) 9 (90.0%) 68.08 (8.27) 12 (92.3%) 
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PCA was used to explore whether the first two principal components could cluster according to 
plate number (see Fig. 6a), and case status (see Fig. 6b). The first two principal components 
explained 43.84% of the variance in this study. No clustering was seen for plate number in this 
study; however, it appeared that the first two principal components of GP1 to GP24 could be 
used to cluster case status. 
 
 
 
 
Figure 6: Scatters showing the first two principal components in terms of: a) plate number; and b) case status. 
 
 
 
  
a b 
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3.1.3   Case-Control Comparisons 
Overall, 12 GPs and six derived traits in the total and neutral IgG glycome had statistically 
significant differences (P < 8.06 x10-4) between cases and controls on performing Students t-
test.  
In the total IgG glycome, there were seven statistically significant differences (P < 8.06 x10-4) 
between groups. The relative abundances of the following five GPs were significantly lower in 
the PD cases compared to the controls (see Fig. 7 and Table 4):  
• GP5, a high-mannose glycan (t [160.289] = -13.7128, P < 2.2 x10-16);  
• GP17, a biantennary digalactosylated monosialylated glycan (t [163.601] = -13.6209,  
P < 2.2 x10-16);  
• GP20, an unknown glycan structure (t [134.135] = -14.0479, P  < 2.2 x10-16);  
• GP21, a biantennary digalactosylated disialylated glycan (t [149.140] = -9.4946, 
 P < 2.2 x10-16);  
• GP22, a biantennary digalactosylated disialylated glycan with bisecting GlcNAc  
(U = 3142.5, P = 3.046 x10-5).  
The relative abundances of the following two GPs were significantly higher in the PD cases 
compared to the controls (see Table 4):  
• GP8, a biantennary core fucosylated monogalactosylated glycan (t [194] = 5.2345,  
P = 4.279x10-7);  
• GP14, a biantennary core fucosylated digalactosylated glycan (t [194] = 4.2332  
P = 3.275 x10-5).  
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Figure 7: Boxplots showing total glycan peaks (GPs) between PD cases and controls.  
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Table 4: Descriptive statistics for the GPs within the total IgG glycome.  
N-glycan 
peak 
PD cases Controls 
Between Group 
Difference 
Median           
(IQR) Range 
Median           
(IQR) Range 
t-statistic         
*U statistic P - value 
GP1 0.080 (0.040) 0.030 - 0.280 0.080 (0.048) 0.030 - 0.830 4655.5* 0.727 
GP2 0.555 (0.328) 0.130 - 2.090 0.615 (0.575) 0.120 - 2.010 -2.4310 0.016 
GP4 22.120 (5.460) 8.100 - 35.310 23.050 (6.110) 9.440 - 35.070 -2.0661 0.040 
GP5 0.240 (0.075) 0.150 - 0.440 0.410 (0.128) 0.190 - 0.950 -13.7128
# < 2.2 x10-16 
GP6 5.805 (1.773) 2.550 - 10.240 6.415 (2.153) 2.790 - 11.350 -3.3072 0.001 
GP7 0.545 (0.260) 0.230 - 1.460 0.575 (0.340) 0.180 - 0.980 -0.8352 0.405 
GP8 19.030 (2.670) 14.170 - 25.300 17.660 (2.620) 11.830 - 22.700 5.2345 4.279 x10
-7 
GP9 9.885 (1.527) 7.080 - 13.050 9.445 (1.872) 5.080 - 13.620 3.0931 0.002 
GP10 5.945 (1.328) 3.780 - 8.510 5.630 (1.307) 3.490 - 10.160 1.4165 0.158 
GP11 0.880 (0.160) 0.540 - 1.450 0.905 (0.218) 0.580 - 1.670 -3.0866 0.002 
GP12 0.785 (0.518) 0.240 - 3.310 0.745 (0.458) 0.240 - 2.410 0.9122 0.363 
GP13 0.340 (0.080) 0.220 - 0.700 0.340 (0.100) 0.220 - 0.800 -0.9727 0.332 
GP14 12.720 (3.190) 6.180 - 25.470 11.150 (3.208) 5.520 - 20.650 4.2532 3.275 x10
-5 
GP15 1.660 (0.445) 0.930 - 2.860 1.530 (0.358) 0.910 - 2.880 2.8166 0.005 
GP16 2.905 (0.622) 2.020 - 4.630 3.215 (0.788) 2.000 - 4.650 -3.2509 0.001 
GP17 1.080 (0.265) 0.720 - 1.940 1.795 (0.733) 0.950 - 6.600 -13.6209
# < 2.2 x10-16 
GP18 8.395 (2.617) 3.940 - 16.520 7.885 (2.377) 3.850 - 19.320 2.1213 0.035 
GP19 1.895 (0.397) 1.320 - 3.310 1.875 (0.442) 1.300 - 4.150 0.4212 0.674 
GP20 0.350 (0.108) 0.220 - 0.670 0.700 (0.315) 0.280 - 2.020 -14.0479
# < 2.2 x10-16 
GP21 0.915 (0.328) 0.460 - 1.740 1.500 (1.063) 0.560 - 4.500 -9.4946
# < 2.2 x10-16 
GP22 0.120 (0.065) 0.050 - 0.930 0.150 (0.088) 0.060 - 0.930 3142.5* 3.046 x10
-5 
GP23 1.145 (0.488) 0.430 - 1.950 1.160 (0.448) 0.600 - 1.940 -0.0580 0.954 
GP24 1.535 (0.535) 0.640 - 2.250 1.560 (0.525) 0.750 - 2.990 -1.6844 0.094 
GPx: glycan peak with ‘x’ corresponding to number; IQR: interquartile range; # Welch’s t-test for unequal variances 
utilised. The degrees of freedom (df) used for each t-test are found in Appendix 7 next to the respective GPs. 
GP values are presented as percentages of the total IgG glycome, i.e. GP1 = GP1/GP * 100. Statistically significant 
differences (P < 8.06 x10-4) were determined using Student’s t-test [df = 194] and bold. Those variables that did not 
have a normal (or log-normal) distribution were analysed using the Mann-Whitney U test. 
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In the neutral IgG glycome (see Table 5), there were five statistically significant differences  
(P < 8.06 x10-4) between groups. The relative abundances of the following three GPs were 
significantly lower in the PD cases compared to the controls:  
• GP5n, a high-mannose glycan (t [153.062] = -14.4049, P < 2.2 x10-16);  
• GP6n, a biantennary core fucosylated glycan with bisecting GlcNAc (t [194] = -4.2282,  
P = 3.676 x10-5);  
• GP11n, a biantennary core fucosylated monogalactosylated glycan with bisecting 
GlcNAc (t [194] = -4.0865, P = 6.406 x10-5).  
The relative abundances of the following two GPs were significantly higher in the PD cases 
compared to the controls:  
• GP8n, a biantennary core fucosylated monogalactosylated glycan (t [194] = 3.6267,  
P = 3.670 x10-4);  
• GP14n, a biantennary core fucosylated digalactosylated glycan (t [194] = 3.4356,  
P = 7.230 x10-4).  
The differences with GP6 and GP11 between groups did not reach statistically significance in 
the total IgG glycome. However, with all the GPs that had glycan structures without terminal 
sialic acid removed in the neutral IgG glycome (i.e. GP16 to GP24), there were statistical 
significant differences for both GP6n and GP11n. Interestingly the major glycan moieties were 
similar in each GP (see Appendix 1), with the addition of a terminal galactose in GP11n.   
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Table 5: Descriptive statistics for the GPs within the neutral IgG glycome.  
N-glycan 
peak 
PD cases Controls 
Between Group 
Difference 
Median           
(IQR) Range 
Median           
(IQR) Range 
t-statistic         
*U statistic P - value 
GP1n 0.100 (0.040) 0.040 - 0.350 0.105 (0.068) 0.040 - 0.990 4553.5* 0.544 
GP2n 0.685 (0.428) 0.170 - 2.540 0.765 (0.680) 0.180 - 2.420 -2.7593 0.006 
GP4n 26.580 (6.310) 10.770 - 41.970 28.890 (7.010) 13.900 - 42.380 -2.9342 0.004 
GP5n 0.295 (0.080) 0.190 - 0.520 0.520 (0.155) 0.260 - 1.130 -14.4049
# < 2.2 x10-16 
GP6n 7.210 (1.855) 3.390 - 12.210 8.180 (2.332) 4.110 - 13.970 -4.2458 3.376 x10
-5 
GP7n 0.660 (0.310) 0.270 - 1.830 0.720 (0.428) 0.270 - 1.250 -1.2463 0.214 
GP8n 23.430 (2.570) 16.280 - 31.310 22.140 (3.610) 14.570 - 33.440 3.6267 3.670 x10
-4 
GP9n 12.300 (1.830) 8.820 - 16.350 11.780 (2.320) 7.490 - 17.720 2.062 0.041 
GP10n 7.215 (1.650) 4.500 - 10.090 7.030 (1.603) 4.560 - 14.960 0.6522 0.515 
GP11n 1.085 (0.218) 0.670 - 1.690 1.150 (0.250) 0.830 - 2.090 -4.0865 6.406 x10
-5 
GP12n 0.970 (0.640) 0.290 - 4.140 0.930 (0.568) 0.350 - 3.010 0.6033 0.547 
GP13n 0.420 (0.108) 0.260 - 0.880 0.430 (0.118) 0.290 - 1.100 4413.5* 0.3378 
GP14n 2.745 (0.279) 1.960 - 3.543 2.650 (0.328) 1.917 - 3.249 3.4356 7.230 x10
-4 
GP15n 0.735 (0.288) 0.104 - 1.295 0.645 (0.244) 0.113 - 1.411 2.0664 0.040 
GPnx: glycan peak with ‘x’ corresponding to number; IQR: interquartile range; # Welch’s t-test for unequal variances 
utilised. The degrees of freedom (df) used for each t-test are found in Appendix 7 next to the respective GPs. 
GP values are presented as percentages of the neutral glycan pool, i.e. GP1n = GP1n/GPn * 100. Statistically 
significant differences (P < 8.06 x10-4) were determined using Students t-test [df = 194] and bold. Those variables 
that did not have a normal (or log-normal) distribution were analysed using the Mann-Whitney U test. 
 
 
Derived traits (see Table 6) were calculated using formulas of the different GPs (see Section 
2.2.6). The statistically significant differences (P < 8.06 x10-4) observed between the PD cases 
and controls in the total IgG glycome were associated with a lower percentage of sialylation of 
core fucosylated glycans without bisecting GlcNAc overall (FGS/(FG+FGS); t [194] = -3.5372,  
P = 5.058 x10-4) which is associated with less anti-inflammatory activity. In the derived traits 
using the GPs of the neutral IgG glycome, statistically significant differences were observed 
between the levels of galactosylated glycans; lower levels of agalactosylation (G0n;  
t [194] = -3.6370, P = 3.535 x10-4) and higher levels of monogalactosylation (G1n; t [189.123] = 
3.8576, P = 1.569 x10-4) in the PD cases compared to the controls. PD cases also had a lower 
ratio of digalactosylated glycans with bisecting GlcNAc divided by all core fucosylated 
digalactosylated glycans with and without bisecting GlcNAc (BG2n/(FG2n+FBG2n); t [194] =  
-3.9751, P = 9.919 x10-5). This was interpreted as a higher level of core fucosylated 
digalactosylated glycans in the neutral IgG glycome of PD cases compared to the control group.
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Table 6: Descriptive statistics for the derived traits from the total and neutral IgG glycome.  
Glycan trait 
PD cases Controls Between Group Difference 
Median           
(IQR) Range 
Median           
(IQR) Range t-statistic          P - value 
Percentage of Sialylation of Fucosylated Structures with Bisecting GlcNAc 
FBGS/(FBG+FBGS) 28.690 (7.290) 15.880 - 44.870 29.460 (7.310) 18.190 - 45.530 -1.427 0.140 
Percentage of Sialylation of Fucosylated Structures without  Bisecting GlcNAc 
FGS/(FG+FGS) 23.380 (3.670) 17.240 - 31.380 24.500 (3.640) 18.980 - 37.320 -3.5372 5.058 x10-4 
Percentage of Sialylation of Fucosylated Galactosylated Glycans with Bisecting GlcNAc 
FBG2S1/(FBG2       
+FBG2S1+FBG2S2) 37.600 (4.940) 26.890 - 50.300 37.530 (4.970) 30.400 - 51.110 -0.2801 0.780 
FBG2S2/(FBG2       
+FBG2S1+FBG2S2) 29.610 (6.600) 15.370 - 38.520 30.930 (6.780) 14.660 - 42.750 -3.0348 0.003 
Percentage of Sialylation of Fucosylated Galactosylated Glycans without Bisecting GlcNAc 
FG1S1/(FG1+FG1S1       
+FG2S2+FG2S2) 9.105 (2.082) 5.700 - 13.610 10.790 (2.400) 6.680 - 15.080 -5.8788 1.777 x10
-8 
FG2S1/(FG1+FG1S1       
+FG2S2+FG2S2) 38.030 (3.450) 31.260 - 43.430 39.120 (3.640) 33.440 - 57.870 -3.9504 1.091 x10
-4 
FG2S2/(FG1+FG1S1       
+FG2S2+FG2S2) 4.950 (1.897) 1.720 - 9.580 5.830 (2.409) 1.920 - 12.800 -2.7751 0.006 
Percentage of Galactosylation 
G0n 34.740 (7.790) 14.470 - 53.110 38.130 (8.310) 18.270 - 55.530 -3.6370 3.535 x10-4 
G1n 45.230 (3.330) 36.340 - 52.010 43.770 (4.570) 34.460 - 57.010 3.8576# 1.569 x10-4 
G2n 19.260 (5.140) 10.100 - 41.460 17.400 (5.460) 9.290 - 32.470 3.2262 0.001 
Percentage of Fucosylation (+/- Bisecting GlcNAc) 
Fn total 96.910 (1.330) 91.910 - 98.650 96.440 (1.770) 93.990 - 98.510 -2.6030 0.010 
FG0n/G0n total 97.970 (1.240) 94.490 - 99.450 97.930 (1.780) 94.210 - 99.550 -1.3187 0.189 
FG1n/G1n total 98.560 (0.720) 95.900 - 99.320 98.310 (1.000) 97.110 - 99.530 -1.9937 0.048 
FG2n/G2n total 92.590 (3.050) 80.520 - 96.460 91.410 (3.940) 84.680 - 96.860 -2.5195 0.013 
Percentage of Fucosylation with Bisecting GlcNAc 
FBn 17.820 (3.490) 11.970 - 24.220 18.340 (3.910) 14.360 - 26.470 -2.4126 0.017 
FBG0n/G0n 21.290 (4.660) 11.650 - 32.750 21.720 (5.040) 14.370 - 31.850 -1.0821 0.281 
FBG1n/G1n 18.460 (3.900) 11.980 - 25.760 19.200 (3.860) 14.600 - 28.620 -1.7795 0.077 
FBG2n/G2n 10.695 (1.856) 7.520 - 17.430 10.820 (2.568) 8.360 - 17.970 -2.0838 0.038 
Percentage of Fucosylation without Bisecting GlcNAc 
Fn 79.090 (4.530) 69.650 - 86.680 77.670 (4.380) 68.890 - 83.620 2.9265 0.004 
FG0n/G0n 76.610 (5.420) 63.480 - 87.800 75.640 (5.220) 64.490 - 85.030 1.3953 0.165 
FG1n/G1n 80.220 (4.490) 71.610 - 86.940 79.210 (4.170) 69.310 - 84.490 2.0542 0.041 
FG2n/G2n 81.860 (3.880) 70.270 - 87.500 80.240 (4.910) 67.400 - 85.670 -3.1790 0.002 
Other Traits 
FBn/(Fn+FBn) 18.400 (3.740) 12.140 - 25.780 19.200 (3.980) 14.650 - 27.760 -2.4793 0.014 
FG2n/(BG2n/FBG2n) 6.345 (1.183) 3.350 - 9.530 5.990 (1.748) 3.060 - 8.200 3.0569 0.003 
BG2n/(FG2n+FBG2n) 23.070 (9.130) 11.720 - 42.250 27.430 (9.900) 14.120 - 83.330 -3.9751 9.919 x10-5 
B, bisecting GlcNAc; F, core fucose; G, galactose; S, sialic acid; # Welch’s t-test for unequal variances utilised. The 
degrees of freedom (df) used for each t-test are found in Appendix 7 next to the respective GPs. 
See 2.2.6 Derived Traits for further details. Statistically significant differences (P < 8.06 x10-4) were determined using 
Students t-test [df = 194] and bold. 
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3.1.4   Associations of Age, BMI, and GPs to other GPs and Derived Traits 
Correlation matrices were conducted for both groups independently. On observing bivariate 
associations in the PD cases, age (see Table 7 and 8) was significantly (P < 8.06 x10-4) and 
positively correlated with: 
• GP4 (rs [194] = 0.37, P = 0.0002),  
• GP5 (rs [194] = 0.41, P = 0.0000),  
• GP6 (rs [194] = 0.36, P = 0.0003),  
• Agalactosylated glycans (G0n; rs [194] = 0.38, P = 0.0002),  
• Core fucosylated digalactosylated glycans with bisecting GlcNAc (FBG2n/G2n;  
rs [194] = 0.40, P = 0.0000).  
Moreover, in the PD cases, age was significantly and negatively correlated with: 
• GP14 (rs [194] = -0.38, P = 0.0002),  
• GP18 (rs [194] = -0.39, P = 0.0001),  
• Digalactosylated glycans (G2n; rs [194] = -0.37, P = 0.0002).  
Age, however, was not significantly correlated with any GP or derived trait in the control 
group. Furthermore, no statistically significant association was found between BMI (see Tables 
9 and 10) and any GP or derived trait within this study.  
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   Table 7: Correlation between age and GPs in both the PD cases and controls. 
N-glycan peak 
       PD cases           Controls 
rs P - value rs P - value 
GP1 0.32 0.0017 0.26 0.0073 
GP2 0.13 0.2162 0.03 0.7917 
GP4 0.37 0.0002 0.31 0.0014 
GP5 0.41 0.0000 0.19 0.0554 
GP6 0.36 0.0003 0.13 0.1788 
GP7 0.00 0.9851 -0.03 0.7590 
GP8 -0.10 0.3513 -0.22 0.0235 
GP9 -0.04 0.7240 0.01 0.9051 
GP10 0.21 0.0423 -0.21 0.0363 
GP11 0.34 0.0009 -0.05 0.6371 
GP12 -0.12 0.2680 -0.17 0.0806 
GP13 0.02 0.8263 -0.14 0.1493 
GP14 -0.38 0.0002 -0.32 0.0009 
GP15 -0.10 0.3407 -0.33 0.0008 
GP16 0.00 0.9662 0.18 0.0696 
GP17 -0.05 0.6313 0.00 0.9766 
GP18 -0.39 0.0001 -0.22 0.0237 
GP19 -0.11 0.2864 -0.01 0.9111 
GP20 -0.08 0.4237 0.01 0.9377 
GP21 -0.05 0.6064 0.10 0.3221 
GP22 -0.10 0.3498 0.09 0.3843 
GP23 -0.24 0.0189 0.10 0.3350 
GP24 -0.07 0.5282 0.09 0.3426 
rs, Spearman’s Rho correlation coefficient 
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                  Table 8: Correlation between age and derived traits in both the PD cases and controls. 
Glycan trait 
PD cases Controls 
rs P - value rs P - value 
Percentage of Sialylation of Fucosylated Structures with Bisecting GlcNAc 
FBGS/(FBG+FBGS) 
 -0.18 0.0867 0.20 0.0400  
Percentage of Sialylation of Fucosylated Structures without  Bisecting GlcNAc 
FGS/(FG+FGS) 
 -0.17 0.1016 0.07 0.4715  
Percentage of Sialylation of Fucosylated Galactosylated Glycans with Bisecting GlcNAc 
FBG2S1/(FBG2       
+FBG2S1+FBG2S2) 0.02 0.8178 0.08 0.4441  
FBG2S2/(FBG2       
+FBG2S1+FBG2S2) 
 
-0.05 0.6650 0.27 0.0062  
Percentage of Sialylation of Fucosylated Galactosylated Glycans without Bisecting GlcNAc 
FG1S1/(FG1+FG1S1       
+FG2S2+FG2S2) 0.06 0.5693 0.23 0.0197  
FG2S1/(FG1+FG1S1       
+FG2S2+FG2S2) 0.11 0.2906 0.18 0.0707  
FG2S2/(FG1+FG1S1       
+FG2S2+FG2S2) 
 
0.01 0.9115 0.27 0.0066  
Percentage of Galactosylation 
G0n 0.38 0.0002 0.32 0.0009  
G1n -0.21 0.0385 -0.29 0.0033  
G2n -0.37 0.0002 -0.32 0.0011  
Percentage of Fucosylation (+/- Bisecting GlcNAc) 
F total 0.03 0.7382 0.07 0.4842  
FG0n/G0n total 0.08 0.4186 0.10 0.3066  
FG1n/G1n total -0.01 0.9165 -0.04  0.7162 
FG2n/G2n total -0.13 0.2243 -0.04  0.6633 
Percentage of Fucosylation with Bisecting GlcNAc 
FBn 0.24 0.0179 -0.09  0.3801 
FBG0n/G0n -0.06 0.5631 -0.24  0.0173 
FBG1n/G1n 0.26 0.0100 -0.11  0.2893 
FBG2n/G2n 0.40 0.0000 0.06  0.5758 
Percentage of Fucosylation without Bisecting GlcNAc 
Fn -0.19 0.0739 0.08  0.4138 
FG0n/G0n 0.06 0.5465 0.22  0.0280 
FG1n/G1n -0.22 0.0299 0.07  0.4555 
FG2n/G2n -0.30 0.0032 -0.08  0.4222 
Other Traits 
FBn/(Fn+FBn) 0.22 0.0294 -0.08  0.4286 
FG2n/(BG2n/FBG2n) -0.39 0.0001 -0.12  0.2363 
BG2n/(FG2n+FBG2n)  0.35  0.0006  0.21  0.0373 
                B, bisecting GlcNAc; F, core fucose; G, galactose; S, sialic acid 
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                Table 9: Correlation between BMI and GPs in both the PD cases and controls. 
N-glycan peak 
       PD cases           Controls 
rs P - value rs P - value 
GP1 0.09 0.3988 0.04 0.6629 
GP2 0.12 0.2666 -0.14 0.1768 
GP4 0.27 0.0111 0.06 0.5644 
GP5 0.13 0.2325 -0.03 0.7772 
GP6 0.12 0.2774 0.06 0.5715 
GP7 -0.01 0.9276 -0.13 0.1872 
GP8 0.06 0.5587 -0.06 0.5779 
GP9 0.07 0.4902 -0.10 0.3468 
GP10 -0.02 0.8323 0.08 0.4588 
GP11 0.03 0.7635 0.02 0.8152 
GP12 -0.08 0.4265 -0.09 0.3508 
GP13 -0.12 0.2534 0.07 0.5171 
GP14 -0.24 0.0210 0.00 0.9765 
GP15 -0.24 0.0211 0.03 0.7519 
GP16 -0.08 0.4381 -0.03 0.7907 
GP17 -0.22 0.0383 0.01 0.9407 
GP18 -0.27 0.0110 -0.01 0.8854 
GP19 -0.08 0.4675 -0.01 0.9112 
GP20 -0.18 0.0960 -0.01 0.9538 
GP21 -0.07 0.5240 0.06 0.5397 
GP22 -0.08 0.4647 -0.02 0.8661 
GP23 -0.17 0.0972 0.13 0.2138 
GP24 -0.11 0.2886 0.02 0.8307 
rs, Spearman’s Rho correlation coefficient 
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                 Table 10: Correlation between BMI and derived traits in both the PD cases and controls. 
Glycan trait 
PD cases Controls 
rs P - value rs P - value 
Percentage of Sialylation of Fucosylated Structures with Bisecting GlcNAc 
FBGS/(FBG+FBGS) 
 -0.07 0.5004 -0.03 0.7364 
Percentage of Sialylation of Fucosylated Structures without  Bisecting GlcNAc 
FGS/(FG+FGS) 
 -0.26 0.0120 0.04 0.7141 
Percentage of Sialylation of Fucosylated Galactosylated Glycans with Bisecting GlcNAc 
FBG2S1/(FBG2       
+FBG2S1+FBG2S2) 0.16 0.1287 -0.04 0.7134 
FBG2S2/(FBG2       
+FBG2S1+FBG2S2) 
 
0.02 0.8616 0.03 0.7436 
Percentage of Sialylation of Fucosylated Galactosylated Glycans without Bisecting GlcNAc 
FG1S1/(FG1+FG1S1       
+FG2S2+FG2S2) -0.14 0.1823 0.01 0.9060 
FG2S1/(FG1+FG1S1       
+FG2S2+FG2S2) -0.13 0.2339 -0.02 0.8413 
FG2S2/(FG1+FG1S1       
+FG2S2+FG2S2) 
 
0.02 0.8760 0.07 0.4688 
Percentage of Galactosylation 
G0n 0.24 0.0202 0.05 0.5941 
G1n -0.08 0.4603 -0.09 0.3998 
G2n -0.26 0.0135 0.00 0.9715 
Percentage of Fucosylation (+/- Bisecting GlcNAc) 
Fn total 0.05 0.6148 0.16 0.1196 
FG0n/G0n total 0.02 0.8251 0.16 0.1087 
FG1n/G1n total 0.04 0.7371 0.12 0.2511 
FG2n/G2n total -0.02 0.8217 0.12 0.2338 
Percentage of Fucosylation with Bisecting GlcNAc 
FBn -0.03 0.7642 0.09 0.3605 
FBG0n/G0n -0.17 0.1085 0.02 0.8107 
FBG1n/G1n -0.02 0.8728 0.10 0.3240 
FBG2n/G2n 0.05 0.6570 0.07 0.5131 
Percentage of Fucosylation without Bisecting GlcNAc 
Fn 0.06 0.5530 -0.01 0.9089 
FG0n/G0n 0.16 0.1420 0.07 0.4917 
FG1n/G1n 0.03 0.7545 -0.08 0.4475 
FG2n/G2n -0.02 0.8464 0.06 0.5323 
Other Traits 
FBn/(Fn+FBn) -0.04 0.7128 0.08 0.4547 
FG2n/(BG2n/FBG2n) -0.07 0.4873 -0.06 0.5293 
BG2n/(FG2n+FBG2n) 0.10 0.3239 0.06 0.5454 
               B, bisecting GlcNAc; F, core fucose; G, galactose; S, sialic acid 
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Comparisons based on independent groups were made between each coefficient 
representative of at least a moderate correlation (rs > |0.5|) in one of the groups. There were 
less statistically significant differences in the correlations of GPs between the groups in the 
neutral IgG glycome (see Appendix 6c) compared to the total IgG glycome (see Appendix 6a). 
Of interest were the statistically significant differences between the PD cases and controls 
where at least one coefficient was suggestive of a strong relationship (rs > |0.7|). In the total 
IgG glycome, GP17 and GP20 had the most differences where at least one coefficient was 
suggestive of a strong relationship (see Appendix 6a). In the neutral IgG glycome, GP8n had 
the most significant differences (see Appendix 6c). The glycan with the most significant 
different correlations between groups was GP5; its correlation with GP20 was the most 
different between the groups in this study (see Fig. 8).  
 
 
 
Figure 8: Two-way scatters of the relative abundance of GP5 and GP20. Correlations according to Spearman’s Rho 
included. Fisher’s r-to-z results confirmed this difference to be highly significant (z = 5.42, P = 0.0000). 
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3.2   Study 2: Utility of IgG N-Glycans in Identifying Risk of Cognitive Decline 
3.2.1   Participants 
Summary statistics for the PD cases with motor subtype data are shown in Table 11. In total 
there were 11 cases with no or incomplete motor subtype data in this study. However, there 
was not a statistically significant difference (P < 8.06 x10-4) between those with and without 
motor subtype data in terms of age (χ2 [1, n=94] = 0.2109, P = 0.646), gender (χ2 [1, n=94] = 
0.9273, P = 0.336) or BMI (χ2 [1, n=94] = 1.7528, P = 0.186). Considering the motor subtype 
comparisons, there was not a statistically significant difference in age (χ2 [1, n=83] = 1.0383,  
P = 0.595), gender (χ2 [1, n=83] = 0.1373, P = 0.934) or BMI (χ2 [1, n=83] = 0.1542, P = 0.926) 
between the three independent groups. As expected, there were far fewer participants 
classified as having an indeterminate (ID) motor subtype (n=9) compared to tremor dominant 
(TD; n=30) and postural instability and gait dysfunction dominant (PIGD; n=44).   
 
 
Table 11: Summary statistics in terms of PD motor subtype. 
  TD PIGD ID Between Group Differences 
    χ2-statistic P-value 
Participants n  30 44 9    
Age   x� (S) 65.33 (10.78) 67.43 (7.33) 65.56 (12.29) 1.0383 0.595 
Gender   n male (%) 21 (70.0%) 29 (65.9%) 6 (66.7%) 0.1373 0.934 
BMI   x� (S) 26.48 (3.89) 26.93 (5.19) 25.89 (4.91) 0.1542 0.926 
ID, indeterminate; PIGD, postural instability and gait disturbance dominant; TD, tremor dominant;  
BMI, body mass index; 𝐱�, sample mean; S, sample standard deviation 
 
 
Summary statistics for the cases with an animal naming task score for semantic fluency are 
shown in Table 12. In total, there were three cases with no animal naming task score in this 
study. However, there was not a statistically significant difference (P < 8.06 x10-4) between 
those with and without animal naming task data in terms of age (χ2 [1, n=94] = 2.3705,  
P = 0.124), gender (χ2 [1, n=94] = 1.3679, P = 0.242) or BMI (χ2 [1, n=94] = 0.3753, P = 0.540). 
Similarly, there was not a statistically significant difference in gender (χ2 [1, n=91] = 0.1514,  
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P = 0.697) or BMI (χ2 [1, n=91] = 0.0920, P = 0.762) between the two independent groups. 
However, participants with an animal naming task score of less than 20 were significantly older 
than those with an animal naming task score equal to or greater than 20 (χ2 [1, n=91] = 
13.1491, P = 0.0003).   
 
 
Table 12: Summary statistics in terms of animal naming task (ANT) score. 
  ANT < 20 ANT ≥ 20 Between Group Differences 
      χ2-statistic P-value 
Participants n  56 35    
Age   x� (S) 69.21 (7.61) 61.91 (9.40) 13.1491 0.0003 
Gender   n male (%) 39 (69.6%) 23 (65.7%) 0.1514 0.697 
BMI   x� (S) 26.28 (4.87) 26.46 (4.58) 0.0920 0.762 
      BMI, body mass index; 𝐱�, sample mean; S, sample standard deviation 
 
 
 
3.2.2   Batch Effects 
Summary statistics for the distribution of PD case samples over the plates used for UPLC 
analysis are shown below for: motor subtype (see Table 13) and animal naming task score  
(see Table 14). Batch effects were also explored within the cases using PCA (Euclidean 
distance) in terms of motor subtype and animal naming task score. The first two principal 
components explained 44.00% of the variance in this study; however, these principal 
components could not be used to cluster the PD cases according to plate number (see Fig. 9a), 
motor subtype (see Fig. 9b) or animal naming task score (see Fig. 9c). This result is in stark 
comparison to Fig6b in Study 1 where the PD cases and controls had almost separate clusters.  
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Table 13: Summary statistics for the distribution of Study 2 samples on plates for UPLC analysis. 
  
Age M  Age M  Age M  x� (S) n (%) x� (S) n (%) x� (S) n (%) 
Plate 1 
TD  (n=15) PIGD  (n=17) ID  (n=6) 
62.60 (11.95) 9 (60.0%) 65.12 (9.23) 11 (64.7%) 64.50 (14.87) 4 (66.7%) 
Plate 2 
TD  (n=10) PIGD  (n=23) ID  (n=3) 
69.90 (6.59) 8 (80.0%) 68.70 (5.90) 14 (60.9%) 67.67 (6.43) 2 (66.7%) 
Plate 3 
TD (n=5) PIGD  (n=4) ID  (n=0) 
64.40 (12.82) 4 (80.0%) 70.00 (2.94) 4 (100.0%)     
ID, indeterminate; PIGD, postural instability and gait disturbance dominant; TD, tremor dominant;  
𝐱� , sample mean; S, sample standard deviation 
 
 
 
 
                Table 14: Summary statistics for the distribution of Study 2 samples on plates for UPLC analysis. 
  
Age M  Age  M  x� (S) n (%) x� (S) n (%) 
Plate 1 
ANT score < 20  (n=23) ANT score ≥ 20  (n=19) 
68.70 (10.08) 15 (65.2%) 58.58 (9.11) 11 (57.9%) 
Plate 2 
ANT score < 20  (n=27) ANT score ≥ 20   (n=13) 
69.52 (5.67) 19 (70.4%) 67.00 (6.24) 9 (69.2%) 
Plate 3 
ANT score < 20  (n=6) ANT score ≥ 20   (n=3) 
69.83 (4.54) 5 (83.3%) 61.00 (15.72) 3 (100.0%) 
           ANT, Animal Naming Task; x�, sample mean; S, sample standard deviation 
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Figure 9: Scatter showing first two principal components 
in terms of: a) plate used for UPLC; b) motor subtype; and 
c) animal naming task score. 
 
 
 
 
 
 
3.2.3   Motor Subtypes Comparisons 
Comparisons between the PD cases in terms of motor subtype in the total IgG glycome  
(see Table 15), the neutral IgG glycome (see Table 16), and derived traits (see Table 17) are 
shown below. There were no statistically significant differences (P < 8.06 x10-4) for either the 
total or neutral IgG glycome, or the derived traits of these.  
  
a b 
 
c 
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Table 15: Descriptive statistics for the GPs within the total IgG glycome according to PD motor subtype.  
N-glycan peak 
Tremor Dominant PIGD Dominant Indeterminate Type Between Group Difference 
Median           
(IQR) Range 
Median           
(IQR) Range 
Median            
(IQR) Range χ2 statistic P - value 
GP1 0.08 (0.18) 0.04 - 0.22 0.09 (0.25) 0.03 - 0.28 0.08 (0.08) 0.04 - 0.12 2.2230 0.527 
GP2 0.47 (1.93) 0.16 - 2.09 0.58 (1.44) 0.13 - 1.57 0.66 (0.79) 0.19 - 0.98 1.3553 0.716 
GP4 20.86 (16.86) 10.72 - 27.58 22.61 (26.03) 9.28 - 35.31 19.18 (22.28) 8.10 - 30.38 0.6503 0.199 
GP5 0.23 (0.27) 0.17 - 0.44 0.24 (0.22) 0.17 - 0.39 0.23 (0.24) 0.15 - 0.39 2.6753 0.444 
GP6 5.82 (6.27) 3.78 - 10.05 5.77 (6.19) 4.05 - 10.24 4.70 (6.99) 2.55 - 9.54 1.1231 0.772 
GP7 0.51 (0.69) 0.27 - 0.96 0.56 (1.23) 0.23 - 1.46 0.60 (0.34) 0.38 - 0.72 0.7241 0.868 
GP8 19.06 (9.52) 15.78 - 25.30 18.87 (7.35) 14.17 - 21.52 19.29 (8.77) 15.39 - 24.16 2.0626 0.560 
GP9 9.88 (5.79) 7.26 - 13.05 9.96 (5.75) 7.08 - 12.83 9.47 (2.19) 8.02 - 10.21 5.8514 0.119 
GP10 6.08 (3.89) 4.22 - 8.11 5.94 (4.73) 3.78 - 8.51 6.21 (3.53) 4.58 - 8.11 1.2631 0.738 
GP11 0.90 (0.56) 0.54 - 1.10 0.85 (0.82) 0.63 - 1.45 0.92 (0.50) 0.61 - 1.11 0.9429 0.815 
GP12 0.78 (2.17) 0.40 - 2.57 0.80 (3.07) 0.24 - 3.31 1.05 (1.41) 0.56 - 1.97 2.9664 0.397 
GP13 0.34 (0.23) 0.23 - 0.46 0.33 (0.48) 0.22 - 0.70 0.33 (0.16) 0.27 - 0.43 1.1388 0.768 
GP14 13.13 (11.43) 8.01 - 19.44 12.50 (15.70) 6.18 - 21.88 14.20 (18.00) 7.47 - 25.47 3.2563 0.354 
GP15 1.71 (1.46) 1.09 - 2.55 1.56 (1.93) 0.93 - 2.86 1.94 (1.34) 1.40 - 2.74 3.3797 0.337 
GP16 2.92 (2.56) 2.07 - 4.63 2.86 (2.07) 2.07 - 4.14 2.70 (1.40) 2.02 - 3.42 9.2705 0.026 
GP17 1.08 (1.14) 0.74 - 1.88 1.10 (1.22) 0.72 - 1.94 1.09 (0.76) 0.81 - 1.57 0.1828 0.980 
GP18 8.70 (7.60) 6.23 - 13.83 8.22 (12.58) 3.94 - 16.52 9.05 (10.00) 5.37 - 15.37 2.9195 0.404 
GP19 2.02 (1.36) 1.38 - 2.74 1.84 (1.99) 1.32 - 3.31 1.79 (1.03) 1.73 - 2.76 5.4112 0.144 
GP20 0.35 (0.29) 0.22 - 0.51 0.34 (0.44) 0.23 - 0.67 0.41 (0.25) 0.30 - 0.55 2.6296 0.452 
GP21 0.92 (0.88) 0.52 - 1.40 0.92 (1.28) 0.46 - 1.74 0.74 (0.44) 0.49 - 0.93 6.8917 0.075 
GP22 0.12 (0.26) 0.05 - 0.31 0.11 (0.16) 0.05 - 0.21 0.10 (0.86) 0.07 - 0.93 1.9771 0.577 
GP23 1.21 (1.44) 0.51 - 1.95 1.12 (1.33) 0.43 - 1.76 0.85 (1.01) 0.54 - 1.55 7.4973 0.058 
GP24 1.68 (1.61) 0.64 - 2.25 1.40 (1.47) 0.71 - 2.18 1.33 (0.84) 0.88 - 1.72 11.9966 0.007 
GP values are presented as percentages of the total IgG glycome, i.e. GP1 = GP1/GP * 100. Statistically significant differences (P < 8.06 x10-4) were determined using the Mann-Whitney U test.
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Table 16: Descriptive statistics for the GPs within the neutral IgG glycome according to PD motor subtype.  
 
N-glycan peak 
Tremor Dominant PIGD Dominant Indeterminate Type Between Group Difference 
Median           
(IQR) Range 
Median           
(IQR) Range 
Median           
(IQR) Range χ2 statistic P - value 
GP1n 0.09 (0.22) 0.05 - 0.27 0.11 (0.31) 0.04 - 0.35 0.10 (0.09) 0.05 - 0.14 2.0333 0.566 
GP2n 0.58 (2.34) 0.20 - 2.54 0.72 (1.64) 0.17 - 1.81 0.80 (0.88) 0.25 - 1.13 1.4485 0.694 
GP4n 25.61 (19.02) 14.63 - 33.65 27.84 (29.63) 12.34 - 41.97 23.17 (25.51) 10.77 - 36.28 4.9731 0.174 
GP5n 0.28 (0.31) 0.21 - 0.52 0.29 (0.24) 0.21 - 0.45 0.28 (0.28) 0.19 - 0.47 3.2756 0.351 
GP6n 7.25 (7.53) 4.68 - 12.21 7.08 (6.62) 5.15 - 11.77 5.89 (7.58) 3.39 - 10.97 1.0655 0.785 
GP7n 0.64 (0.84) 0.35 - 1.19 0.71 (1.56) 0.27 - 1.83 0.71 (0.40) 0.47 - 0.87 0.7160 0.865 
GP8n 23.58 (11.92) 19.39 - 31.31 23.34 (10.36) 16.28 - 26.64 23.28 (9.01) 20.19 - 29.20 2.3018 0.512 
GP9n 12.20 (7.53) 8.82 - 16.35 12.23 (6.25) 8.94 - 15.19 11.30 (4.00) 9.58 - 13.58 5.0515 0.168 
GP10n 7.60 (4.96) 5.13 - 10.09 7.09 (5.39) 4.50 - 9.89 7.36 (3.87) 5.83 - 9.70 1.6804 0.641 
GP11n 1.12 (0.68) 0.67 - 1.35 1.05 (0.90) 0.79 - 1.69 1.16 (0.59) 0.74 - 1.33 1.3628 0.714 
GP12n 0.96 (3.02) 0.49 - 3.51 1.00 (3.85) 0.29 - 4.14 1.28 (2.01) 0.67 - 2.68 2.9768 0.395 
GP13n 0.42 (0.31) 0.28 - 0.59 0.41 (0.62) 0.26 - 0.88 0.44 (0.26) 0.32 - 0.58 1.3517 0.717 
GP14n 16.35 (16.81) 9.73 - 26.54 15.32 (21.38) 7.10 - 28.48 17.81 (25.65) 8.92 - 34.57 3.1218 0.373 
GP15n 2.12 (2.15) 1.33 - 3.48 1.96 (2.52) 1.11 - 3.63 2.39 (2.03) 1.62 - 3.65 2.0333 0.566 
GPnx: glycan peak with ‘x’ corresponding to number; IQR: interquartile range 
GP values are presented as percentages of the neutral glycan pool, i.e. GP1n = GP1n/GPn * 100. Statistically significant differences (P < 8.06 x10-4) were using the Mann-Whitney U test. 
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Table 17: Descriptive statistics for the derived traits from the total and neutral IgG glycome according to PD motor subtype.  
N-glycan peak 
Tremor Dominant PIGD Dominant Indeterminate Type Between Group Difference 
Median           
(IQR) Range 
Median            
(IQR) Range 
Median            
(IQR) Range χ2 statistic P - value 
Percentage of Sialylation of Fucosylated Structures with Bisecting GlcNAc 
FBGS/(FBG+FBGS) 29.52 (24.28) 15.88 – 40.16 28.55 (28.76) 16.11 – 44.87 24.93 (12.97) 21.91 – 34.88 5.6691 0.129 
Percentage of Sialylation of Fucosylated Structures without  Bisecting GlcNAc 
FGS/(FG+FGS) 23.63 (12.14) 17.24 – 29.38 22.05 (14.14) 17.24 – 31.38 22.61 (9.00) 18.30 – 27.30 3.7153 0.294 
Percentage of Sialylation of Fucosylated Galactosylated Glycans with Bisecting GlcNAc 
FBG2S1/(FBG2       
+FBG2S1+FBG2S2) 37.14 (13.62) 30.64 – 44.26 37.66 (23.41) 26.89 – 50.30 36.21 (16.45) 33.46 – 49.91 0.2168 0.975 
FBG2S2/(FBG2       
+FBG2S1+FBG2S2) 30.84 (20.24) 15.88 – 36.12 28.95 (23.15) 15.37 – 38.52 24.77 (12.61) 17.67 – 30.28 14.6426 0.002 
Percentage of Sialylation of Fucosylated Galactosylated Glycans without Bisecting GlcNAc 
FG1S1/(FG1+FG1S1       
+FG2S2+FG2S2) 9.24 (7.53) 6.08 – 13.61 8.94 (6.28) 6.08 – 12.36 8.88 (4.26) 5.70 – 9.96 6.5143 0.089 
FG2S1/(FG1+FG1S1       
+FG2S2+FG2S2) 38.42 (12.17) 31.26 – 43.43 36.95 (12.03) 31.26 – 43.29 36.60 (7.06) 35.31 – 42.37 3.0054 0.391 
FG2S2/(FG1+FG1S1       
+FG2S2+FG2S2) 4.95 (5.19) 2.28 – 7.47 5.09 (7.86) 1.72 – 9.58 3.71 (2.98) 2.41 – 5.39 14.7113 0.002 
Percentage of Galactosylation 
G0n 33.62 (24.55) 21.59 – 46.14 36.25 (34.10) 19.01 – 53.11 29.17 (33.53) 14.47 – 48.00 4.2337 0.237 
G1n 45.69 (12.16) 39.85 – 52.01 44.61 (13.49) 36.34 – 49.83 45.94 (10.56) 39.94 – 50.50 4.6870 0.196 
G2n 19.76 (20.48) 13.64 – 34.12 18.62 (24.36) 10.10 – 34.46 21.64 (29.87) 11.59 – 41.46 3.1522 0.369 
  B, bisecting N-acetylglucosamine; F, core fucose; G, galactose; S, sialic acid.  
See 2.2.6 Derived Traits for further details. Statistically significant differences (P < 8.06 x10-4) were determined using the Mann-Whitney U test. 
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Table 17 cont: Descriptive statistics for the derived traits from the total and neutral IgG glycome according to PD motor subtype.  
N-glycan peak 
Tremor Dominant PIGD Dominant Indeterminate Type Between Group Difference 
Median            
(IQR) Range 
Median            
(IQR) Range 
Median            
(IQR) Range χ2 statistic P - value 
Percentage of Fucosylation (+/- Bisecting GlcNAc) 
Fn total 97.17 (4.50) 93.66 – 98.16 96.80 (6.74) 91.91 – 98.65 96.65 (1.95) 95.27 – 97.22 1.9089 0.592 
FG0n/G0n total 98.24 (4.85) 94.49 – 99.34 97.82 (4.45) 95.00 – 99.45 97.82 (1.35) 97.26 – 98.61 1.2529 0.740 
FG1n/G1n total 98.64 (2.16) 97.07 – 99.23 98.45 (3.42) 95.90 – 99.32 98.24 (0.96) 98.04 – 99.00 1.1786 0.758 
FG2n/G2n total 93.12 (11.08) 84.83 – 95.91 92.59 (15.48) 80.52 – 96.00 91.43 (5.05) 90.28 – 95.33 1.0366 0.792 
Percentage of Fucosylation with Bisecting GlcNAc 
FBn 17.95 (12.08) 12.11 – 24.19 17.82 (12.25) 11.97 – 24.22 18.79 (9.41) 13.51 – 22.92 0.1528 0.985 
FBG0n/G0n 21.57 (14.28) 14.79 – 29.07 20.73 (21.10) 11.65 – 32.75 23.46 (10.85) 17.58 – 28.43 2.5095 0.474 
FBG1n/G1n 18.72 (13.48) 11.98 – 25.46 18.39 (12.73) 13.03 – 25.76 20.72 (9.37) 13.72 – 23.09 1.3476 0.718 
FBG2n/G2n 10.89 (6.47) 7.53 – 14.00 10.54 (9.91) 7.52 – 17.43 11.26 (6.45) 8.00 – 14.45 0.3746 0.945 
Percentage of Fucosylation without Bisecting GlcNAc 
Fn 78.88 (15.92) 69.65 – 85.57 79.09 (14.14) 72.54 – 86.68 78.45 (9.15) 73.28 – 82.43 0.2533 0.969 
FG0n/G0n 76.47 (15.44) 68.02 – 83.45 76.92 (24.32) 63.48 – 87.80 74.79 (10.48) 69.20 – 79.68 2.3811 0.497 
FG1n/G1n 79.86 (15.33) 71.61 – 86.94 80.23 (13.63) 72.66 – 86.29 78.03 (9.33) 75.13 – 84.46 1.2121 0.750 
FG2n/G2n 81.94 (16.14) 71.36 – 87.50 81.76 (16.88) 70.27 – 87.15 82.30 (9.06) 76.99 – 86.05 0.2839 0.963 
Other Traits 
FBn/(Fn+FBn) 0.23 (0.21) 0.14 – 0.35 0.23 (0.19) 0.14 – 0.33 0.24 (0.15) 0.16 – 0.31 0.1392 0.987 
FG2n/(BG2n/FBG2n) 6.35 (5.25) 4.28 – 9.53 6.37 (6.09) 3.35 – 9.44 6.11 (4.05) 4.47 – 8.52 0.3919 0.942 
BG2n/(FG2n+FBG2n) 22.01 (22.10) 15.75 – 37.85 23.52 (28.55) 13.70 – 42.25 23.57 (22.57) 11.72 – 34.29 1.7484 0.626 
 B, bisecting N-acetylglucosamine; F, core fucose; G, galactose; S, sialic acid.  
See 2.2.6 Derived Traits for further details. Statistically significant differences (P < 8.06 x10-4) were determined using the Mann-Whitney U test. 
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3.2.4   Risk of Cognitive Decline 
Comparisons between the PD cases in terms of animal naming task score in the total IgG 
glycome (see Table 18), the neutral IgG glycome (see Table 19), and derived traits (see Table 
20) are shown below. There were no statistically significant differences (P < 8.06 x10-4) in 
either the total or neutral IgG glycome, or the derived traits of these.  
 
 
Table 18: Descriptive statistics for the GPs within the total IgG glycome according to animal naming task (ANT) 
score.  
N-glycan peak 
ANT < 20 ANT ≥ 20 
Between Group 
Difference 
Median           
(IQR) Range 
Median           
(IQR) Range U-statistic          P - value 
GP1 0.09 (0.25) 0.03 - 0.28 0.08 (0.19) 0.03 - 0.22 1200.50 0.071 
GP2 0.56 (1.44) 0.13 - 1.57 0.48 (1.92) 0.17 - 2.09 1113.50 0.278 
GP4 22.28 (22.58) 11.74 - 34.32 20.25 (27.21) 8.10 - 35.31 1184.00 0.097 
GP5 0.25 (0.29) 0.15 - 0.44 0.22 (0.15) 0.17 - 0.32 1251.00 0.027 
GP6 5.88 (6.63) 3.61 - 10.24 5.66 (7.50) 2.55 - 10.05 1133.00 0.214 
GP7 0.55 (1.15) 0.31 - 1.46 0.50 (0.80) 0.23 - 1.03 1040.00 0.627 
GP8 19.23 (11.13) 14.17 - 25.30 18.67 (8.77) 15.39 - 24.16 1138.00 0.199 
GP9 9.84 (5.01) 7.82 - 12.83 9.99 (5.97) 7.08 - 13.05 991.00 0.932 
GP10 6.04 (4.34) 4.17 - 8.51 5.81 (4.33 0.61 - 1.35 1077.00 0.431 
GP11 0.89 (0.91) 0.54 - 1.45 0.86 (0.74) 0.61 - 1.35 1088.50 0.378 
GP12 0.76 (2.94) 0.37 - 3.31 0.89 (2.59) 0.24 - 2.83 890.00 0.465 
GP13 0.34 (0.47) 0.23 - 0.70 0.33 (0.26) 0.22 - 0.48 1038.00 0.638 
GP14 12.08 (15.82) 6.18 - 22.00 13.63 (17.46) 8.01 - 25.47 696.00 0.021 
GP15 1.62 (1.77) 1.09 - 2.86 1.71 (1.81) 0.93 - 2.74 804.00 0.152 
GP16 2.90 (2.07) 2.07 - 4.14 2.90 (2.61) 2.02 - 4.63 1033.50 0.665 
GP17 1.08 (1.22) 0.72 - 1.94 1.07 (1.09) 0.79 - 1.88 914.50 0.596 
GP18 8.28 (8.53) 3.94 - 12.47 8.93 (10.29) 6.23 - 16.52 742.00 0.053 
GP19 1.86 (1.99) 1.32 - 3.31 1.94 (1.35) 1.39 - 2.74 888.50 0.458 
GP20 0.34 (0.44) 0.22 - 0.66 0.35 (0.44) 0.23 - 0.67 953.00 0.829 
GP21 0.91 (1.25) 0.49 - 1.74 0.91 (0.94) 0.46 - 1.40 944.50 0.775 
GP22 0.12 (0.26) 0.05 - 0.31 0.11 (0.87) 0.06 - 0.93 993.50 0.915 
GP23 1.12 (1.47) 0.43 - 1.90 1.19 (1.39) 0.56 - 1.95 847.50 0.282 
GP24 1.52 (1.54) 0.64 - 2.18 1.53 (1.54) 0.71 - 2.25 946.50 0.788 
ANT, animal naming task; GPx: glycan peak with ‘x’ corresponding to number; IQR: interquartile range 
GP values are presented as percentages of the total IgG glycome, i.e. GP1 = GP1/GP * 100. Statistically significant 
differences (P < 8.06 x10-4) were determined using the Mann-Whitney U test. 
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Table 19: Descriptive statistics for the GPs within the neutral IgG glycome according to animal naming task (ANT) 
score.  
N-glycan 
peak 
ANT < 20 ANT ≥ 20 
Between Group 
Difference 
Median           
(IQR) Range 
Median           
(IQR) Range U-statistic P - value 
GP1n 0.11 (0.31) 0.04 - 0.35 0.10 (0.23) 0.04 - 0.27 1163.50 0.134 
GP2n 0.70 (1.64) 0.17 - 1.81 0.59 (2.33) 0.21 - 2.54 1099.50 0.332 
GP4n 27.46 (24.54) 14.89 - 39.43 25.62 (31.20) 10.77 - 41.97 1182.50 0.099 
GP5n 0.30 (0.33) 0.19 - 0.52 0.27 (0.17) 0.21 - 0.38 1224.50 0.046 
GP6n 7.24 (7.26) 4.51 - 11.77 7.04 (8.82) 3.39 - 12.21 1116.00 0.269 
GP7n 0.66 (1.44) 0.39 - 1.83 0.64 (0.99) 0.27 - 1.26 1008.50 0.819 
GP8n 23.46 (15.03) 16.28 - 31.31 23.32 (10.19) 19.01 - 29.20 1008.50 0.819 
GP9n 12.27 (7.00) 8.94 - 15.94 12.59 (7.53) 8.82 - 16.35 937.50 0.732 
GP10n 7.28 (4.78) 5.11 - 9.89 7.13 (5.59) 4.50 - 10.09 1016.50 0.769 
GP11n 1.08 (1.02) 0.67 - 1.69 1.09 (0.88) 0.74 - 1.62 1059.00 0.522 
GP12n 0.92 (3.70) 0.44 - 4.14 1.10 (3.22) 0.29 - 3.51 880.50 0.419 
GP13n 0.42 (0.59) 0.29 - 0.88 0.43 (0.33) 0.26 - 0.59 979.00 0.997 
GP14n 15.00 (20.65) 7.10 - 27.75 16.95 (24.96) 9.61 - 34.57 684.50 0.016 
GP15n 2.03 (2.34) 1.29 - 3.63 2.12 (2.54) 1.11 - 3.65 791.00 0.124 
ANT, animal naming task; GPx: glycan peak with ‘x’ corresponding to number; IQR: interquartile range 
GP values are presented as percentages of the neutral glycan pool, i.e. GP1n = GP1n/GPn * 100. Statistically 
significant differences (P < 8.06 x10-4) were using the Mann-Whitney U test. 
 
 
  
62 
 
Table 20: Descriptive statistics for the derived traits from the total and neutral IgG glycome according to animal 
naming task (ANT) score.  
Glycan trait 
ANT < 20 ANT ≥ 20 Between Group Difference 
Median           
(IQR) Range 
Median           
(IQR) Range U-statistic          P - value 
Percentage of Sialylation of Fucosylated Structures with Bisecting GlcNAc 
FBGS/(FBG+FBGS) 28.52 (28.99) 15.88 - 44.87 29.76 (21.01) 16.84 - 37.85 903 0.533 
Percentage of Sialylation of Fucosylated Structures without  Bisecting GlcNAc 
FGS/(FG+FGS) 23.30 (10.54) 17.24 - 27.78 23.48 (12.58) 18.80 - 31.38 804 0.152 
Percentage of Sialylation of Fucosylated Galactosylated Glycans with Bisecting GlcNAc 
FBG2S1/(FBG2       
+FBG2S1+FBG2S2) 37.61 (19.32) 2.28 - 9.58 37.05 (18.82) 26.89 - 45.71 1042 0.616 
FBG2S2/(FBG2       
+FBG2S1+FBG2S2) 29.69 (22.64) 30.98 - 50.30 29.20 (20.36) 15.37 - 35.73 1020.5 0.744 
Percentage of Sialylation of Fucosylated Galactosylated Glycans without Bisecting GlcNAc 
FG1S1/(FG1+FG1S1       
+FG2S2+FG2S2) 9.00 (6.28) 6.08 - 12.36 9.23 (7.91) 5.70 - 13.61 951.5 0.819 
FG2S1/(FG1+FG1S1       
+FG2S2+FG2S2) 38.08 (12.03) 31.26 - 43.29 37.22 (10.78) 32.65 - 43.43 973.5 0.961 
FG2S2/(FG1+FG1S1       
+FG2S2+FG2S2) 4.88 (7.30) 2.28 - 9.58 5.07 (6.61) 1.72 - 8.33 1029 0.692 
Percentage of Galactosylation 
G0n 35.67 (33.28) 19.83 - 53.11 32.87 (33.45) 14.47 - 47.92 1178 0.107 
G1n 45.09 (15.67) 36.34 - 52.01 45.62 (8.50) 39.85 - 48.35 1036.5 0.648 
G2n 18.61 (23.92) 10.10 - 34.02 20.66 (30.20) 11.26 - 41.46 701 0.023 
Percentage of Fucosylation (+/- Bisecting GlcNAc) 
Fn total 96.96 (6.35) 91.91 - 98.26 96.90 (4.99) 93.66 - 98.65 992.5 0.922 
FG0n/G0n total 98.03 (3.25) 96.15 - 99.40 97.97 (4.96) 94.49 - 99.45 1018.5 0.757 
FG1n/G1n total 98.56 (3.30) 95.90 - 99.20 98.66 (2.25) 97.07 - 99.32 946.5 0.788 
FG2n/G2n total 92.38 (15.48) 80.52 - 96.00 92.91 (11.72) 84.74 - 96.46 854 0.306 
Percentage of Fucosylation with Bisecting GlcNAc 
FBn 17.94 (12.10) 12.11 - 24.21 17.70 (12.25) 11.97 - 24.22 1019 0.754 
FBG0n/G0n 20.68 (14.28) 14.79 - 29.07 22.21 (21.10) 11.65 - 32.75 831.5 0.227 
FBG1n/G1n 18.71 (13.78) 11.98 - 25.76 18.52 (12.43) 13.03 - 25.46 1047 0.588 
FBG2n/G2n 10.77 (9.90) 7.53 - 17.43 10.48 (6.48) 7.52 - 14.00 1136.5 0.203 
Percentage of Fucosylation without Bisecting GlcNAc 
Fn 78.97 (13.82) 71.75 - 85.57 79.39 (17.03) 69.65 - 86.68 938.5 0.738 
FG0n/G0n 77.02 (14.62) 68.84 - 83.46 76.11 (24.32) 63.48 - 87.80 1116 0.269 
FG1n/G1n 79.35 (14.28) 72.66 - 86.94 80.27 (14.68) 71.61 - 86.29 916 0.604 
FG2n/G2n 81.57 (17.23) 70.27 - 87.50 82.90 (15.48) 71.36 - 86.84 766 0.082 
Other Traits 
FBn/(Fn+FBn) 18.59 (12.63) 12.4 – 25.03 18.19 (13.64) 14.12 – 25.78 1019.5 0.75 
FG2n/(BG2n/FBG2n)  6.14 (6.18) 3.35 – 9.53 6.63 (4.99) 4.28 – 9.27 728.5 0.041 
BG2n/(FG2n+FBG2n) 25.10 (29.93) 12.32 – 42.25 20.27 (27.22) 11.72 – 38.94 1333.5 0.004 
ANT, animal naming task; B, bisecting N-acetylglucosamine; F, core fucose; G, galactose; S, sialic acid.  
See 2.2.6 Derived Traits for further details. Statistically significant differences (P < 8.06 x10-4) were determined using 
the Mann-Whitney U test. 
63 
 
4.0   Discussion 4.1   Study 1: IgG N-Glycans as a Novel Biomarker of PD 
This was the first study, to our knowledge, that investigated the potential of using IgG glycomic 
biomarkers to identify people with PD using a case-control epidemiological approach. It was 
hypothesised that the peripheral IgG glycome would be different in people with PD compared 
with a control population, and that these modifications would infer a more pro-inflammatory 
fraction of IgG. Therefore, the purpose of Study 1 was to identify changes present in the 
peripheral IgG glycome of people with PD that may represent an interphenotype of the 
disorder: a link between the genome, the environment and the disease phenotype. PD has a 
heterogeneous presentation of clinical symptoms, and many genetic and environmental 
factors contribute to the development of the disease. Whether this clinical heterogeneity 
between PD patients had an influence on the peripheral glycosylation of IgG was the 
motivation of Study 2. It was evident from the current study that the PD cases did have a 
different glycosylation profile to the controls.  
 
4.1.1   Batch Effects 
Batch effects exist because laboratory conditions, reagents and technicians vary between 
different batches, and can compound the biological effects within the data (Leek et al., 2010). 
Importantly, batch effects can be detrimental to results of a study as incorrect conclusions can 
be made. Mild batch effects were present, as indicated by some of the boxplots of GPs 
separated according to plate number (see Appendix 4). However, blocking appeared to be 
effective in averting the influence of batch effects in this study, as evident by the inability of 
PCA to cluster samples according to plate number (see Fig. 6a). This is a positive finding as PCA 
would have been effective, even if only partially, in clustering participant samples according to 
plate number if batch effects were detrimental to the results of this study. There was, 
however, evidence of some separation of the samples according to case status (see Fig. 6b), 
thus indicating that the glycan variables in this study were able to segregate samples according 
to whether a participant was a PD case or a control.  
 
4.1.2  Influence of Age and BMI on GPs and Derived Traits 
Advancing age has previously been associated with changes in the glycosylation of IgG that 
alter the effector functions of these glycoproteins, making them pro-inflammatory. Pro-
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inflammatory modifications to the peripheral IgG glycome infer the presence of low-grade 
inflammation which is capable of fuelling an inflammatory vicious loop (Dall’Olio et al., 2013). 
Specifically, an increase in agalactosylated biantennary glycans and a concurrent decrease in 
digalactosylated biantennary glycans, with or without bisecting GlcNAc (Pucic et al., 2011; 
Ruhaak et al., 2010), has been found to be associated with advancing age. The current study 
corroborates these associations; however, the association between advancing age and an 
increase in agalactosylation (G0n) or a decrease in digalactosylation (G2n) only reached 
statistical significance in the PD cases and not in the controls (see Table 8). Therefore, these 
associations were greater in the PD cases. Hence, people with PD may have an accelerated 
development of pro-inflammatory IgG with advancing age.  
This may be an expected result for an age-related chronic disease population. What was not 
expected, however, was an overall difference indicative of a decreased pro-inflammatory 
capacity of peripheral IgG in the PD cases (see Table 6). In the current study, a significant 
decrease in agalactosylated biantennary glycans (G0n) and an increase in digalactosylated 
biantennary glycans (G2n) were found in the PD cases compared to controls, though the latter 
result did not reach statistical significance. This perceived decrease in pro-inflammatory 
capacity, albeit perplexing, may be under genetic influence and a result of inter-population 
allelic frequency differences rather than associated to PD. Although the overall trend of the PD 
cases was to have lower levels of pro-inflammatory IgG, there was a sharper increase in the 
pro-inflammatory capacity of peripheral IgG as people with PD aged, at least in the context of a 
cross-sectional study. Though this will need to be further validated in a longitudinal study, it 
may be resolved that the peripheral IgG in people with PD have a propensity to become more 
pro-inflammatory faster than what would be expected as they aged. This would therefore 
support the hypothesis that modifications to the peripheral IgG glycome would infer more pro-
inflammatory ability through the presence of low-grade inflammation.  
As well as the overall levels of agalactosylated and digalactosylated biantennary glycans, 
alterations in many individual GPs have been found to be associated with advancing age, both 
biological and chronological (Krištić et al., 2014). Individual GP changes associated with age 
were only found to be statistically significant in the PD cases in this study: five in total and four 
of these previously associated with advancing age (Krištić et al., 2014). The lack of a significant 
association in the control population may be a result of the small sample size in the current 
study, and hence reduced power, compared with the sample size used in Krištić and colleagues 
study (2014). Though this is the circumstance, the associations of age and these GPs were 
greater in the PD cases. The three GPs that were associated with a moderate increase as a 
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result of advancing age in people with PD were GP4, GP5, and GP6, all of which are GPs with 
agalactosylated biantennary glycan moieties (see Appendix 1). Likewise, the two GPs that 
were associated with a moderate decrease with advancing age in people with PD were GP14  
 and GP18, both of which are GPs containing digalactosylated biantennary glycan moieties (see 
Appendix 1). Although GP5 is indeed an agalactosylated glycan, it was not associated with 
advancing age in previous studies and may therefore be unique to PD.  
It has been demonstrated that changes in BMI can alter plasma protein glycosylation. 
Significant increases in triantennary glycan structures and significant decreases in core 
fucosylated glycans, monosialylated glycans and biantennary glycans have been connected to 
an increase in BMI (Knezevic et al., 2010; Nikolac Perkovic et al., 2014). Nikolac Perkovic and 
colleagues (2014) reported an increase in BMI to be associated with an increase in 
agalactosylated biantennary glycans, and hence a tendency for more pro-inflammatory IgG. 
Nevertheless, BMI did not have a statistical influence over the interpretation of the GPs and 
derived traits in the current study. Though BMI was significantly different (t [194] = 3.7622,  
P = 0.0002) between the PD cases and controls, whereby the control group had a higher 
average BMI (28.61; SD=3.40) compared with the PD cases (26.40; SD=4.76), it did not have a 
statistically significant association to any of the GPs or derived traits in either of the groups 
(see Tables 9 and 10). This was unsurprising given that Nikolac Perkovic et al. (2014) only 
found an increase in BMI to have a weak positive association with agalactosylated glycans of 
IgG, BMI explaining only 2% of the variation in their study, with statistical significance due to 
increased sample size and therefore increased power in the study. 
 
4.1.3   Differing Glycosylation Profiles of IgG in People with PD 
Changes in peripheral IgG glycosylation are associated with a number of chronic diseases, 
including: rheumatoid arthritis (Gindzienska-Sieskiewicz et al., 2007; Malhotra et al., 1995; 
Troelsen et al., 2012), metabolic syndrome (Lauc et al., 2013; Lu et al., 2011), inflammatory 
bowel disease (Lauc et al., 2013; Nakajima et al., 2011), systemic lupus erythematosus (Lauc et 
al., 2013), haematological cancers (Lauc et al., 2013), thyroid cancer (Chen et al., 2012), gastric 
cancer (Kodar et al., 2012), lung cancer (Chen et al., 2013), ovarian cancer (Saldova et al., 
2007), multiple sclerosis (Lauc et al., 2013), and more recently AD and progressive MCI 
(Lundström et al., 2014). In the current study, several deviations in the peripheral IgG glycome 
were seen in the PD cases compared with the controls. The majority of the between group GP 
differences were reflected as trends in the derived traits. For example, lower relative 
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abundances of GPs primarily comprised of monosialylated and disialylated digalactosylated 
biantennary glycans without bisecting GlcNAc (GP17 and GP21, respectively) occurred in 
parallel to lower relative abundances of the same glycan structures that were additionally core 
fucosylated in the derived traits. These derived traits are used to sum up the trends in the 
whole IgG glycome; that is, an overall increase or decrease in sialylation, core fucosylation, 
galactosylation or bisecting GlcNAc, and any combination of these traits (see 2.2.6 Derived 
Traits). The derived traits are useful for inferring whether a change of an individual GP has a 
downstream change on the IgG glycome and whether this change causes the IgG glycoprotein 
as a whole to become more anti-inflammatory or pro-inflammatory.  
A reduced level of sialylation, particularly monosialylation, was seen in the PD cases compared 
with the controls. GP17, comprised predominantly of monosialylated digalactosylated 
biantennary glycans without bisecting GlcNAc (see Appendix 1), was significantly reduced in 
the PD cases. GP21, comprised of disialylated digalactosylated biantennary glycans without 
bisecting GlcNAc (see Appendix 1) was also significantly reduced in the PD cases. Parallel to 
this, there was an overall reduction in sialylation of fucosylated galactosylated glycans within 
the PD cases (FGS/(FG+FGS). Following further inspection, this reduction was significant 
specifically for lower levels of monosialylation in fucosylated monogalactosylated (FG1S1/(FG1 
+ FG1S1 + FG2S1 + FG2S2) and digalactosylated (FG2S1/( FG1 + FG1S1 + FG2S1 + FG2S2)) 
biantennary glycans without a bisecting GlcNAc. However, there was no statistically significant 
difference in disialylated fucosylated digalactosylated biantennary glycans without a bisecting 
GlcNAc (FG2S2/( FG1 + FG1S1 + FG2S1 + FG2S2)). Disialylated digalactosylated biantennary 
glycans with a bisecting GlcNAc (GP22; see Appendix 1) were reduced in the PD cases. 
However, this was not reflected as an overall effect in the core fucosylated galactosylated 
biantennary glycans with bisecting GlcNAc (FBGS/(FBG + FBGS)). Higher levels of sialylation are 
associated with an increased anti-inflammatory fraction of IgG due to a reduced capacity to 
bind to FcγRIIIa receptors on natural killer cells thereby lowering inflammatory activity via 
ADCC (Böhm et al., 2012; Scallon et al., 2007). It has been postulated that the mechanism by 
which sialylated, particularly α2-6 sialylated, IgG-Fc glycans can have an anti-inflammatory 
effect is by binding DC-SIGN, a C-type lectin which is present on dendritic cells, to the protein 
portion of the IgG-Fc which causes the production of more FcγRIIb receptors on natural killer 
cells (Anthony, 2011). FcγRIIb are inhibitory receptors that act to reduce inflammation by 
preventing the activation of FcγRIIIa and other excitatory receptors (Anthony, 2011). 
Therefore, these results suggest a reduced capacity for people with PD compared with controls 
in the current study to prevent ADCC caused inflammation, at least in terms of sialylation. 
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There was no significant difference overall in core fucosylation (see Table 6), despite the fact 
that two of the three GPs which contain core fucosylated glycan moieties and together 
constitute more than half of the IgG glycome were significantly increased in the PD cases 
compared to the controls, i.e. GP8 and GP14, but not GP4 (see Table 4). Interestingly, all three 
of these GPs contain glycans that are structurally similar, the only difference being the number 
of galactoses terminally attached (see Appendix 1). GP8, comprised predominantly of core 
fucosylated monogalactosylated biantennary glycans, was significantly increased in the PD 
cases. Likewise, GP14, comprised of core fucosylated digalactosylated biantennary glycans, 
was significantly increased in the PD cases. The attachment of core fucose is very important for 
the pro-inflammatory capability of IgG and its absence leads to a 50-fold enhanced ability to 
cause ADCC (Pucic et al., 2011; Shields et al., 2002). As expected for IgG, there was a large 
proportion of N-glycans that were core fucosylated in both the PD cases and controls, ~97% 
and ~96.5%, respectively (Fn total; see Table 6). Therefore, core fucosylation was not 
significantly different between groups  and thus ADCC activation was no different in the PD 
cases compared with the controls in this study.  
GP5 and GP20 were the most significantly different GPs between PD cases and controls in this 
study (see Table 4). GP5 is predominantly comprised of a high-mannose glycan moiety that 
constitutes a small proportion of the total IgG glycome (<1%). This small percentage has been 
replicated in other studies (Lauc et al., 2013; Pucic et al., 2011). Although it may present as a 
small difference in terms of the total IgG glycome, the majority of the PD cases had a lower 
value than the controls in this study and this difference was highly significant (GP5). Mannose-
rich glycans have an increased affinity for MBL which initiates the lectin complement cascade 
via opsonisation of IgG and the cells to which they are bound (Fujita, 2002; Malhotra et al., 
1995). Both mannose and GlcNAc (GlcNAc to a lesser degree than mannose) are prominent 
ligands for MBL and are usually found on the surface of pathogens, such as bacteria and 
viruses (Fujita, 2002; Malhotra et al., 1995). Other monosaccharides, such as sialic acid and 
galactose, normally attach to mammalian glycoproteins and have undetectable affinity for MBL 
(Fujita, 2002; Malhotra et al., 1995). This enables the specific recognition of glycans on 
pathogen cell surfaces. However, this innate immunity system can malfunction and has been 
implicated in many disease processes due to an increase in agalactosylated and mannose-rich 
N-glycans. For example, MBL recognises clusters of agalactosylated IgG within the synovial 
joints of rheumatoid arthritis patients and activates the lectin complement cascade which 
contributes to inflammation by damaging the surrounding tissue (Arnold et al., 2007; Malhotra 
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et al., 1995). Therefore, both IgG with high-mannose glycans and agalactosylated glycans could 
cause an increased activation of complement-caused inflammation.  
Interestingly in the current study, both high-mannose glycans (GP5) and agalactosylated 
glycans (G0n) had lower relative abundances in the PD cases compared with the controls. 
Moreover, a higher relative abundance of GP5 in the neutral glycome (GP5n) was associated 
with a higher relative abundance of agalactosylated glycans (G0n) in both the PD cases and 
controls. GP5 is an agalactosylated glycan structure. Consequently an increase in GP5 was 
expected to cause an increase in total agalactosylated structures. As previously discussed (see 
Section 4.1.2), advancing age was significantly associated with both an increase in GP5 and 
other agalactosylated (G0n) biantennary glycans in the PD cases but not the controls. Due to 
age and gender-matching of PD cases and controls in the current study, differences between 
the two independent groups associated with advancing age may indicate a propensity for the 
IgG in people with PD to become more pro-inflammatory at a faster rate than those in the 
general population. Therefore, the presence of PD appears to be associated with more rapid 
biologically ageing, as evidenced by the modifications of peripheral IgG glycosylation.  
GP20 was another peak that was found to be significantly different between groups. As 
illustrated in Appendix 1, and reported previously (Krištić et al., 2014; Lauc et al., 2013; Pucic 
et al., 2011), it is unknown what type of N-glycans contribute to GP20. However, similar to 
GP5, GP20 was significantly reduced in nearly all PD cases compared to the controls. 
Furthermore, GP5 and GP20 were significantly and strongly correlated in the control group (rs 
= 0.71, P = 0.0000) but there was no significant correlation found in the PD cases (rs = 0.10, P = 
0.347), mainly due to both GPs having small relative abundances in these individuals. 
Unsurprising, these two correlations produced a highly significant difference when analysing 
with Fisher’s r-to-z transformation (z = 5.42, P = 0.0000). While the inflammatory influence of 
GP20 on IgG cannot be deduced for the purpose of this study, this may be the first evidence 
that the N-glycans of GP20 are produced out of a similar biosynthetic pathway as GP5. It was 
unclear from the current study how different genetic or environmental factors contributed to 
this observation, but further investigation may be warranted. 
The addition of terminal sialic acid and the lack of core fucose are two modifications in the IgG 
glycome that can be considered as being in equilibrium, at least in terms of ADCC activation. 
Increased sialic acid leads to an increased inhibition of ADCC and decreased core fucose leads 
to a significant increase in ADCC activation, up to 50-fold in in vitro studies (Pucic et al., 2011; 
Shields et al., 2002). Thus the results in Study 1 support the hypothesis that the peripheral IgG 
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glycome profile is different in people with PD compared with the control population, and this 
difference infers an increased pro-inflammatory capacity by activating complement-caused 
inflammation rather than inflammation caused by activating ADCC, as people with PD age. 
Longitudinal studies are required for validation of this hypothesis. 
 
 4.2   Study 2: Utility of IgG N-Glycans in Identifying Risk of Cognitive Decline 
Owing to the clinical heterogeneity of the disease, it was hypothesised that the peripheral IgG 
glycome within a population of people with PD would have a different glycosylation profile 
between different clinical motor subtypes. Specifically, the PIGD motor subtype infers a high 
risk of cognitive impairment and therefore would have utility in identifying people with PD 
who are at risk of developing cognitive impairment. Moreover, it was hypothesised that 
differences would exist in the peripheral IgG glycome of people with PD who have semantic 
fluency impairment, and hence are at higher risk of developing cognitive impairment. 
Therefore, the purpose of Study 2 was to determine whether the IgG glycome had utility in 
identifying risk of cognitive decline in people with PD. In order to achieve this, PD cases were 
separated into respective clinical motor subtypes, according to MDS-UPDRS guidelines (Goetz 
et al., 2008), or separated on how they performed on the animal naming task. Semantic 
fluency impairment for the purpose of the current was study defined as a score of less than 20 
which was congruent with previous studies (Pereira et al., 2014; Williams-Gray et al., 2009).  
 
4.2.1   Batch Effects 
Mild batch effects may have been present, as indicated by some of the boxplots of GPs 
separated according to plate number in Study 1 (see Appendix 4) and the inability to block for 
clinical motor subtype and animal naming task score as well as case status. However, batch 
effects did not have an influence in this study, as evident by the inability of PCA to cluster 
samples according to plate number in section 3.2.2 Batch Effects (see Fig. 9a). There was also 
no evidence of separation in the PD case according to motor subtype (see Fig. 9b) or animal 
naming task score (see Fig. 9c), thus indicating that the peripheral IgG glycome may not be 
useful in identifying risk of cognitive decline.  
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4.2.2   Influence of Motor Subtype on the IgG Glycome 
Previous studies have indicated the differential progression of PD according to clinical motor 
subtype using longitudinal study designs and also [123I]FP-CIT-SPECT (Alves et al., 2006; Eggers 
et al., 2011; Eggers et al., 2012). In particular, the speed of disease progression and 
subsequent development of dementia have been linked to people classified as having a PIGD, 
non-tremor dominant motor subtype (Alves et al., 2006). This suggests that these subtypes 
have different aetiopathological pathways leading to the development of PD, thereby 
warranting the interest in analysing the IgG glycome in terms of motor subtype. The same 
statistical comparisons were performed in terms of motor subtype. However, as earlier 
indicated by PCA, no difference in the relative abundances of either GPs or derived traits 
reached statistical significance (P < 8.06 x10-4) in this component of Study 2. Thus, the 
glycosylation of peripheral IgG cannot be used to class people with PD according to their motor 
subtype, and therefore rejects the hypothesis that it has utility in identifying people with PD 
who are at risk of cognitive decline as determined by their clinical motor subtype.  
 
4.2.3   Influence of the Animal Naming Task Score on the IgG Glycome 
Impairment of semantic fluency is associated with a higher risk of cognitive impairment and 
dementia development in people with PD (Hu et al., 2014; Pereira et al., 2014; Williams-Gray 
et al., 2009). Therefore, the risk of cognitive impairment was determined using the animal 
naming task, with impaired semantic fluency defined as a score less than 20 (Williams-Gray et 
al., 2009). In unison with the evaluation of the peripheral IgG glycome in terms of clinical 
motor subtype, similar comparisons were performed in terms of impaired (score less than 20) 
or normal (score equal to or greater than 20) semantic fluency in people with PD. However, as 
indicated by PCA, no difference in either GPs or derived traits reached statistical significance  
in this component of Study 2 (see Section 3.2.4). Thus, the glycosylation of peripheral IgG 
cannot be used to identify people with PD that may be at risk of dementia development, and 
therefore rejects the hypothesis that it has utility in identifying people with PD who are at risk 
of cognitive decline as determined by impaired semantic fluency.  
Using the results of Study 2, it can be hypothesised that the peripheral IgG glycome profile in 
people with PD was affected by factors outside the CNS or close to sites of bi-directional 
interaction between the CNS and the periphery. Consequently, the modifications in the 
peripheral IgG glycome profiles presented in Study 1 may have utility of not only identifying 
clinical PD presence, but rather prodromal disease presence, as alpha-synuclein inclusions are 
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hypothesised to begin in the ENS and progress along the vagal nerve to the CNS during the 
prodromal phase. 
 
 4.3   A Novel Biomarker of PD Presence but not Risk of Cognitive Decline 
Given the results presented in Studies 1 and 2, the IgG glycome may be useful as a novel 
biomarker of idiopathic PD presence but not risk of cognitive decline. It was demonstrated in 
Study 1 that the peripheral IgG glycome in the PD cases was indicative of an increased capacity 
to biologically age, as evident by the significant association of advancing age and an increase in 
the relative abundance of agalactosylated biantennary glycans, as well as a concurrent 
decrease in the relative abundance of digalactosylated biantennary glycans, in the PD cases 
but not the controls. These two modifications in IgG-Fc glycosylation make the IgG more pro-
inflammatory, a hallmark feature in a number of chronic diseases. In PD, the severity of the 
underlying pathology increases as the disease progresses, which occurs as an individual ages 
and, therefore, was a confounder of the effect of advancing age on pro-inflammation. There 
were no statistically significant differences between the PD cases and controls in terms of age 
and gender. Consequently, any association related to age alone should have been measured 
concurrently in the control population. However, advancing age did not reach a significant 
association with any GP or derived trait in the control group of the study. Thus it may be 
considered that the peripheral IgG in people with PD have a propensity to become more pro-
inflammatory at a faster rate as they age, and this may be linked to the severity of pathology 
during the course of the disorder. 
One could then wonder whether the propensity of IgG to become more pro-inflammatory was 
associated with specific motor subtypes of PD. For example, people with a PIGD dominant 
motor subtype are more likely to develop PD dementia and other disturbances, such as 
depression and sleep disorders, as the disease progresses (Alves et al., 2006; Thenganatt & 
Jankovic, 2014). Indeed, imaging studies have shown that different sections of the brain are 
affected during the progression of these motor subtypes (Eggers et al., 2011; Eggers et al., 
2012). Additionally, longitudinal studies have also implicated a low animal naming score as 
identifying people with PD that have impaired semantic memory, and are therefore at an 
increased risk for cognitive impairment and dementia development (Hu et al., 2014; Pereira et 
al., 2014; Williams-Gray et al., 2009). This is an important point as approximately 80% of 
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people with PD will develop dementia in due course (Aarsland et al., 2003; Hely et al., 2008). 
However, when analysing the IgG glycome in terms of these factors, there were no significant 
differences evident. 
Inflammation may facilitate the neuron-to-neuron propagation of PD pathology (Holmes et al., 
2009; Menza 2010; Reale et al, 2009; Rocha et al., 2014; Lema Tome 2013). It has been 
demonstrated that CSF IgG from people with PD can induce dopaminergic neuron injury after 
stereotaxic injection into the SN of mice. Furthermore, dopaminergic neurons within PD brains 
show strong immunolabelling for IgG, and IgG specific for alpha-synuclein have been found in 
both CSF and blood plasma (Sanchez-Guajardo et al., 2013). The proportion of IgG 
immunolabelled neurons within the brain is positively associated with the number of activated 
microglia and negatively associated with the number of dopaminergic neurons (Sanchez-
Guajardo et al., 2013). Consequently, as PD progresses an increase in pro-inflammatory IgG 
would be expected. While the overall trend of the PD cases in the current study was to have 
lower relative abundances of N-glycans that infer a larger fraction of pro-inflammatory IgG, 
they had IgG that pertain to an increased activation of complement-caused inflammation as 
they aged in the context of a cross-sectional study. This will need to be validated in a 
longitudinal study.  
It would be expected that the level of neuroinflammation within the CNS would be different 
between clinical motor subtypes of PD, as evident by the interaction of CNS IgG with 
peripheral IgG. However, as shown in Study 2 this is not the case. Taken together, these results 
may be indicative of the peripheral IgG interacting with PD pathology in the ENS and as it 
propagates from the ENS to the CNS along the vagal nerve, a known bi-directional interaction 
site (Takeda et al., 2014). This conjecture is based on the notion that although the clinical 
motor subtypes of PD have different aetiopathological pathways of neurodegeneration within 
the CNS, and consequently the neurons containing alpha-synuclein aggregates are 
differentially exposed to the known sites of bi-directional interaction between the CNS and the 
periphery, there was no evidence of a more severe motor subtype in terms of modifications to 
the glycosylation of peripheral IgG. The ENS has no protective layer like the BBB and contains 
one of two vulnerable nervous tissues, in terms of risk to environmental exposure, in the body. 
Due to this lack of a protective layer, the ENS also interacts with the peripheral inflammatory 
system. Furthermore, alpha-synuclein inclusions, particularly Lewy neurites, increase in 
severity as PD pathology progresses, much like the staging of alpha-synuclein inclusions in the 
brain (Braak, de Vos, et al., 2006). Thus the increases in pro-inflammatory IgG associated with 
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age in people with PD presented in Study 1 are reasonable in terms of the hypothesised 
disease process. 
Interestingly, GP5 was not previously associated with advancing age and may therefore be 
unique to PD. GP5 contains predominantly high mannose glycans that are classed as 
agalactosylated biantennary glycan moieties. Therefore, an increase in GP5 was expected to 
cause an increase in total agalactosylated biantennary N-glycans. GP5 and GP20 were 
significantly reduced in nearly all PD cases compared to the matched controls. Subsequently, 
GP5 and GP20 were significantly and strongly correlated in the control group but there was no 
significant correlation found in the PD cases (see Fig. 8). Furthermore, GP20 was not 
associated with advancing age in either group, unlike GP5 or agalactosylated biantennary 
glycans (G0n). It is not known what glycan moieties constitute GP20, and therefore, the 
inflammatory influence that the GP20 N-glycans have on IgG cannot be deduced for the 
purpose of this thesis. Even so, this may be the first evidence that the N-glycans of GP20 are 
involved in a similar biosynthetic pathway as GP5. Whether this is under genetic or 
environmental control is unclear from Study 1, but it warrants further investigation.  
The modifications of peripheral IgG glycosylation in people with PD may represent an 
interphenotype of the disease: the mutual interaction between the genetic makeup, the 
environment and the disease phenotype. Therefore, a reasonable explanation for the 
peripheral IgG glycome not having utility in indicating risk of cognitive decline in people with 
PD is that the peripheral IgG glycoproteins are interacting with the ENS and vagal nerve 
neurons that have alpha-synuclein inclusions, and the increase in peripheral pro-inflammatory 
IgG is due to the increase in severity of these inclusions. Hence, peripheral IgG N-glycans may 
be useful biomarkers in identifying people with prodromal PD, which is hypothesised to begin 
in the ENS.  
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5.0   Summary 5.1   Findings 
It was demonstrated in Study 1 that the peripheral IgG glycome in the PD cases was indicative 
of an increased capacity to biologically age. This was evident by the significant association of 
advancing age and an increase in the relative abundance of agalactosylated biantennary 
glycans, and a concurrent decrease in the relative abundance of digalactosylated biantennary 
glycans in the PD cases but not the controls. While advancing age has previously been 
associated with modifications to the glycosylation of IgG, making them more pro-
inflammatory, advancing age was only associated with significant increases in modifications to 
IgG glycosylation that infer more pro-inflammatory IgG in the PD cases and not the controls. 
Thus, the peripheral IgG of people with PD has a propensity to become more pro-inflammatory 
and lead to an increased activation of complement-caused inflammation as they aged.  
PD has a heterogeneous presentation of clinical symptoms, and many genetic and 
environmental factors contribute to the development of the disease. While this is true, it was 
demonstrated in Study 2 that the peripheral IgG glycome does not have utility in 
differentiating between clinical motor subtypes of PD, which result from different 
aetiopathological pathways of PD development and progression within the CNS, particularly 
from the SN to the neocortex. Combined, these results are indicative of the peripheral IgG 
interacting with PD pathology in the ENS as well as when it propagates from the ENS to the 
CNS along the vagal nerve. Inflammation may facilitate the neuron-to-neuron propagation of 
PD inclusions along this pathway and thus be a contributor to PD development during the 
prodromal phase. Hence, the peripheral IgG glycome may be useful as a novel biomarker of PD 
presence in the prodromal phase of the disease and may represent an interphenotype of PD.  
 
 5.2   Strengths 
The innovation and strength of this thesis was that for the first time the potential of using 
peripheral IgG glycomic biomarkers to identify people with PD, as well as identify people with 
PD who are at risk of cognitive decline, was investigated. This was done using an established 
PD cohort based in Perth, Western Australia; another strength of the thesis. A further strength 
was that the technology used to analyse the glycans, i.e. UPLC, is a validated method that is 
utilised in research worldwide and published frequently (Knezevic et al., 2009; Krištić et al., 
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2014; Lauc et al., 2013; Lu et al., 2011; Pucic et al., 2011). Furthermore, the statistical methods 
used in these studies influenced the way data was analysed in this thesis. 
 
 5.3   Limitations  
Although this thesis presented some strong results, there were some limitations. Firstly, the 
sample size included in this thesis was relatively small compared to other studies analysing 
modifications to the glycosylation of IgG. This may have contributed to some of the deviation 
from previous findings, such as a weak but statistically insignificant correlation between BMI 
and agalactosylated glycans. Secondly, although both populations are Caucasian in descent, 
they are from different geographical parts: Australia and Croatia. This was a predetermined 
aspect of the study out of the control of the researcher. Plasma glycome variability has been 
reported between different populations in previous studies (Knezevic et al., 2009). However, 
this inter-population variability has not been fully explored in terms of the peripheral IgG 
glycome. Therefore, the consequence of using Caucasian controls from a different population 
in this thesis is unknown. Lastly, due to time constraints not all non-motor aspects of clinical 
PD were explored, such as depression and sleep disorders. Thus the peripheral IgG glycome 
may have utility as a biomarker of these non-motor aspects of PD as well. 
 
 5.4   Implications for Future Research 
The utility in using the peripheral IgG glycome as a means of identifying people with PD, 
particularly in the prodromal phase, needs to be further investigated. This will involve a 
longitudinal study design with at-risk, suboptimally healthy individuals who do not have any 
current signs of PD. Moreover, the contribution of environmental or genetic influences to the 
changes reported in this thesis needs to be further investigated. Importantly, it would be 
recommended that future studies analysing the IgG glycome for use as a biomarker of an 
interphenotype of disease utilise intra-population controls and a larger study sample.   
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Appendix 1 – The Glycan Moieties of IgG 
Below are pictorial representations of the dominant glycan moieties in each peak of UPLC. All exist in 
the total glycome. However, the neutral glycome is the sum of all the glycans within the IgG glycome 
that do not have terminal sialic acid, i.e. GP1:15=GPn. GP3 was excluded from all analyses because in 
some samples it coeluted with a contaminant that significantly affected its value. GP20 is represented as 
a question mark as its glycan moiety is yet to be determined.  
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Appendix 2 – Animal Naming Task 
Semantic fluency dysfunction is associated with a higher risk of cognitive impairment and 
dementia development (Hu et al., 2014; Pereira et al., 2014; Williams-Gray et al., 2009). 
Therefore, the risk of cognitive decline was determined using the animal naming task. Details 
regarding the animal naming task have been adapted from the Parkinson’s Centre procedures 
manual.  
The animal naming task is a timed task whereby participants are asked to name as many 
animals (the category) as they can in 60 seconds. It is administered to each participant the 
same way using a script by trained staff within the Parkinson’s Centre research group. The task 
is administered following a similar verbal fluency task that involves specific letters of the 
alphabet (F, A, S). Therefore, participants are prompted if they are sticking to the previous 
rules. The score is the total number of correct animals generated in 60 seconds. Rule breaks 
receive no penalty or score. 
 
Instructions to Participant 
Administrator: “Now we are doing something a little bit different. This time, you will have one 
minute to think of as many animals as you can. You can name any animal (pause) including 
mammals, birds, fish, reptiles, and insects and you can use any letter of the alphabet. Again, if 
you draw a blank, use this time to think.” 
(pause)  
“Does that make sense?”  
(wait for response) 
“You have one minute to name as many animals as you can (pause) starting now.”  
*If the participant begins to name specific breeds of animals, i.e. Beagle, Labrador, Great 
Dance, etc. prompt: 
“Try to name different animals rather than breeds of animals.” 
*If the participant is sticking to previous rules and using the same letter of the alphabet for all 
animals, prompt: 
“You can use any letter of the alphabet.” 
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Scoring Conditions 
• A type of animal, followed by specific types of animals (e.g. birds, then parrot, 
cockatoo) is scored as incorrect, but the following specific types are all scored as 
correct. However, if a type of animal (e.g. birds) but no further specific types are given, 
the type of animal is scored as one correct answer. 
• Age variants (e.g. cow, then calf) are not acceptable and scored a rule break.  
• Extinct, imaginary or magic animals are acceptable (these are animals such as unicorn, 
not made up animals). 
• Insects, mammals, reptiles; all types of animals are correct regardless of the category 
to which they belong.  
• Names of animals (e.g. Fido or Rover) are not acceptable and are classified as rule 
breaks. 
• Repetitions are direct repetitions of previously said animals, and are a rule break. 
• Repetitions and rule breaks cannot be retracted and are counted as incorrect 
answers, even if the participant recognises the error has been made. 
• Sexual variants (e.g. bull, heifer) are acceptable. 
• Species variation, are acceptable as they are classed as distinct animals (e.g. gorilla, 
monkey and chimpanzee). This also includes variations such as different possums (e.g. 
sugar glider possum, ring tail possum). It could be argued that smaller variations (e.g. 
Appaloosa horse, Arabian horse) may not be acceptable. However, these will also be 
scored as correct.  
 
Score Card Example 
1-15sec 
 
 
 
16-30sec 
31-45sec 46-60sec 
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Appendix 3 – Blocking Data 
Below are the raw plate layouts, in the format “CaseStatus_Age_Gender”. For easy viewing, the PD Cases are in orange boxes and the Controls (Cont) are in 
the light green boxes. The yellow boxes represent samples that did not pass visual quality control following UPLC. The purple boxes represent samples which 
were removed from the study due to meeting ParkC exclusion criteria. Reference standards and sample blanks are included as a normal part of quality 
control for UPLC.   
PLATE 1 
           
 
1 2 3 4 5 6 7 8 9 10 11 12 
A Case_51_M Cont_51_M Case_40_F Cont_40_F Case_54_M Cont_54_M Case_54_F Cont_54_F Case_56_M Cont_56_M Case_54_F Cont_54_F 
B Cont_56_F STANDARD Cont_56_M Case_56_M Cont_58_F Case_58_F Cont_58_M Case_58_M Cont_58_F Case_58_F Cont_58_M Case_58_M 
C Case_82_F Cont_82_F Case_78_M Cont_90_M Case_79_F Cont_79_F Case_85_1 Cont_90_M Case_77_F Cont_77_F Case_85_M Cont_85_M 
D Case_70_M Cont_70_M Case_62_M Cont_62_M Case Cont_70_M STANDARD Case_66_M Case_70_M Cont_70_M Case_62_M Cont_62_M 
E Cont_82_M Case_82_M Cont_77_F Case_77_F Cont_81_M Case Cont_76_F Case_76_F Cont_81_M Case_80_M Cont_73_F Case_73_F 
F Case_46_F Cont_46_F Case_57_M Cont_57_M Case_58_F Cont_58_F Case_58_M Cont_58_M Case_56_F STANDARD Case_60_M Control 
G Cont_60_M Case_60_M Cont_59_F Case_59_F Cont_60_M Case_60_M Cont_59_F Case_59_F Cont_61_M Case_61_M Cont_62_F Case 
H Cont_63_M Case Cont_66_M Case_66_M Cont_63_M Case_63_M Cont_66_M Case_66_M Cont_63_M Case_63_M Cont_66_M BLANK 
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PLATE 2 
           
 1 2 3 4 5 6 7 8 9 10 11 12 
A Case_58_F Cont_58_F Case_62_M Cont_62_M Case_62_F Cont_62_F Case_63_M Cont_63_M Case_75_M Cont_75_M Case_63_M Cont_63_M 
B Cont_79_M STANDARD Cont_70_F Case_70_F Cont_79_M Case_79_M Cont_70_F Case_70_F Cont_78_M Case_78_M Cont_69_F Case_69_F 
C Case_68_F Cont_68_F Case Cont_78_M Case_67_F Cont_67_F Case Cont_77_M Case_65_F Cont_65_F Case_77_M Cont_77_M 
D Cont_77_M Case_77_M Cont_64_M Case_63_M Cont_77_M Case_77_M STANDARD Case_79_M Cont_64_M Case_63_M Cont_76_M Case_76_M 
E Case_63_F Cont_63_F Case_63_M Cont_64_M Case Cont_63_F Case_64_M Cont_64_M Case_64_F Cont_64_F Case_64_M Cont_64_M 
F Cont_76_M Case_76_M Cont_76_M Case_76_M Cont_74_M Case_74_M Cont_72_M Case_72_M Control STANDARD Cont_74_M Case_74_M 
G Case_64_M Cont_64_M Case_64_F Cont_64_F Case_72_M Cont_72_M Case_65_F Cont_65_F Case_67_M Control Case_68_M Cont_68_M 
H Cont_65_M Case_65_M Cont_66_M Case_66_M Cont_74_M Case_74_M Cont_66_M Case_66_M Cont_73_M Case Case_75_M BLANK 
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PLATE 3 
           
 1 2 3 4 5 6 7 8 9 10 11 12 
A Case Cont_70_M Case Control Case Control Case Control Case_68_M Cont_68_M Case Cont_71_M 
B Case STANDARD Cont_67_M Case_73_M Cont_73_M Case_67_M Cont_67_M Case_71_M Cont_71_M Case_72_M Cont_73_M Case_74_M 
C Cont_74_M Case_72_M Cont_73_M Case_73_M Cont_73_M Case_62_F Cont_62_F Case_43_M Cont_43_M BLANK STANDARD STANDARD 
D STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD 
E STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD 
F STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD 
G STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD 
H STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD STANDARD 
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Appendix 4 – Boxplots of Batch Comparisons 
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Appendix 5 – Q-Q Plot for Visual Inspection of Normality 
Below are the Q-Q plot for the PD cases and controls at each variable before transformation. 
Transformation details can be found in Appendix 6.  
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Appendix 6 – Data Transformation Tables 
Normality of Study 1 data was determined using Q-Q plots. Details of transformations used are tabulated below. Transformed data was only used for the 
purpose of employing Student’s t-test. Samples were independent of each other.   
Variable Nature Transformation Notes Variable Nature Transformation Notes 
Case 
   
Control 
  
  
GP1 pos skew 
 
doesn't normalise GP1 pos skew 
 
doesn't normalise 
GP2 pos skew ln(1+x) 
 
GP2 pos skew ln(1+x)   
GP4 normal 
  
GP4 normal 
 
  
GP5 pos skew ln(1+x) 
 
GP5 pos skew ln(1+x) possible outlier 
GP6 pos skew ln 
 
GP6 pos skew ln   
GP7 pos skew ln(1+x) possible outlier GP7 slight pos skew ln(1+x) match transformation 
GP8 pos skew ln 
 
GP8 slight pos skew ln match transformation 
GP9 normal 
  
GP9 normal 
 
  
GP10 normal ln match transformation GP10 pos skew ln   
GP11 pos skew ln(1+x) 
 
GP11 pos skew ln(1+x)   
GP12 pos skew ln(1+x) possible outlier GP12 pos skew ln(1+x) possible outlier 
GP13 pos skew ln(1+x) possible outlier GP13 pos skew ln(1+x)   
GP14 pos skew ln 
 
GP14 pos skew ln   
GP15 pos skew ln(1+x) 
 
GP15 pos skew ln(1+x)   
GP16 pos skew ln 
 
GP16 normal ln match transformation 
GP17 pos skew ln(1+x) 
 
GP17 pos skew ln(1+x) possible outlier 
GP18 pos skew ln 
 
GP18 pos skew ln   
GP19 pos skew ln 
 
GP19 pos skew ln   
GP20 pos skew ln(1+x) possible outlier GP20 pos skew ln(1+x) possible outlier 
GP21 pos skew ln(1+x) 
 
GP21 pos skew ln(1+x)   
GP22 pos skew 
 
possible outlier GP22 pos skew 
 
doesn't normalise 
GP23 normal 
  
GP23 normal 
 
  
GP24 normal     GP24 normal   possible outlier 
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Variable Nature Transformation Notes Variable Nature Transformation Notes 
GP1n pos skew 
 
doesn't normalise GP1n pos skew 
 
doesn't normalise 
GP2n pos skew ln(1+x) 
 
GP2n pos skew ln(1+x)   
GP4n normal 
  
GP4n normal 
 
  
GP5n pos skew ln(1+x) 
 
GP5n pos skew ln(1+x) possible outlier 
GP6n normal ln match transformation GP6n pos skew ln   
GP7n pos skew ln(1+x) possible outlier GP7n pos skew ln(1+x)   
GP8n normal 
  
GP8n normal 
 
possible outlier 
GP9n normal 
  
GP9n normal 
 
  
GP10n normal ln match transformation GP10n pos skew ln   
GP11n pos skew ln(1+x) 
 
GP11n pos skew ln(1+x) possible outlier 
GP12n pos skew ln(1+x) possible outlier GP12n pos skew ln(1+x)   
GP13n pos skew 
 
possible outlier GP13n pos skew 
 
doesn't normalise 
GP14n pos skew ln 
 
GP14n pos skew ln   
GP15n pos skew ln   GP15n pos skew ln   
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Variable Nature Transformation Notes Variable Nature Transformation Notes 
Percentage of Sialylation of Fucosylated Structures with Bisecting GlcNAc   
FBGS/(FBG+FBGS) normal 
  
FBGS/(FBG+FBGS) normal 
 
  
Percentage of Sialylation of Fucosylated Structures without  Bisecting GlcNAc   
FGS/(FG+FGS) normal ln match transformation FGS/(FG+FGS) pos skew ln possible outlier 
Percentage of Sialylation of Fucosylated Galactosylated Glycans with Bisecting GlcNAc   
FBG2S1/(FBG2       
+FBG2S1+FBG2S2) normal ln match transformation 
FBG2S1/(FBG2       
+FBG2S1+FBG2S2) pos skew ln   
FBG2S2/(FBG2       
+FBG2S1+FBG2S2) normal 
  
FBG2S2/(FBG2       
+FBG2S1+FBG2S2) normal 
 
  
Percentage of Sialylation of Fucosylated Galactosylated Glycans without Bisecting GlcNAc   
FG1S1/(FG1+FG1S1)       
normal 
  
FG1S1/(FG1+FG1S1       
+FG2S2+FG2S2) normal 
 
  
FG2S1/(FG2 
+FG2S1+FG2S2) normal ln match transformation 
FG2S1/(FG1+FG1S1       
+FG2S2+FG2S2) pos skew ln possible outlier 
FG2S2/(FG2 
+FG2S1+FG2S2) normal ln match transformation 
FG2S2/(FG1+FG1S1       
+FG2S2+FG2S2) pos skew ln   
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Variable Nature Transformation Notes Variable Nature Transformation Notes 
Percentage of Galactosylation   
G0n normal 
  
G0n normal 
 
  
G1n normal 
  
G1n normal 
 
possible outlier 
G2n pos skew ln 
 
G2n pos skew ln   
Percentage of Fucosylation (+/- Bisecting GlcNAc)   
Fn total neg skew ln(100-x) 
 
Fn neg skew ln(100-x)   
FG0n/G0n total neg skew ln(101-x) 
 
FG0n/G0n neg skew ln(101-x)   
FG1n/G1 n total neg skew ln(101-x) 
 
FG1n/G1n neg skew ln(101-x)   
FG2n/G2 n total neg skew ln(98-x) 
 
FG2n/G2n neg skew ln(98-x) possible outlier 
Percentage of Fucosylation with Bisecting GlcNAc   
FBn normal ln match transformation FBn pos skew ln   
FBG0n/G0n normal 
  
FBG0n/G0n normal 
 
  
FBG1n/G1n normal ln match transformation FBG1n/G1n pos skew ln   
FBG2n/G2n pos skew ln 
 
FBG2n/G2n pos skew ln   
Percentage of Fucosylation without Bisecting GlcNAc   
Fn normal 
  
Fn normal 
 
  
FG0n/G0n normal 
  
FG0n/G0n normal 
 
  
FG1n/G1n normal 
  
FG1n/G1n normal 
 
  
FG2n/G2n neg skew ln(90-x) 
 
FG2n/G2n neg skew ln(90-x)   
Other Traits   
FBn/(Fn+FBn) normal 
  
FBn/(Fn+FBn) normal 
 
  
FG2n/(BG2n+FBG2n) normal 
  
FG2n/(BG2n+FBG2n) normal 
 
  
BG2n/(FG2n+FBG2n) pos skew ln   BG2n/(FG2n+FBG2n) pos skew ln   
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Appendix 7 – Levene’s Test 
Levene’s test [1, 194] was conducted on all normal and log-normal variables (according to the 
transformation tables in Appendix 6) to test the assumption of homogeneity of variances. For the 
test, P < 0.05 is considered to be a significant difference and thus not meet this assumption, i.e. the 
variable has heterogeneous variances between groups. The differences between the means of the 
variables with heterogeneous variances (bolded below) could still be performed with Welch’s 
correction, and this is easily programed into the Student’s t-test (‘stats’ package) R code. The degrees 
of freedom (df) to be used for Student’s t-test for each variable are specified below. 
 
 
Variable F-statistic P - value  df Variable F-statistic P - value  df 
GP2 3.2628 0.072 194 GP2n 4.2439 0.041 194 
GP4 0.0572 0.811 194 GP4n 0.2462 0.620 194 
GP5 18.5170 2.668 X10-5 160.289 GP5n 25.1910 1.171 x10-6 153.062 
GP6 0.2299 0.632 194 GP6n 0.2639 0.608 194 
GP7 1.2590 0.263 194 GP7n 1.5193 0.219 194 
GP8 1.0880 0.298 194 GP8n 1.2102 0.273 194 
GP9 2.0384 0.155 194 GP9n 1.5239 0.219 194 
GP10 0.4796 0.489 194 GP10n 0.4478 0.504 194 
GP11 0.3763 0.540 194 GP11n 0.2338 0.629 194 
GP12 1.4810 0.225 194 GP12n 1.4794 0.225 194 
GP13 1.9887 0.160 194 GP14n 0.3655 0.546 194 
GP14 0.6940 0.406 194 GP15n 0.0002 0.988 194 
GP15 0.0877 0.768 194 
    GP16 0.0027 0.959 194 
    GP17 14.8470 1.584 x10-4 163.601 
    GP18 0.0247 0.875 194 
    GP19 0.6028 0.438 194 
    GP20 35.1200 1.393 X10-8 134.135 
    GP21 47.2640 8.276 X10-11 149.140 
    GP23 1.1053 0.294 194 
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Variable F-statistic P - value  df 
Percentage of Sialylation of Fucosylated Structures with Bisecting GlcNAc   
FBGS/(FBG+FBGS) 0.0946 0.759 194 
Percentage of Sialylation of Fucosylated Structures without  Bisecting GlcNAc   
FGS/(FG+FGS) 1.4582 0.229 194 
Percentage of Sialylation of Fucosylated Galactosylated Glycans with Bisecting GlcNAc   
FBG2S1/(FBG2+FBG2S1+FBG2S2) 0.0482 0.826 194 
FBG2S2/(FBG2+FBG2S1+FBG2S2) 0.4907 0.484 194 
Percentage of Sialylation of Fucosylated Galactosylated Glycans without Bisecting 
GlcNAc   
FG1S1/(FG1+FG1S1)       1.5984 0.208 194 
FG2S1/(FG2+FG2S1+FG2S2) 0.0001 0.991 194 
FG2S2/(FG2+FG2S1+FG2S2) 1.3216 0.252 194 
Percentage of Galactosylation   
G0n 0.5758 0.449 194 
G1n 3.9443 0.048 189.123 
G2n 0.3070 0.580 194 
Percentage of Fucosylation (+/- Bisecting GlcNAc)   
Fn total 0.1689 0.682 194 
FG0n/G0n total 3.7264 0.055 194 
FG1n/G1n total 1.7655 0.186 194 
FG2n/G2n total 0.3311 0.566 194 
Percentage of Fucosylation with Bisecting GlcNAc   
FBn 0.0789 0.779 194 
FBG0n/G0n 0.2858 0.594 194 
FBG1n/G1n 0.1087 0.742 194 
FBG2n/G2n 0.8610 0.355 194 
Percentage of Fucosylation without Bisecting GlcNAc   
Fn 0.0184 0.892 194 
FG0n/G0n 0.2203 0.639 194 
FG1n/G1n 0.0019 0.965 194 
FG2n/G2n 0.5445 0.462 194 
Other Traits   
FBn/(Fn+FBn) 0.0489 0.825 194 
FG2n/(BG2n+FBG2n) 0.4573 0.500 194 
BG2n/(FG2n+FBG2n) 0.5301 0.467 194 
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Appendix 8 – Correlation Matrices 
Spearman’s correlation coefficients (rs) comparing the GPs of the total IgG glycome to each other, age and BMI. Comparisons were made if at least one group produced a 
coefficient showing a moderate relationship (rs > |0.5|). Comparisons where at least one coefficient showed a strong relationship (rs > |0.7|) are boxed. Statistically 
significant differences between the groups are highlighted for P < 0.05 (red), P < 0.01 (yellow) and P < 0.001 (green).  
Cases                                                 
  Age BMI GP1 GP2 GP4 GP5 GP6 GP7 GP8 GP9 GP10 GP11 GP12 GP13 GP14 GP15 GP16 GP17 GP18 GP19 GP20 GP21 GP22 GP23 
Age 
                       
  
BMI -0.02 
                      
  
GP1 0.32 0.09 
            
  <0.05 
       
  
GP2 0.13 0.12 0.31 
           
  <0.01 
       
  
GP4 0.37 0.27 0.62 0.24 
          
  <0.001 
       
  
GP5 0.41 0.13 0.61 0.30 0.56 
                  
  
GP6 0.36 0.12 0.52 0.44 0.53 0.52 
                 
  
GP7 0.00 -0.01 0.19 0.85 -0.07 0.22 0.24 
                
  
GP8 -0.10 0.06 -0.28 0.02 -0.19 -0.19 -0.42 0.00 
               
  
GP9 -0.04 0.07 -0.20 -0.32 -0.05 -0.01 -0.18 -0.37 -0.07 
              
  
GP10 0.21 -0.02 0.01 0.12 -0.23 0.09 0.53 0.18 -0.06 -0.27 
             
  
GP11 0.34 0.03 0.17 0.08 0.16 0.41 0.66 -0.03 -0.40 0.25 0.59 
            
  
GP12 -0.12 -0.08 -0.06 0.54 -0.41 -0.11 -0.10 0.80 0.03 -0.40 0.15 -0.26 
           
  
GP13 0.02 -0.12 0.08 0.33 -0.31 0.19 0.07 0.54 0.03 -0.10 0.37 0.19 0.51 
          
  
GP14 -0.38 -0.24 -0.55 -0.36 -0.88 -0.57 -0.66 -0.08 0.23 0.05 -0.01 -0.35 0.32 0.12 
         
  
GP15 -0.10 -0.24 -0.36 -0.22 -0.76 -0.31 -0.08 0.06 -0.12 -0.05 0.61 0.24 0.37 0.45 0.64 
        
  
GP16 0.00 -0.08 -0.13 -0.29 -0.15 -0.04 -0.10 -0.26 -0.21 0.42 -0.03 0.25 -0.32 -0.01 -0.07 -0.02 
       
  
GP17 -0.05 -0.22 0.13 0.43 -0.19 0.03 0.00 0.58 -0.27 -0.37 -0.04 -0.16 0.73 0.40 0.08 0.17 -0.13 
      
  
GP18 -0.39 -0.27 -0.59 -0.43 -0.83 -0.60 -0.66 -0.14 0.07 -0.02 -0.04 -0.33 0.24 0.02 0.82 0.52 0.33 0.13 
     
  
GP19 -0.11 -0.08 -0.15 -0.12 -0.11 -0.07 -0.04 -0.23 -0.17 0.22 -0.20 0.14 -0.13 -0.01 0.01 0.11 0.13 0.19 0.02 
    
  
GP20 -0.08 -0.18 0.18 0.03 -0.33 0.10 -0.13 0.15 -0.16 -0.10 0.12 0.10 0.25 0.51 0.25 0.32 0.15 0.42 0.21 0.15   
  
  
GP21 -0.05 -0.07 0.19 0.08 -0.01 0.06 -0.01 0.04 -0.26 -0.13 -0.10 -0.09 0.04 0.02 -0.06 -0.09 0.30 0.40 0.11 0.09 0.41 
  
  
GP22 -0.10 -0.08 0.10 0.29 -0.23 -0.06 -0.09 0.34 -0.14 -0.17 -0.04 -0.13 0.40 0.28 0.03 0.05 0.34 0.55 0.25 0.13 0.40 0.69 
 
  
GP23 -0.24 -0.17 -0.24 -0.32 -0.23 -0.38 -0.56 -0.29 -0.02 0.15 -0.53 -0.46 -0.12 -0.20 0.21 -0.15 0.50 0.16 0.48 0.32 0.15 0.55 0.45   
GP24 0.07 -0.11 -0.17 -0.15 -0.19 -0.19 -0.14 -0.19 -0.14 0.11 -0.15 -0.03 -0.12 -0.01 -0.03 -0.01 0.63 0.20 0.28 0.56 0.17 0.54 0.57 0.75 
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Controls                                               
  Age BMI GP1 GP2 GP4 GP5 GP6 GP7 GP8 GP9 GP10 GP11 GP12 GP13 GP14 GP15 GP16 GP17 GP18 GP19 GP20 GP21 GP22 GP23 
Age 
                       
  
BMI -0.04 
                      
  
GP1 0.26 0.04 
                     
  
GP2 0.03 -0.14 0.03 
                    
  
GP4 0.31 0.06 0.50 0.13 
                   
  
GP5 0.19 -0.03 0.55 0.19 0.36 
                  
  
GP6 0.13 0.06 0.32 0.39 0.57 0.37 
                 
  
GP7 -0.03 -0.13 -0.01 0.85 -0.08 0.07 0.20 
                
  
GP8 -0.22 -0.06 -0.56 -0.09 -0.55 -0.56 -0.48 0.03 
               
  
GP9 0.01 -0.10 0.00 -0.32 -0.05 -0.12 -0.35 -0.18 -0.10 
              
  
GP10 -0.21 0.08 -0.21 -0.02 -0.43 -0.19 0.27 0.06 0.22 -0.27 
             
  
GP11 -0.05 0.02 0.36 -0.04 0.13 0.37 0.40 0.01 -0.51 0.29 0.40 
            
  
GP12 -0.17 -0.09 -0.28 0.67 -0.42 -0.08 -0.03 0.81 0.28 -0.23 0.17 -0.19 
           
  
GP13 -0.14 0.07 0.17 0.31 -0.19 0.07 0.08 0.52 0.07 0.02 0.31 0.42 0.36 
          
  
GP14 -0.32 0.00 -0.49 -0.29 -0.89 -0.48 -0.64 -0.07 0.60 0.16 0.31 -0.22 0.33 0.11 
         
  
GP15 -0.33 0.03 -0.29 -0.22 -0.76 -0.29 -0.20 0.01 0.27 -0.03 0.76 0.26 0.29 0.35 0.71 
        
  
GP16 0.18 -0.03 0.18 -0.33 -0.03 0.11 -0.38 -0.27 -0.30 0.47 -0.31 0.19 -0.38 0.00 -0.07 -0.13 
       
  
GP17 0.00 0.01 0.13 0.34 -0.05 0.64 0.13 0.28 -0.30 -0.21 -0.17 0.06 0.27 0.02 -0.22 -0.12 0.03 
      
  
GP18 -0.22 -0.01 -0.42 -0.35 -0.82 -0.38 -0.72 -0.16 0.45 0.09 0.14 -0.28 0.21 -0.01 0.83 0.54 0.29 -0.10 
     
  
GP19 -0.01 -0.01 0.04 -0.03 -0.07 -0.05 -0.11 -0.07 -0.04 -0.02 0.04 0.17 -0.09 0.09 0.01 0.19 0.03 0.00 -0.01 
    
  
GP20 0.01 -0.01 0.28 0.15 -0.06 0.71 0.06 0.09 -0.37 -0.08 -0.13 0.23 0.04 0.11 -0.17 -0.07 0.22 0.83 -0.03 -0.01   
  
  
GP21 0.10 0.06 0.17 0.16 0.01 0.55 0.08 0.06 -0.38 -0.15 -0.19 0.06 0.00 -0.06 -0.27 -0.18 0.21 0.81 -0.12 -0.02 0.76 
  
  
GP22 0.09 -0.02 0.15 0.44 -0.07 0.28 0.00 0.36 -0.20 -0.33 -0.12 -0.10 0.33 0.20 -0.14 -0.06 0.15 0.45 -0.03 0.18 0.42 0.54 
 
  
GP23 0.10 0.13 -0.07 -0.14 -0.06 -0.06 -0.44 -0.16 -0.05 0.02 -0.54 -0.41 -0.10 -0.26 0.01 -0.26 0.36 0.26 0.24 0.18 0.19 0.50 0.36   
GP24 0.09 0.02 0.01 -0.07 -0.04 -0.06 -0.19 -0.13 -0.12 -0.10 -0.20 -0.09 -0.14 -0.07 -0.08 -0.06 0.29 0.17 0.10 0.57 0.13 0.42 0.43 0.75 
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Spearman’s correlation coefficients (rs) comparing the GPs of the total IgG glycome to the derived traits. Comparisons were made if at least one group produced a 
coefficient showing a moderate relationship (rs > |0.5|). Comparisons where at least one coefficient showed a strong relationship (rs > |0.7|) are boxed. Statistically 
significant differences between the groups are highlighted for P < 0.05 (red), P < 0.01 (yellow) and P < 0.001 (green). 
Cases                                   
  DT1 DT2 DT3 DT4 DT5 DT6 DT7 DT8 DT9 DT10 DT11 DT12 DT13 DT14 DT15 DT16 DT17 
Age -0.17 -0.18 -0.34 -0.28 0.06 0.11 0.01 0.02 -0.05 -0.02 0.08 0.02 0.18 0.16 0.17 0.29 0.29 
BMI -0.26 -0.07 -0.27 -0.11 -0.14 -0.13 0.02 0.16 0.02 -0.06 0.02 0.04 0.17 0.17 0.17 0.11 0.10 
GP1 -0.24 -0.07 -0.51 -0.27 0.02 -0.04 0.12 0.24 -0.04 -0.13 -0.08 0.11 0.31 0.31 0.31 0.21 0.22 
GP2 -0.36 -0.15 -0.40 -0.31 -0.21 -0.09 -0.03 0.14 -0.05 -0.05 0.06 0.07 0.30 0.28 0.26 0.31 0.31 
GP4 -0.43 0.11 -0.78 -0.18 -0.10 0.05 0.36 0.53 0.11 -0.32 -0.25 0.13 0.52 0.53 0.53 0.23 0.23 
GP5 -0.35 -0.10 -0.55 -0.30 0.05 0.00 0.04 0.29 -0.07 -0.05 0.08 0.15 0.33 0.36 0.35 0.41 0.41 
GP6 -0.30 -0.36 -0.53 -0.60 0.10 0.09 -0.11 0.11 -0.15 0.00 0.25 0.14 0.48 0.46 0.45 0.74 0.74 
GP7 -0.20 -0.29 -0.13 -0.34 -0.14 -0.08 -0.22 -0.14 -0.15 0.15 0.22 0.04 -0.03 -0.04 -0.06 0.19 0.19 
GP8 -0.38 -0.02 -0.12 0.08 -0.54 -0.26 -0.07 0.09 0.01 0.06 -0.04 0.04 -0.08 -0.05 -0.05 -0.21 -0.21 
GP9 -0.01 0.26 0.05 0.29 0.20 -0.19 0.13 0.18 0.06 -0.07 -0.13 0.05 0.08 0.12 0.11 -0.10 -0.10 
GP10 -0.06 -0.75 0.00 -0.70 0.09 0.10 -0.54 -0.49 -0.32 0.41 0.62 0.02 -0.04 -0.08 -0.09 0.62 0.62 
GP11 -0.07 -0.34 -0.19 -0.41 0.35 0.15 -0.23 -0.02 -0.22 0.17 0.39 0.15 0.32 0.30 0.29 0.70 0.69 
GP12 0.04 -0.27 0.20 -0.18 -0.17 -0.12 -0.32 -0.30 -0.22 0.24 0.22 0.04 -0.24 -0.23 -0.24 -0.06 -0.05 
GP13 -0.05 -0.27 0.07 -0.19 0.04 -0.10 -0.31 -0.28 -0.17 0.21 0.27 0.01 -0.03 -0.03 -0.05 0.25 0.25 
GP14 0.29 -0.08 0.65 0.19 -0.13 -0.29 -0.39 -0.39 -0.25 0.40 0.21 0.05 -0.62 -0.56 -0.56 -0.45 -0.45 
GP15 0.26 -0.44 0.51 -0.21 0.09 -0.10 -0.58 -0.55 -0.41 0.48 0.51 0.10 -0.34 -0.31 -0.31 0.15 0.15 
GP16 0.68 0.32 0.54 0.35 0.89 0.66 0.42 -0.29 0.60 -0.33 -0.24 -0.64 -0.12 -0.25 -0.27 0.03 0.02 
GP17 0.26 0.11 0.22 0.10 0.11 0.12 0.11 -0.06 0.04 -0.15 -0.15 -0.06 0.06 0.03 0.04 -0.08 -0.08 
GP18 0.72 0.07 0.93 0.33 0.30 0.23 -0.10 -0.54 0.09 0.18 0.06 -0.30 -0.69 -0.72 -0.72 -0.46 -0.46 
GP19 0.18 0.64 0.13 0.64 0.14 0.04 0.32 0.50 0.15 -0.42 -0.36 0.11 0.62 0.61 0.61 0.13 0.13 
GP20 0.27 0.02 0.29 0.11 0.24 -0.01 -0.03 -0.21 0.00 0.00 0.00 -0.10 -0.10 -0.12 -0.11 -0.06 -0.05 
GP21 0.44 0.32 0.28 0.26 0.42 0.25 0.57 -0.24 0.60 -0.59 -0.55 -0.63 0.08 -0.08 -0.08 -0.18 -0.18 
GP22 0.49 0.26 0.40 0.26 0.43 0.33 0.36 -0.29 0.51 -0.42 -0.33 -0.59 0.01 -0.15 -0.16 -0.05 -0.06 
GP23 0.68 0.74 0.60 0.82 0.43 0.36 0.75 -0.08 0.73 -0.67 -0.79 -0.64 -0.09 -0.20 -0.19 -0.59 -0.59 
GP24 0.64 0.67 0.50 0.69 0.61 0.51 0.66 -0.09 0.81 -0.75 -0.61 -0.72 0.30 0.10 0.10 0.03 0.03 
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Controls                                 
  DT1 DT2 DT3 DT4 DT5 DT6 DT7 DT8 DT9 DT10 DT11 DT12 DT13 DT14 DT15 DT16 DT17 
Age 0.07 0.20 -0.14 0.09 0.23 0.18 0.27 0.08 0.27 -0.21 -0.21 -0.18 0.12 0.06 0.05 -0.01 0.00 
BMI 0.04 -0.03 -0.02 -0.03 0.01 -0.02 0.07 -0.04 0.03 -0.08 -0.13 -0.07 0.02 0.00 -0.02 -0.14 -0.15 
GP1 0.03 0.15 -0.32 -0.06 0.35 0.17 0.31 0.24 0.10 -0.20 -0.19 0.03 0.25 0.24 0.23 0.07 0.08 
GP2 -0.22 0.01 -0.29 -0.16 -0.16 -0.03 0.13 0.12 0.00 -0.13 -0.12 0.05 0.24 0.22 0.22 0.10 0.12 
GP4 -0.22 0.31 -0.76 -0.08 0.19 0.18 0.55 0.48 0.29 -0.41 -0.42 0.03 0.46 0.45 0.45 -0.03 -0.01 
GP5 0.11 0.08 -0.22 -0.15 0.35 0.25 0.25 0.15 0.05 -0.14 -0.15 0.04 0.18 0.17 0.18 0.03 0.04 
GP6 -0.33 -0.21 -0.66 -0.55 -0.05 0.05 0.11 0.19 -0.08 -0.13 -0.03 0.17 0.42 0.41 0.42 0.38 0.39 
GP7 -0.21 -0.13 -0.12 -0.19 -0.20 -0.10 -0.04 -0.05 -0.11 0.03 0.04 0.06 0.05 0.05 0.05 0.07 0.08 
GP8 -0.25 -0.21 0.23 0.06 -0.61 -0.32 -0.42 -0.13 -0.19 0.28 0.26 0.07 -0.28 -0.22 -0.21 -0.07 -0.08 
GP9 -0.09 0.08 0.07 0.14 0.16 -0.17 -0.10 0.06 -0.09 0.20 0.14 0.09 -0.20 -0.17 -0.17 -0.15 -0.14 
GP10 -0.18 -0.71 0.07 -0.51 -0.25 -0.15 -0.62 -0.31 -0.52 0.43 0.59 0.25 -0.07 -0.04 -0.02 0.57 0.55 
GP11 -0.05 -0.28 -0.18 -0.32 0.31 0.08 -0.15 0.04 -0.28 0.17 0.30 0.23 0.20 0.19 0.22 0.50 0.50 
GP12 -0.14 -0.21 0.15 -0.14 -0.37 -0.22 -0.25 -0.20 -0.23 0.19 0.17 0.10 -0.16 -0.15 -0.15 -0.02 -0.02 
GP13 -0.05 -0.27 0.03 -0.22 0.05 -0.09 -0.22 -0.14 -0.24 0.17 0.25 0.11 0.00 0.01 0.01 0.30 0.30 
GP14 0.07 -0.32 0.63 0.05 -0.35 -0.36 -0.63 -0.39 -0.37 0.48 0.46 0.09 -0.53 -0.47 -0.47 -0.11 -0.12 
GP15 0.06 -0.51 0.46 -0.16 -0.19 -0.23 -0.65 -0.39 -0.52 0.47 0.56 0.21 -0.24 -0.20 -0.19 0.35 0.33 
GP16 0.70 0.26 0.50 0.36 0.87 0.59 0.20 -0.17 0.35 -0.01 -0.02 -0.40 -0.25 -0.34 -0.34 -0.10 -0.09 
GP17 0.24 0.19 0.10 0.09 0.22 0.16 0.32 -0.07 0.21 -0.28 -0.31 -0.19 0.13 0.05 0.07 -0.11 -0.11 
GP18 0.53 -0.15 0.92 0.21 0.06 0.14 -0.42 -0.46 -0.12 0.40 0.36 -0.14 -0.64 -0.65 -0.65 -0.22 -0.23 
GP19 0.11 0.54 0.07 0.63 0.09 -0.01 0.21 0.51 0.11 -0.35 -0.22 0.15 0.68 0.70 0.70 0.44 0.44 
GP20 0.30 0.10 0.17 0.03 0.36 0.21 0.22 -0.11 0.14 -0.15 -0.17 -0.16 0.06 -0.01 0.00 -0.07 -0.07 
GP21 0.37 0.30 0.14 0.21 0.38 0.21 0.53 -0.23 0.50 -0.50 -0.51 -0.52 0.18 0.00 0.02 -0.17 -0.17 
GP22 0.30 0.31 0.18 0.30 0.30 0.14 0.37 -0.09 0.39 -0.42 -0.37 -0.38 0.24 0.12 0.12 0.03 0.03 
GP23 0.56 0.70 0.43 0.74 0.31 0.19 0.70 -0.20 0.79 -0.69 -0.77 -0.73 0.12 -0.08 -0.08 -0.51 -0.50 
GP24 0.49 0.73 0.32 0.77 0.35 0.11 0.61 -0.10 0.79 -0.77 -0.64 -0.68 0.51 0.27 0.27 0.14 0.15 
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Spearman’s correlation coefficients (rs) comparing the GPs of the neutral IgG glycome to each other, age 
and BMI. Comparisons were made if at least one group produced a coefficient showing a moderate 
relationship (rs > |0.5|). Comparisons where at least one coefficient showed a strong relationship (rs > 
|0.7|) are boxed. Statistically significant differences between the groups are highlighted for P < 0.05 
(red), P < 0.01 (yellow) and P < 0.001 (green). 
Cases                               
  Age BMI GP1n GP2n GP4n GP5n GP6n GP7n GP8n GP9n GP10n GP11n GP12n GP13n GP14n 
Age 
              
  
BMI -0.02 
             
  
GP1n 0.29 0.08 
         
  <0.05 
 
  
GP2n 0.11 0.10 0.27 
        
  <0.01 
 
  
GP4n 0.35 0.27 0.58 0.17 
       
  
<0.00
1 
 
  
GP5n 0.38 0.09 0.56 0.23 0.47 
         
  
GP6n 0.34 0.09 0.48 0.38 0.45 0.43 
        
  
GP7n -0.04 -0.04 0.15 0.82 -0.17 0.17 0.17 
       
  
GP8n -0.24 -0.06 -0.48 -0.09 -0.47 -0.37 -0.64 -0.03 
      
  
GP9n -0.13 0.00 -0.29 -0.40 -0.16 -0.09 -0.31 -0.38 -0.03 
     
  
GP10n 0.14 -0.08 -0.09 0.03 -0.41 0.00 0.44 0.15 -0.06 -0.27 
    
  
GP11n 0.29 -0.03 0.08 -0.01 0.03 0.35 0.61 -0.09 -0.48 0.22 0.57 
   
  
GP12n -0.14 -0.10 -0.09 0.53 -0.47 -0.12 -0.13 0.82 0.12 -0.31 0.19 -0.24 
  
  
GP13n -0.03 -0.18 0.02 0.26 -0.45 0.16 -0.01 0.52 0.09 -0.04 0.40 0.19 0.53 
 
  
GP14n -0.39 -0.25 -0.55 -0.34 -0.89 -0.53 -0.65 -0.03 0.46 0.22 0.11 -0.25 0.34 0.20   
GP15n -0.15 -0.26 -0.37 -0.24 -0.83 -0.28 -0.10 0.07 0.08 0.09 0.68 0.30 0.38 0.51 0.68 
Controls                             
  Age BMI GP1n GP2n GP4n GP5n GP6n GP7n GP8n GP9n GP10n GP11n GP12n GP13n GP14n 
Age 
              
  
BMI -0.04 
             
  
GP1n 0.28 0.05 
            
  
GP2n 0.03 -0.14 0.00 
           
  
GP4n 0.34 0.05 0.50 0.10 
          
  
GP5n 0.19 -0.01 0.54 0.18 0.35 
         
  
GP6n 0.13 0.06 0.29 0.37 0.49 0.35 
        
  
GP7n -0.03 -0.14 -0.04 0.84 -0.14 0.07 0.16 
       
  
GP8n 0.24 -0.06 -0.58 -0.11 -0.72 -0.46 -0.64 0.04 
      
  
GP9n 0.01 -0.09 0.00 -0.34 -0.16 -0.08 -0.48 -0.17 -0.02 
     
  
GP10n -0.21 0.06 -0.26 -0.06 -0.56 -0.17 0.22 0.03 0.23 -0.28 
    
  
GP11n -0.07 0.01 0.33 -0.06 0.02 0.38 0.34 0.00 -0.48 0.28 0.37 
   
  
GP12n -0.18 -0.10 -0.30 0.67 -0.46 -0.04 -0.06 0.82 0.32 -0.18 0.18 -0.16 
  
  
GP13n -0.15 0.07 0.12 0.26 -0.30 0.08 0.00 0.49 -0.01 0.02 0.29 0.40 0.36 
 
  
GP14n -0.30 0.00 -0.46 -0.28 -0.92 -0.38 -0.65 -0.03 0.71 0.23 0.35 -0.17 0.35 0.18   
GP15n -0.31 0.01 -0.28 -0.21 -0.82 -0.21 -0.23 0.04 0.38 0.05 0.75 0.29 0.32 0.40 0.74 
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Spearman’s correlation coefficients (rs) comparing the GPs of the neutral IgG glycome to the derived traits. Comparisons were made if at least one group produced a 
coefficient showing a moderate relationship (rs > |0.5|). Comparisons where at least one coefficient showed a strong relationship (rs > |0.7|) are boxed. Statistically 
significant differences between the groups are highlighted for P < 0.05 (red), P < 0.01 (yellow) and P < 0.001 (green). 
 
Cases                                               
  DT1 DT2 DT3 DT4 DT5 DT6 DT7 DT8 DT9 DT10 DT11 DT12 DT13 DT14 DT15 DT16 DT17 DT18 DT19 DT20 DT21 DT22 DT23 
Age 0.38 -0.21 -0.37 0.03 0.08 -0.01 -0.13 -0.19 0.06 -0.22 -0.30 0.24 -0.06 0.26 0.40 0.23 0.22 -0.22 -0.04 0.37 0.38 -0.39 0.35 
BMI 0.24 -0.08 -0.26 0.05 0.02 0.04 -0.02 0.06 0.16 0.03 -0.02 -0.03 -0.17 -0.02 0.05 -0.04 -0.04 0.05 -0.17 0.03 0.04 -0.07 0.10 
GP1n 0.64 -0.62 -0.50 -0.10 0.01 -0.25 -0.28 -0.17 0.10 -0.16 -0.35 0.16 -0.12 0.13 0.27 0.17 0.16 -0.16 0.02 0.31 0.31 -0.40 0.53 
GP2n 0.27 -0.25 -0.26 -0.79 -0.88 -0.84 -0.81 -0.43 -0.34 -0.26 -0.66 0.23 0.17 0.13 0.10 0.29 0.28 -0.28 0.29 0.23 0.22 -0.31 0.54 
GP4n 0.96 -0.68 -0.92 0.24 0.23 0.07 -0.06 0.15 0.51 0.13 -0.16 -0.07 -0.53 -0.11 0.24 -0.08 -0.09 0.10 -0.45 0.21 0.22 -0.31 0.49 
GP5n 0.53 -0.35 -0.48 -0.12 -0.02 -0.22 -0.26 -0.20 0.04 -0.20 -0.38 0.20 -0.07 0.17 0.33 0.21 0.21 -0.21 0.16 0.38 0.37 -0.46 0.62 
GP6n 0.65 -0.52 -0.59 -0.10 -0.10 -0.25 -0.30 -0.72 -0.44 -0.69 -0.62 0.79 0.44 0.69 0.79 0.78 0.78 -0.77 0.00 0.81 0.81 -0.81 0.59 
GP7n -0.06 -0.12 0.08 -0.97 -0.91 -0.98 -0.89 -0.48 -0.50 -0.33 -0.67 0.21 0.34 0.17 -0.03 0.28 0.27 -0.29 0.55 0.13 0.13 -0.20 0.38 
GP8n -0.59 0.76 0.43 0.02 -0.09 0.15 0.14 0.38 0.20 0.39 0.35 -0.40 -0.23 -0.37 -0.50 -0.39 -0.40 0.39 0.09 -0.48 -0.51 0.50 -0.31 
GP9n -0.25 0.37 0.17 0.39 0.35 0.42 0.45 0.43 0.27 0.46 0.46 -0.35 -0.21 -0.41 -0.19 -0.38 -0.37 0.37 -0.06 -0.27 -0.26 0.28 -0.22 
GP10n -0.22 0.22 0.19 -0.16 -0.13 -0.12 -0.12 -0.81 -0.78 -0.88 -0.43 0.87 0.83 0.91 0.67 0.87 0.87 -0.87 0.40 0.67 0.67 -0.57 0.12 
GP11n 0.18 -0.01 -0.20 0.11 0.12 0.07 0.04 -0.56 -0.45 -0.59 -0.32 0.70 0.51 0.64 0.77 0.68 0.68 -0.68 0.18 0.72 0.71 -0.66 0.35 
GP12n -0.39 0.02 0.45 -0.90 -0.77 -0.79 -0.75 -0.36 -0.51 -0.25 -0.49 0.09 0.39 0.12 -0.19 0.15 0.15 -0.16 0.56 -0.05 -0.04 0.03 0.03 
GP13n -0.35 0.22 0.31 -0.57 -0.45 -0.48 -0.50 -0.42 -0.49 -0.36 -0.47 0.26 0.45 0.27 0.13 0.31 0.31 -0.33 1.00 0.22 0.21 -0.29 0.42 
GP14n -0.94 0.55 0.98 -0.05 -0.04 0.11 0.28 0.16 -0.22 0.16 0.44 -0.22 0.25 -0.16 -0.49 -0.21 -0.21 0.20 0.20 -0.50 -0.50 0.59 -0.74 
GP15n -0.72 0.39 0.75 -0.17 -0.08 -0.02 0.06 -0.46 -0.67 -0.49 -0.09 0.43 0.73 0.49 0.21 0.43 0.44 -0.45 0.50 0.21 0.22 -0.10 -0.31 
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Controls                                             
  DT1 DT2 DT3 DT4 DT5 DT6 DT7 DT8 DT9 DT10 DT11 DT12 DT13 DT14 DT15 DT16 DT17 DT18 DT19 DT20 DT21 DT22 DT23 
Age 0.32 -0.29 -0.32 0.07 0.10 -0.04 -0.04 0.08 0.22 0.07 -0.08 -0.09 -0.24 -0.11 0.06 -0.08 -0.08 0.08 -0.14 0.08 0.08 -0.12 0.21 
BMI 0.05 -0.09 0.00 0.16 0.16 0.12 0.12 -0.01 0.07 -0.08 0.06 0.09 0.02 0.10 0.07 0.07 0.08 -0.08 0.04 0.08 0.06 -0.06 0.06 
GP1n 0.49 -0.49 -0.46 0.05 0.19 -0.08 -0.13 0.03 0.29 -0.02 -0.23 0.01 -0.23 0.02 0.31 0.01 0.01 -0.01 0.11 0.32 0.31 -0.38 0.50 
GP2n 0.24 -0.24 -0.20 -0.90 -0.93 -0.88 -0.85 -0.44 -0.45 -0.22 -0.68 0.17 0.17 0.06 0.01 0.22 0.22 -0.23 0.30 0.15 0.16 -0.24 0.43 
GP4n 0.96 -0.88 -0.94 0.15 0.23 -0.06 -0.23 0.18 0.46 0.19 -0.25 -0.15 -0.48 -0.20 0.21 -0.15 -0.16 0.16 -0.29 0.22 0.24 -0.32 0.53 
GP5n 0.39 -0.38 -0.36 -0.18 -0.04 -0.16 -0.27 -0.12 0.07 -0.09 -0.34 0.09 -0.08 0.07 0.26 0.10 0.10 -0.11 0.08 0.30 0.30 -0.34 0.35 
GP6n 0.68 -0.64 -0.61 -0.19 -0.12 -0.31 -0.44 -0.65 -0.43 -0.59 -0.61 0.67 0.43 0.56 0.58 0.68 0.67 -0.67 0.01 0.63 0.63 -0.63 0.53 
GP7n -0.02 0.00 0.06 -0.95 -0.87 -0.97 -0.85 -0.42 -0.48 -0.22 -0.65 0.12 0.22 0.04 -0.04 0.18 0.18 -0.20 0.53 0.10 0.11 -0.20 0.42 
GP8n -0.77 0.79 0.69 -0.04 -0.16 0.15 0.24 0.18 -0.10 0.17 0.40 -0.21 0.07 -0.17 -0.48 -0.22 -0.21 0.21 -0.01 -0.48 -0.49 0.54 -0.60 
GP9n -0.28 0.34 0.20 0.26 0.25 0.26 0.37 0.50 0.37 0.51 0.44 -0.46 -0.34 -0.46 -0.24 -0.48 -0.47 0.47 0.01 -0.31 -0.30 0.30 -0.14 
GP10n -0.41 0.43 0.39 -0.05 -0.09 0.05 0.07 -0.75 -0.76 -0.84 -0.23 0.83 0.87 0.87 0.51 0.82 0.82 -0.82 0.28 0.48 0.47 -0.36 -0.09 
GP11n 0.10 -0.01 -0.14 0.02 0.10 -0.01 -0.04 -0.42 -0.25 -0.47 -0.34 0.49 0.35 0.51 0.67 0.48 0.48 -0.49 0.39 0.63 0.64 -0.61 0.41 
GP12n -0.35 0.22 0.43 -0.86 -0.82 -0.74 -0.64 -0.35 -0.54 -0.19 -0.40 0.09 0.34 0.07 -0.26 0.14 0.14 -0.15 0.40 -0.13 -0.13 0.11 0.00 
GP13n -0.23 0.20 0.26 -0.45 -0.34 -0.44 -0.40 -0.41 -0.37 -0.38 -0.46 0.29 0.34 0.31 0.29 0.31 0.32 -0.34 1.00 0.37 0.35 -0.43 0.53 
GP14n -0.96 0.80 0.99 0.02 -0.06 0.21 0.41 0.09 -0.21 0.04 0.49 -0.08 0.27 0.00 -0.40 -0.09 -0.08 0.08 0.17 -0.43 -0.45 0.53 -0.67 
GP15n -0.75 0.64 0.78 -0.04 -0.06 0.10 0.21 -0.40 -0.53 -0.48 0.03 0.45 0.65 0.53 0.22 0.44 0.45 -0.45 0.38 0.18 0.17 0.06 -0.32 
 
 
 
